Characterization of CAMTA1 and Nkx2.2 in the context of glioblastoma cancer stem cell biology by Wankerl, Ludwig
 
Characterization of CAMTA1 and Nkx2.2 in the 
context of glioblastoma cancer stem cell biology 
 
 
 
Dissertation zur Erlangung des Doktorgrades der 
Naturwissenschaften (Dr. rer. nat.) der Fakultät für Biologie und 
Vorklinische Medizin der Universität Regensburg 
 
 
vorgelegt von 
Ludwig Wankerl 
 
aus 
Regensburg 
 
im Jahr 
2015 
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Das Promotionsgesuch wurde eingereicht am: 
03. Juli 2015 
 
Die Arbeit wurde angeleitet von: 
Prof. Dr. rer. nat. Gunter Meister 
 
Unterschrift: 
 
  
III 
 
 
 
 
 
 
 
 
 
 
Our greatest weakness lies in giving up.  
The most certain way to succeed is always to try just one more time. 
Thomas A. Edison
IV 
 
 
  
V 
 
 
 
Abstract 
Glioblastoma multiforme (glioblastoma) is the most malignant type of tumor in the 
human brain. For glioblastomas and several other cancer types, the existence of so called 
"cancer stem cells" was described. Cancer stem cells are characterized by stem cell-like 
traits such as the capacity of self-renewal and differentiation. Moreover, there is 
evidence that these cells contribute to cancer recurrence after therapy. 
Several molecular-pathological factors are crucial for the emergence of glioblastomas in 
general and for glioblastoma cancer stem cells in particular. For example, certain 
microRNAs (miRNAs) such as the miRNA pair miR-9/9* are specifically enriched in 
glioblastoma cancer stem cells. This miRNA pair acts as oncogene for glioblastomas by 
repressing the tumor suppressor Calmodulin-binding transcription activator 1 
(CAMTA1). 
In this thesis, the upstream and downstream pathways of the CAMTA1 transcription 
factor were investigated in terms of their relevance in cancer biology. Therefore, 
siRNAs and antibodies against CAMTA1 were generated and established. Beyond that, 
a potential interaction partner of CAMTA1, Nkx2.2, was identified. Nkx2.2 is an 
important transcription factor for neural development and is also a potential tumor 
suppressor for glioblastomas. The tumor-suppressive effect of Nkx2.2 reported 
previously was further confirmed by this thesis. In this regard, it was shown that an 
overexpression of Nkx2.2 affected glioblastoma cancer stem cells negatively and 
impaired the proliferation of glioma cells. Additionally, a positive correlation between 
Nkx2.2 expression and survival of glioma patients was revealed.   
Furthermore, it was hypothesized that Nkx2.2 and CAMTA1 act in concert to 
stimulate the transcription of NPPA, which encodes for the precursor of the natriuretic 
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peptide (ANP). This activation was thought to be the main mechanism for these two 
transcription factors to cause their tumor-suppressive effects. Consistently, it was shown 
that an overexpression of Nkx2.2 elevated the NPPA mRNA levels and that Nkx2.2 can 
strongly induce the NPPA promoter.  
Nkx2.2 was further characterized in terms of additional interaction partners and a 
potential regulation by miRNAs. 
The findings of this thesis allow to postulate a model which describes a possible 
regulatory network important for understanding glioblastomas, in particular the 
formation and traits of glioblastoma cancer stem cells. This will advance therapy 
strategies that "tackle" these persistent cells.  
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Zusammenfassung 
Glioblastoma multiforme (Glioblastom) ist eine Tumorform, die im Gehirn auftritt und 
unter den Gehirntumoren den höchsten Grad an Malignität aufweist. Für Glioblastome 
und diverse andere Krebsarten wurde die Existenz von sog. "Krebs-Stammzellen" 
nachgewiesen. Krebs-Stammzellen zeichnen sich durch ähnliche Charakteristika aus 
wie Stammzellen von normalem, gesundem Gewebe, d.h. sie sind fähig, sich zu 
differenzieren und selbst zu erneuern. 
Verschiedene molekular-pathologische Faktoren tragen zur Entstehung von 
Glioblastomen bzw. deren Krebs-Stammzellen bei. So sind beispielsweise bestimmte 
mikroRNAs (miRNAs) wie das bifunktionelle miRNA-Paar miR-9/9* vermehrt in 
diesen Krebs-Stammzellen exprimiert. Dieses spezielle miRNA-Paar reprimiert den 
Tumorsuppressor Calmodulin-binding transcription activator 1 (CAMTA1) und wirkt 
dadurch onkogen für Glioblastome. 
In dieser Arbeit sollte das zelluläre Netzwerk von CAMTA1, durch welches die tumor-
suppressive Wirkung hervorgerufen wird, näher untersucht werden. Dazu wurden 
siRNAs und Antikörper gegen CAMTA1 generiert und auf ihre Funktionalität 
überprüft. Darüber hinaus konnte der Transkriptionsfaktor Nkx2.2 als ein potentieller 
Interaktionspartner von CAMTA1 identifiziert werden. Nkx2.2 spielt bei der 
Entwicklung des zentralen Nervensystems eine wichtige Rolle und gilt ebenfalls als 
potentieller Tumorsuppressor für Glioblastome. Diese tumor-suppressive Wirkung von 
Nkx2.2 wurde in einer früheren Studie gezeigt und konnte durch diese Arbeit bestätigt 
werden: Eine Überexpression von Nkx2.2 beeinflusste Glioblastom-Krebs-Stammzellen 
negativ und verminderte deutlich die Proliferation von Glioma-Zellen. Zudem konnte 
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ein Zusammenhang zwischen einer erhöhter Nkx2.2-Expression und einer höheren 
Überlebensrate von Patienten mit Gliomen festgestellt werden. 
In dieser Arbeit wurde die Hypothese aufgestellt, dass CAMTA1 und Nkx2.2 
miteinander interagieren, um die Transkription des Gens NPPA zu steigern. NPPA 
kodiert für den Vorläufer des atrialen natriuretischen Peptids (ANP). Die Aktivierung 
des NPPA-Gens stellt vermutlich einen zentralen Mechanismus dar, über den die 
beiden Transkriptionsfaktoren CAMTA1 und Nkx2.2 ihre tumor-suppressive Wirkung 
vermitteln. Es konnte gezeigt werden, dass eine Überexpression von Nkx2.2 tatsächlich 
zu einer Erhöhung der NPPA-Expression führte und dass Nkx2.2 in der Lage ist, den 
Promotor dieses Gens zu aktivieren. 
Ferner wurde untersucht, ob für Nkx2.2 weitere potentielle Interaktionspartner 
identifiziert werden können und ob Nkx2.2 durch miRNAs reguliert wird.  
Mit den in dieser Arbeit erbrachten Ergebnissen lässt sich ein Modell entwerfen, wie 
die Entstehung von Glioblastoma multiforme und dessen Krebsstam-Zellen durch einen 
Regulationsmechanismus potentiell unterdrückt wird. Dieses Modell kann dazu 
beitragen, die molekularen Mechanismen für die Entstehung von Glioblastomen, 
insbesondere von deren Krebs-Stammzellen, besser zu verstehen. Dadurch lassen sich 
möglicherweise neue Therapieansätze entwickeln. 
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1. Introduction 
1.1. Cancer stem cells 
Cancer describes a very diverse disease, which can emerge in almost every tissue of the 
human body. The progression of the several types of cancer is rather complex and 
involves disruptions of various cellular networks on different levels including alterations 
of the genome, transcriptome, proteome, and/or interactome. 
In cancer research, it was thought for a long time that tumors are bulks of cells 
characterized by de-regulated proliferation. However, during the last twenty years, this 
simplified view of cancer has drastically changed: Many tumors form sophisticated and 
heterogeneous, almost organ-like, tissues which are sometimes also called "tumor 
microenvironment". This microenvironment is essential for the survival of the tumor 
and also for its distribution throughout the body by metastasis or migration. For 
example, it recruits blood vessels to supply tumor cells with nutrients and oxygen or it 
protects the tumor against the immune system (1). 
But how can one single transformed cell or a small population of abnormal cells 
generate such a diversity? A likely explanation for this would be given by the existence 
of so-called cancer stem cells (CSCs) or tumor initiating cells (TICs). It was postulated 
that these CSCs behave like their normal counterparts in the body, i.e. these cells are 
capable of self-renewal and differentiation as normal stem cells are (Figure 1.1). By 
means of these stem cell-like abilities such cancer cells can constantly renew the tumor 
and generate the heterogeneous, differentiated tumor mass (1, 2).  
The cancer stem cell hypothesis emerged at the end of the last century when for human 
acute myeloid leukemia a distinct, relatively small population of cells was identified (3, 
4). The isolated cells differed from other cells of this cancer type regarding their 
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phenotype and functionality: These cells expressed the same pattern of cell surface 
proteins as normal hematopoietic stem cells. Furthermore, they were capable of self-
renewal and promoted the formation of human leukemia when these cells were injected 
into (immuno-deficient) mice (3, 4). In 2003, CSCs were also found for breast cancer 
(5) and for brain tumors (6). The latter CSCs were isolated from human brain tumors 
(gliomas and medulloblastomas) and characterized by the expression of the cell surface 
protein CD133 (6, 7), which is normally a specific marker for neural stem cells (8). 
Remarkably, the injection of only 100 CD133-positve (CD133+) cells into brains of 
immuno-deficient mice was sufficient to initiate the formation of new tumors, whereas 
even the injection of 100,000 CD133-negative (CD133-) could not (7). Characteristics 
of CSCs in human brain tumors, particularly in glioblastoma multiforme, are described in 
more detail below (see paragraph 1.2.). 
This hierarchical concept of a small subpopulation of CSCs and the residual 
differentiated tumor cells forming the bulk of the tumor was also reported for further 
types of cancer such as pancreatic (9), colon (10), or lung cancer (11). Hence, today, the 
cancer stem cell hypothesis is widely accepted. 
 
 
Figure 1.1: The concept of cancer stem cells (CSCs). CSCs possess the abilities of self-renewal 
and to differentiate comparable to normal stem cells. In the tumor, CSCs represent a relatively 
small sub-population whereas the tumor mass is constituted of more differentiated cancer cells. 
[Figure adapted and modified from (12)]. 
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Interestingly, signaling pathways such as Sonic Hedgehog (SHH) or Notch, which are 
important for differentiation from pluripotent stem cells and strictly regulated during 
normal development, are often found to be de-regulated in CSCs (2, 13). This also 
illustrates that CSCs seem indeed to be abnormal counterparts of normal stem cells. But 
what kind of cell is transformed into a CSCs? Up to now, this remains largely unknown 
and depends probably on the cellular origin from which the tumor emerges. It is 
generally assumed that cells in every phase of their individual differentiation process can 
possibly transform into a CSCs (Figure 1.1) (1, 2). 
 
1.2. Glioblastoma multiforme 
Origin, molecular characteristics, and therapy 
Glioblastoma multiforme1 is not only the most frequent brain tumor in humans but also 
the most malignant. The World Health Organization (WHO) classifies human brain 
tumors into four grades due to their malignancy (14). In this regard, glioblastoma 
belongs to the highest WHO grade IV (lower-grade gliomas are for example 
astrocytomas) (14). Indeed, the median survival after diagnosis with best proceeding 
therapy is only 15 months, which drastically illustrates its malignancy. One reason for 
the fatal prognosis for glioblastomas is the fact that their cancer cells show a high degree 
of diffuse invasiveness into surrounding healthy brain tissue. Although the occurrence of 
glioblastomas is rare compared to other forms of cancer, glioblastomas are the most 
common type of all malignant gliomas (60 - 70 %) and they represent about 30 % of all 
human brain tumors (15-17). 
As the name "glioblastoma" already implicates, it is thought that the origin of this brain 
tumor are most likely glia cells or their progenitor cells (16). Figure 1.2 illustrates the 
potential lineage origin of human brain tumors including glioblastomas. It also shows 
that glioblastomas are histological heterogeneous due to their cellular lineage origins. 
This heterogeneity can also be observed on the molecular-pathological level. In this 
                                                
1 Hereinafter shortened called glioblastoma 
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regard, Verhaak et al. classified glioblastomas, on the basis of genomic aberrations and 
corresponding alterations in expression levels of a large number of genes, into four 
distinct subtypes: classical, mesenchymal, proneural, and neural (18). The classical 
subtype is characterized by a massive EGFR amplification (encodes for the epidermal 
growth factor receptor). A hemizygous deletion of the NF1 containing locus (encodes 
for neurofibromin 1, a known tumor suppressor) is the main feature of the mesenchymal 
subtype (18). For the proneural subtype, a significant higher (compared to the other 
subtypes) amplification for Pdgfra (encodes for Pdgf receptor α, a receptor tyrosine 
kinase) as well as point mutations in IDH1 (encodes for isocitrate dehydrogenase 1) 
were observed (18). The neural subtype is characterized by the expression of certain 
neuron markers, e.g. neurofilament light polypeptide (NEFL) (18). Furthermore, 
Verhaak et al. linked all these characterized subtypes to cellular lineages of normal brain 
cell types: The proneural class reflected a oligodendrocytic signature but not the 
astrocytic signature which was in contrast associated with the classical type (18). The 
neural subtype showed both signatures as well as a neuron expression pattern and the 
mesenchymal type was associated with astroglial lineage (18). 
Moreover, glioblastomas can be classified into primary and secondary glioblastomas: 
Primary glioblastomas arise de novo (i.e. due to a transformation of a normal cell of the 
brain), whereas secondary glioblastomas originate from lower-grade gliomas such as 
astrocytomas. Most glioblastomas are primary (15, 16, 19). Although there is no 
difference between primary and secondary glioblastomas concerning their 
morphological and malignant features, distinctions were identified at the molecular 
level: For example, primary glioblastomas show a frequent amplification of EGFR, in 
contrast to secondary glioblastomas which are characterized by TP53 mutations 
(encodes for the tumor suppressor p53) (15, 16, 19).  
Besides removal by surgery (which is often only possible to a limited extent without 
causing damage in healthy brain regions), combined radio- and chemotherapy applying 
the alkylating reagent temozolomide is the usual treatment (20). However, even with 
optimal therapy the survival of patients can only be extended for a few months.    
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Figure 1.2: Suggested cellular origins of human brain tumors (medulloblastomas and gliomas). 
Red arrows indicate the possible transformation of a normal cell. Lineage origin based on 
histological and/or molecular features. It was suggested that glioblastoma emerge in the 
subventricular zone in the brain where (in adults) neural stem and progenitor cells can be found 
(21). [Figure adapted from (16)].  
 
Glioblastoma cancer stem cells 
As already mentioned in paragraph 1.1., CSCs expressing CD133 were identified about 
ten years ago in glioblastomas. In this work, Singh et al. showed that CD133-positive 
cells effectively induce the emergence of new tumors when they are injected into mouse 
brains. Notably, the newly formed tumors contained both CD133+ and C133- cells 
although only CD133+ cells were injected. This demonstrated that the CD133-positive 
cells can differentiate (7). Furthermore, Singh et al. showed a constant renewal and 
proliferation of the CD133+ pool (7). Besides their capability of self-renewal and 
differentiation, these cells are also more resistant to irradiation and chemotherapeutics 
such as temozolomide (22-24). These traits of glioblastoma CSCs gives a possible 
explanation for the poor therapy success for glioblastomas.  
Furthermore, it was demonstrated by Bao et al. that these cells secret the vascular 
endothelial growth factor (VEGF) which causes angiogenesis, the formation of blood 
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vessels by the surrounding tissue (25). This is essential for supplying the tumor with 
oxygen and nutrients. 
The population of the CD133-positive CSCs within the tumor is small compared to 
the other differentiated cells of the tumor. Though, primary and secondary 
glioblastomas are divergent regarding their respective portion of CD133-positive cells: 
Primary glioblastomas contain significantly more CD133-positive cells than secondary 
glioblastomas (26). However, also glioblastoma CSCs were identified which do not 
express the CD133 marker but show tumorigenicity to a similar extent as CD133-
positive cells (26). Thus, also other (more general) markers were suggested to define 
glioblastoma CSCs, e.g. the stage specific embryonic antigen 1 (SSEA1 or CD15) (27) 
or Nestin (28). 
When primary glioblastoma cells, in particular CD-133 positive cells, are cultured in 
vitro under normal stem-cell like growth conditions, they form non-adherent spheres, 
called "neurosphere-like clones/colonies" (Figure 1.3). In this way cultured glioblastoma 
CSCs maintain their stem cell-like features and their capability to induce tumor 
formation in vivo (26, 29, 30).  
 
Figure 1.3: Cultured primary glioblastoma cells form neurosphere-like clones when cultured 
under stem cell-like growth conditions.  A: Primary glioblastoma cells used in this thesis: (1) R11, 
(2) ZH161. B: Schematic illustration of a neurosphere-like colony. 
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1.3. The role of microRNAs in glioblastoma biology 
MicroRNAs (miRNAs, miRs) are small non-coding RNAs that regulate fundamental 
cellular processes and are hence crucial factors for development, differentiation, and cell 
metabolism (31-33). Since miRNAs are important regulators, a de-regulation of 
miRNA expression is often associated with several types of diseases including cancer. 
Such miRNAs are also often referred to as "oncomiRs" (34, 35). On the one hand, 
oncomiRs can either act as tumor suppressors targeting oncogenes, on the other hand as 
oncogenes themselves inhibiting certain tumor suppressors (34, 35). Latter oncomiRs 
are often overexpressed and thus promote cancer progression. This paragraph focuses on 
several miRNAs (miR-26a, miR-17, miR-9/9*) which act as oncomiRs during 
glioblastoma progression. But first, the biogenesis of miRNAs and their mechanism of 
transcript regulation in mammals will be described. 
 
1.3.1. miRNA biogenesis and miRNA-directed transcript regulation  
MiRNA genes are normally transcribed by RNA-polymerase II, which leads to primary 
miRNA transcripts (pri-miRNAs) (36). These transcripts were first processed by a 
protein complex called microprocessor, which contains the RNase III Drosha and its 
co-factor DiGeorge syndrome critical region 8 (DGCR8). This processing step results 
in the miRNA precursor (pre-miRNA), which is characterized by a hairpin structure 
and a two nucleotide-overhang at the 3'-end (37-39). The precursor is afterwards 
exported by Exportin 5 from the nucleus into the cytoplasm (40-42), where the hairpin 
is cleaved off by another RNase III enzyme, Dicer. This yields a double-stranded 
miRNA (miRNA-duplex) with a length of about 22 nucleotides (43, 44). One strand of 
the duplex, the mature miRNA, is loaded into a protein of the Argonaute family 
whereas the other is usually degraded (referred to as miRNA*). Argonaute (Ago) 
proteins are the core components of the miRNA-induced silencing complex (miRISC) 
(45). The miRNA within the miRISC guides the silencing complex to the 3'-UTR of 
its target mRNA, whereas Ago recruits a member of the GW protein family (termed 
TNRC6A, B, and C in humans). TNRC6 proteins act by inhibiting translation or 
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inducing mRNA degradation and are therefore important mediators of miRNA-guided 
target repression (46, 47). For the target recognition by the miRNA itself, the 
nucleotides 2 to 8 of the miRNA are important. This so called "seed sequence" is 
complementary to the target site within the particular mRNA (32). The biogenesis of 
miRNAs and its mRNA-mediated gene silencing are illustrated in Figure 1.4. 
 
Figure 1.4: miRNA biogenesis and miRNA-induced transcript silencing. The first steps of the 
miRNA biogenesis take place in the nucleus and the maturation process is completed in the 
cytoplasm by transferring one strand of the miRNA duplex into an Ago protein. A rare event in 
mammals is a direct cleavage of mRNAs by cleavage-competent Ago2 loaded with a miRNA that 
is fully complementary to its target (45). This mechanism is comparable to an siRNA-directed 
knockdown. 
 
 
1.3.2. Several miRNAs are important for glioblastoma progression and glioblastoma 
cancer stem cell maintenance 
Various studies previously reported altered expression for many different miRNAs in 
gliomas, respectively in glioblastomas. This paragraph highlights four miRNAs 
important in glioblastoma biology. 
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miR-26a 
In high-grade gliomas, miR-26a is frequently overexpressed (48). This results from a 
gene amplification of one of two miR-26a genomic loci (miR-26a-2) (48). Interestingly, 
this amplification is associated with a monoallelic deletion of PTEN (but was not 
observed for a homozygous PTEN deletion) (48). PTEN encodes for Phosphatase and 
Tensin homolog, which acts as a tumor suppressor and is a direct target of miR-26a in 
glioblastomas (48). It has been suggested that during glioblastoma progression, the 
monoallelic deletion of PTEN occurs before the gene amplification of miR-26a-2 (48). 
The remaining PTEN is then post-transcriptionally repressed by the overexpressed 
miR-26a. This mechanism is basically equal to a homozygous loss of PTEN.  
 
miR-17 
Mammalian primary miRNA transcripts are often polycistronic, i.e. one primary 
transcript is transcribed from a cluster of various miRNA genes (49). This single 
primary transcript gives rise to several distinct mature miRNAs. MiR-17 is part of the 
miR-17~92 cluster. This particular miRNA is a well characterized oncogenic miRNA 
for several types of cancer (35, 50) and was found to be significantly higher expressed in 
glioblastomas (51, 52). Moreover, inhibition of all miR-17~92 cluster members in 
primary glioblastoma cells led to a decrease of proliferation on the one hand and had a 
stimulating effect on apoptosis on the other hand (52). In addition, miR-17-5p belongs 
to group of miRNAs, which are specifically enriched in CD133-positive glioblastoma 
cancer stem cells (53). An inhibition of this particular miRNA significantly reduces 
formation of neurosphere-like colonies of cultured CD133-postive glioblastoma cells 
(53). Other miRNAs showing also specific expression in CD133-positive cells are miR-
106b, which is part of a miR-17~92 paralogous cluster (miR-106b~25) and has the 
same seed sequence as miR-17-5p (50), and the miRNA pair miR-9/9* (53). 
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miR-9/9* 
The miR-9/9* duplex belongs to a type of miRNA duplexes characterized by a 
functional guide and passenger strand (54). Different from the usual miRNA 
biogenesis, where the miRNA* strand is normally degraded, both strands are loaded to 
Ago, yielding two distinct miRISCs each with particular targets.  
MiR-9/9* is mainly expressed in the nervous system where it is an important factor for 
neurogenesis (54, 55). In this context, the transcription factor REST (repressor 
element-1 silencing transcription factor) was identified to be a target for miR-9 and its 
co-factor CoREST is regulated by miR-9* (54). REST and CoREST are highly 
expressed in neural stem cells, but not in differentiated neural cells. By repression of 
both factors via miR-9/9*, neural stem cells differentiate (54). Furthermore, the specific 
inhibition of miR-9 strongly decreased the proliferation rate of differentiating neural 
precursor cells and increased cell migration (55). Both effects are caused by stathmin, 
which is important for microtubule dynamics and a target of miR-9 (55). 
Besides its role in neural development, a de-regulation of miR-9/9*, indicated by high 
expression levels, was observed in brain tumors like glioblastomas (56) and also in other 
cancers such as breast cancer (57). For glioblastomas, Schraivogel et al. showed that 
miR-9/9* is highly abundant in CD133-positive glioblastoma stem cells (53). 
Importantly, a specific inhibition of miR-9 and miR-9* led in both cases to a drastic 
decrease of neurosphere-like clones and to a significant reduction of the CD133-
positive cell population (53). Moreover, the inhibition also promoted differentiation of 
these cancer stem cells (53).  
Taken together, these observations by Schraivogel et al., indicate that miR-9/9* are 
important for maintaining the stem cell character of glioblastoma cancer stem cells. 
This raised the question for transcripts regulated by miR-9/9*. In this context, 
Schraivogel et al. identified the mRNA of the Calmodulin-binding transcription 
activator 1 (CAMTA1) as a potential target for miR-9/9* (53).  
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1.4. The Calmodulin-binding transcription activator 1 is a tumor 
suppressor for glioblastomas 
1.4.1. The CAMTA family of transcription factors: Protein organization 
Human CAMTA1 belongs to a family of transcription factors, which can be found in 
plants as well as in animals. Members of this protein family were first described in 
plants about 15 years ago (58-60). The genome of Arabidopsis thaliana encodes six 
CAMTA proteins (atCAMTA1-6) whereas both in Caenorhabditis elegans and 
Drosophila melanogaster respectively one CAMTA protein could be identified 
(ceCAMTA and dmCAMTA) (60). Mice and humans have two representatives of this 
family (mmCAMTA1/hsCAMTA12 and mmCAMTA2/hsCAMTA22) (60, 61). 
The large CAMTA proteins (e.g. human CAMTA1 has a molecular weight of 180 
kDa) contain several domains with distinct functions. The organization of these 
domains within the protein and their amino acid sequence is highly conserved from 
plants to human (Figure 1.5) (60, 62). By bioinformatical analysis, the following 
domains were identified (from the N- to the C-terminus): A DNA-binding domain, 
called CG-1 domain, a TIG-domain, several ankyrin repeats, and IQ-domains (60, 62).  
 
CG-1 domain 
The CG-1 domain was first described for a DNA binding protein in parsley (63) and is 
characteristic for the CAMTA protein family (60, 62) . In Arabidopsis thaliana a target 
DNA sequence with a length of 6 bp was identified for atCAMTA1 and atCAMTA3 
(59, 64-66). This target with a consensus sequence 5'-(A/C/G)CG(C/T)G(G/T/C)-3' 
was termed "CGCG-box" (59). Moreover, it was shown that in Arabidopsis abscisic 
acid-specific cis elements contain this CGCG-box (ABRE and its related coupling 
element ABRE-CE). These ABREs significantly occur upstream of calcium-induced 
genes suggesting that ABREs function as calcium-responsive cis elements (64, 67). Also 
in Drosophila melanogaster this CGCG-box was indentified within the promoter region 
                                                
2 unless stated otherwise CAMTA1 or CAMTA2 refers always to the human proteins in this thesis 
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of the dmCAMTA target gene dFbxl4 (68). Interestingly, the CG-1 domain of 
dmCAMTA mediates dimerization, which is important for nuclear localization of 
dmCAMTA (69). In mammals it was not known for a long time if the CG-1 domain 
of the mammalian CAMTA representatives binds to a similar target sequence. But 
recently, Long et al. identified a consensus sequence for murine CAMTA2 by in vitro 
binding assays (70). This sequence (5'-(T/C)GCA(G/A/T/C)TGCG-3') is also GC-
rich as the consensus-sequence found in Arabidopsis but it differs from the plant 
sequence. Using reporter assays, Long et al. showed that mmCAMTA1 recognizes this 
motif and activates the reporter even stronger than CAMTA2 (70). The critical residue 
for DNA-binding seems to be a single lysine (K141 for mmCAMTA1 and K108 for 
mmCAMTA2) (70). Furthermore, this study suggests that mammalian CAMTA 
proteins bind probably as dimers to their target DNA sequence (70), which is in line 
with the previously reported dimerization of dmCAMTA (69). Bioinformatic analysis 
revealed a nuclear localization signal (NLS) within the CG-1 domain of almost all 
members of the CAMTA protein family (Figure 1.5) (60, 62). In contrast, for 
mmCAMTA2 the NLS was identified next to the C-terminus and a nuclear export 
signal (NES) in the CG-1 domain (61).  
 
TIG domain 
The organization of the TIG (transcription factor immunoglobulin) domain (as well as 
the ankyrin repeats) of the CAMTA proteins is similar to precursors p100 and p105 of 
the transcription factor NF-κB. The TIG domain mediates non-specific DNA contacts 
of NF-κB family members and is also responsible for dimerization of these proteins 
(71-74).  
 
Ankyrin repeats 
Ankyrin (ANK) repeats can be found in NF-κB family members (74), but also in many 
other eukaryotic proteins. Indeed, ANK repeats belong to the most abundant eukaryotic 
protein motifs and were identified in many proteins involved in a wide range of cellular 
functions (75, 76). One single ANK repeat has a length of about 30 amino acids and is 
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composed of two α-helices (77). The repeats are connected via a β-hairpin consisting of 
two β-sheets (78). These repeats are known as interfaces for protein-protein interactions 
(75, 76, 78). Due to their very frequent occurrence in many proteins with crucial cellular 
function, mutations disrupting protein-protein interactions via ANK repeats are often 
associated with human diseases such as cancer (75, 76). 
 
Figure 1.5: The CAMTA family of transcription factors. The particular proteins are drawn to 
scale: For human (hs), Drosophila melanogaster (dm), Caenorhabditis elegans (ce), and Arabidopsis 
thaliana (at) CAMTAs according to (62), protein information for murine (mm) CAMTAs was 
retrieved from http://www.uniprot.org/ [(A2A891 (mmCAMTA1) and Q80Y50 
(mmCAMTA2)]. The particular, highly conserved, domains are illustrated in different colors: 
CG-1 DNA-binding domain, TIG transcription factor immunoglobulin domain (TIG), ankyrin 
repeats (ANK), IQ domain (IQ), calmodulin-binding domain (CaMBD), and nuclear localization 
signal (NLS). 
 
IQ domain 
The IQ domains, which are located next to the C-terminus of all CAMTA proteins, 
are known to bind Calmodulin (CaM) or CaM-related proteins, whereby binding can 
also occur in the absence of calcium (79, 80). These domains are characterized by the 
repetitive motif IQXXXRGXXXR, hence they are termed "IQ motifs" (79, 80). The 
number of IQ domains for the respective CAMTA proteins differs within the protein 
family: For ceCAMTA no IQ domain was identified, whereas atCAMTA6 contains 
five IQ domains (see also Figure 1.5) (60). But not only the number of IQ-domains is 
different, also the ability of CaM binding varies. AtCAMTA1 showed basically no 
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binding of its IQ domains to Ca2+-CaM (60). In contrast, a Ca2+-independent CaM-
binding motif within the IQ domain was characterized for dmCAMTA (68).  
Up to now, it remains unknown if the IQ-motifs of the mammalian CAMTA 
representatives can also bind CaM (neither in presence nor absence of Ca2+). However, 
it was shown recently that an elevated intracellular calcium concentration obviously 
results in an increased CAMTA1 mRNA level in human mesenchymal stem cells (81). 
This gives a first hint for a possible Ca2+-dependent transcription regulation of 
CAMTA1. 
 
Other domains 
Besides the highly conserved domains described before, some CAMTA proteins have 
less conserved domains. In this context, for atCAMTA1 (60), dmCAMTA (68), and 
mmCAMTA2 (61) a functional transcription activation domain (TAD) was identified. 
In the case of atCAMTA1 and mammalian CAMTA2, this domain is located between 
their particular CG-1 and TIG domains (62). However, no consensus sequence for this 
domain was found via bioinformatic analysis (60).  
 
1.4.2. Function of CAMTA proteins from plants to mammals 
The function of CAMTA proteins in plants was extensively investigated during the last 
ten years. Obviously, plant CAMTA proteins act as key mediators of cellular response 
to signals caused by abiotic (e.g. wounding, drought, temperature extremes, salt 
concentration) and biotic (e.g. pathogens) stress (59, 65, 66, 82-85). These proteins 
function as relays between intracellular signal transducers such as calcium (stress 
signaling commonly results in an increased cytosolic Ca2+ concentration) and a 
comprehensive transcriptome response of the cell to stress (65, 66, 82-84). In this 
context, the CAMTA target sequence described above was found in many stress-
responsive genes (65-67, 82, 83). 
In contrast, the role of CAMTA proteins and the cellular processes controlled by these 
proteins in animals remain vague.  
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DmCAMTA1 is mainly expressed in photoreceptor cells where it functions as a 
important regulator of the visual process (68). As mentioned before, dmCAMTA 
stimulates the transcription of the F-box gene dFbxl4 which leads to a deactivation of 
light-induced rhodopsin, a G-protein coupled photoreceptor (68). For this transcription 
regulation dimerization-induced nuclear localization of dmCAMTA (69) and Ca2+-
independent CaM-binding to dmCAMTA (68) are essential. 
For mammalian CAMTA2 it was reported previously that it has an essential function 
during cardiac hypertrophy which describes the hypertrophic growth of heart muscle 
cells. Heart hypertrophy is caused for example by mechanical stress such as elevated 
blood pressure and calcium is an important intracellular transducer for this cellular stress 
(86, 87). Since murine and human CAMTA2 show a specific expression in cardiac 
myocytes of the adult heart (61), it appears to be likely that there is a calcium-
dependent stress response mediated by CAMTA2 (maybe in similar way as observed in 
plants). Song et al. further demonstrated that CAMTA2 acts as a co-activator of the 
NPPA gene in cardiac myocytes (see also paragraph 1.5.1.) (61). This co-activation is 
blocked by HDAC5 (61), a member of class II histone deacetylases, which are known as 
negative regulators of cardiac hypertrophy (87). Thereby, HDAC5 directly interacts 
with the ankyrin repeats of CAMTA2 (61). 
Mammalian CAMTA1 was found to be expressed mainly in the fetal heart and in the 
central nervous system, in particular in the brain (61, 88-91). During development of 
the murine brain, CAMTA1 is expressed ubiquitously, whereas later in development 
the expression is constricted to the cerebellum, hippocampi, and the olfactory bulbs 
(91). The cerebellum is important for motor coordination. Interestingly, it was reported 
before that heterozygous intragenic aberrations of the human CAMTA1 gene were 
associated with ataxia and in some cases with intellectual disability (91, 92). These 
aberrations concern exclusively the 5'-end of the CAMTA1 locus and are characterized 
by deletions of certain exons of which most are involved in coding for the CG-1 DNA-
binding domain (91, 92). The described deletions lead either to frame shift mutations, 
and therefore to an early translation termination, or to non-functional protein (91, 92). 
These findings are in line with a study recently published by Long et al., which describes 
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an ataxic phenotype observed for a neural-specific CAMTA1 knockout in mice (70). 
This phenotype was caused by a significant degeneration of Purkinje Cells in the 
cerebellum of CAMTA1-knockout mice. Since the organization of the cerebellum was 
normal in these mice, Long et al. concluded that CAMTA1 is less important for a 
proper development of the cerebellum but rather for the maintenance of cerebellar 
neurons (70). Moreover, Long et al. used microarray analysis to investigate which genes 
are de-regulated as a result of the CAMTA1 knockout. Among the down-regulated 
genes in CAMTA1-knockout mice are Snhg11, fbxl3a, and Gtl2. These genes contain 
the mammalian DNA-binding site for CAMTA proteins (70). The F-box gene fbxl3a 
is involved in protein degradation. The function of Snhg11 is still unknown but it shows 
a high expression level in Purkinje cells (70). Gtl2 encodes for a long non-coding RNA 
reported previously to act as a tumor suppressor (93). This might be of particular 
importance since CAMTA1 has also a function as a tumor suppressor (see paragraph 
1.4.2.).  
A further function suggested for mammalian CAMTA1 is a role in episodic memory 
performance. CAMTA1 expression is increased in memory-related human brain 
regions and a poorer memory performance seems to be associated with single nucleotide 
polymorphisms within the CAMTA1 allele (90).  
Summing up, CAMTA1 seems be an important factor for normal function of the 
mammalian brain, in particular for a proper motor coordination. Furthermore, it was 
also reported before that it acts as tumor suppressor for neural tumors such as 
neuroblastoma and glioblastoma. This function will be described more closely in the 
next paragraph. 
 
1.4.3. CAMTA1 acts as tumor suppressor in neural tumors 
It was found that deletion located in the short arm of chromosome 1 is frequently 
associated with tumors originating from neural tissues such as neuroblastomas and 
glioblastomas (89, 94-103). This deletion is localized at position 1p36.3, which 
represents the genomic locus of CAMTA1 (89, 95-97, 99-102). Therefore, CAMTA1 
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was regarded as a potential tumor suppressor protein for neuroblastomas and 
glioblastomas for more than a decade. In 2006, it was shown for neuroblastoma patients 
carrying this specific deletion that a lower level of CAMTA1 expression correlates 
indeed with a poor prognosis for this tumor (99). Neuroblastomas originate from cells 
of the sympathetic nervous system and occur mainly during childhood (101). The above 
described 1p-deletion can be observed in about 30 % of all neuroblastomas and thereof 
mainly in high-malignant forms (94, 97). This corresponds to a significantly lower 
CAMTA1-expression in higher-stage neuroblastomas (99). A 2011 published study by 
Henrich et al. showed further that a constitutive overexpression of CAMTA1 in 
inducible neuroblastoma cell lines influenced the cell cycle significantly: The 
overexpression changed the cell population by decreasing the proportion of cells in the 
S-phase and increasing the proportion of cells in the G1/G0-phase (104). Moreover, this 
study demonstrated in vitro and in vivo an antiproliferative effect for overexpressed 
CAMTA1 (104). Increased CAMTA1 levels also cause induction of neural 
differentiation markers and, vice versa, an up-regulation of CAMTA1 was observed by 
Henrich et al. during neuroblastoma differentiation (104). Furthermore, microarray 
analyses conducted by this group revealed several genes which were de-regulated by 
CAMTA1 overexpression: In general, genes involved in differentiation and cell cycle 
inhibition showed up-regulation whereas genes promoting for example mitosis were 
down-regulated by CAMTA1 (104). 
In gliomas the deletion of the 1p36-locus is often observed in oligodendrogliomas and is 
also associated with lower CAMTA1 expression (in an analogous manner as described 
for neuroblastomas): Oligodendrogliomas characterized by this deletion show a decrease 
of CAMTA1 expression of about 50 % compared to oligodendrogliomas without this 
deletion (89). However, the 1p36-deletion also occurs frequently in higher-grade 
gliomas such as glioblastomas (103). These glioblastomas often have hemizygous 
deletions at the CAMTA1-locus (103), which correlates with a lower CAMTA1-
expression in glioblastomas compared to lower-grade gliomas such as astrocytomas 
(102). In 2011, Schraivogel et al. further supported the hypothesis that CAMTA1 is a 
tumor suppressor candidate for glioblastomas. As already mentioned in paragraph 
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1.3.2., CAMTA1 was identified as a potential target for miR-9/9*. Indeed, miR-9/9* 
predicted target sites in the 3'-UTR of the CAMTA1 mRNA were validated by 
Schraivogel et al. (53). Moreover, a CAMTA1 overexpression showed a tumor-
suppressive effect in vitro and in vivo: The formation of neurosphere-like clones was 
significantly reduced by CAMTA1 overexpression in primary glioblastoma cells and the 
CD133+ cell population was also decreased drastically (53). An overexpression in these 
primary cells also led to a clear reduction of tumor growth when those cells were 
implanted in mouse brains (53). Interestingly, for the effect on primary glioblastoma 
cells the CG-1 DNA-binding domain of CAMTA1 is necessary since an 
overexpression of a CG-1 deletion mutant had no effect on these cells (53). As 
previously observed for CAMTA1 in neuroblastomas, an elevated CAMTA1 level 
correlates also here with patient survival: Patients with higher CAMTA1 levels survived 
significantly longer than patients with a normal or lower CAMTA1 expression. 
Remarkably, a CAMTA1 overexpression in stable glioblastoma cell lines also distinctly 
resulted in elevated NPPA mRNA levels (53). Therefore, it seems likely that 
CAMTA1 acts as (co-)activator of the NPPA gene as previously reported for 
CAMTA2 in heart. Schraivogel et al. furthermore demonstrated a connection between 
up-regulated NPPA expression and patient survival whereupon patients with increased 
NPPA expression survived much longer (53). 
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1.5. Nkx2.2: A glioblastoma tumor suppressor candidate 
1.5.1. The Nkx protein family: Transcription factors essential for development 
Nkx2.2 belongs to a family of vertebrate transcription factors characterized by a highly 
conserved homeobox-binding domain (HD). These transcription factors are known for 
more than twenty years to be important factors for proper development of different 
tissues. Together with other Nkx proteins such as Nkx2.1 or Nkx2.5, Nkx2.2 
constitutes in vertebrates the Nk-2 class of transcription factors, whose homologs were 
first identified in Drosophila melanogaster (105, 106). In total, eleven Nk-2 class 
members are known and all of them show organ-specific expression patterns (106). 
The HD of Nkx2.1, 2.2, and 2.5 binds to a DNA sequence (NK-response element, 
shortened NKE) which contains the core consensus sequence 5'-AAGTG-3' (Figure 
1.6 C) and is highly conserved in mammals (107-110). For Nkx2.2, however, also an 
alternative core sequence (5'-GAGT-3') was postulated in 2011 (111). Besides the HD, 
Nk-2 class proteins feature other conserved domains: A transcriptional repression TN-
domain which is located at the N-terminus, an Nk-2 specific domain (NK-2 SD), and a 
transcription activation domain (TAD) next to the C-terminus (see Figure 1.6 A) (105, 
110). Thereby, the Nk-2 specific domain is thought to be an intrinsic repression 
domain for the TAD of the C-terminus due to its hydrophobic character (110). 
Moreover, it was suggested to function as interface for specific protein-protein 
interactions (110).  
Regarding their function as key factors for the development of different organs, Nkx2.1, 
2.2, and 2.5 belong to the best studied members of the Nk-2 class proteins. Nkx2.1 is 
known for its important role during lung development (112-114). Consistently, Nkx2.1 
knocked out mice die soon after birth from respiratory failure caused by malformed 
lungs (112, 113). Nkx2.1 was also linked to lung cancer biology: In several studies 
Nkx2.1 was reported both as suppressor of malignant progression and as oncogene 
promoting lung adenocarcinomas. The two-sided function of Nkx proteins is discussed 
more closely in paragraph 3.2.3.  
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Figure 1.6: Nk-2 class of homeobox-binding domain containing transcription factors. A: Nkx2.2 
with its Nk-2 class-typical domains (highlighted in different colors): Transcriptional repression 
domain (TN), homeobox-binding domain (HD), Nk2-specific domain (NK2-SD), and 
transcription activation domain (TAD). [(Illustration based on structural information available at 
http://www.uniprot.org/ for human Nkx2.2 (O95096)]. B: The HD of the Nk-2 class members 
Nkx2.1, Nk2.2, and Nkx2.5 is highly conserved. Sequence alignment was performed using 
ClustalW2 (http://www.ebi.ac.uk/). C: Structure of the Nkx2.5 HD. The domain consists of three 
α-helices of which α3 mediates specific interactions with the NK response element (NKE). 
Within α3 a specific tyrosine (Y191 for Nkx2.5; highlighted in red in B and C) is essential for 
NKE recognition. Adopted from (115).  
 
Nkx2.2 is essential for neural development, in particular for glia cell maturation, which 
is highlighted in the next paragraph (see 1.5.2.). 
The crucial role of Nkx2.5 in heart development and maintenance of a normal heart 
function was extensively investigated in several studies before (109, 116-123). In this 
context, it was shown previously that a homozygous knockout of Nkx2.5 in mouse is 
embryonic lethal, because heart development is severely impaired (117, 118). As a 
transcriptional target for Nkx2.5, NPPA was identified already twenty years ago  (108, 
109). Nkx2.5 stimulates its expression via binding to the NKE sites in the NPPA 
promoter (108, 109, 115). NPPA in turn is the precursor of ANP, a secreted peptide 
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and a marker for cardiomyocyte differentiation (124). For the stimulation of the NPPA 
promoter, a member of the GATA family of transcription factors, GATA-4, was 
identified as an Nkx2.5 interaction partner during the maturation of cardiomyocytes 
(109, 123). Another co-inducer of NPPA, which can also interact with Nkx2.5, is the 
T-box transcription factor Tbx5 (119, 120). 
As already mentioned in paragraph 1.4.2., CAMTA2 is also a co-activator of NPPA 
during cardiac hypertrophy. In this context, it was shown by Song et al. that CAMTA2 
directly interacts with Nkx2.5 to stimulate the NPPA promoter (61). This interaction is 
mainly mediated by the CG-1 domain of CAMTA2 and the HD of Nkx2.5 (61). It is 
believed that these two transcription factors interact to promote cardiac hypertrophy as 
response to cellular stress. 
Recently, the binding of the Nkx2.5 HD to the NKE site of its target NPPA was 
structurally resolved: Nkx2.5 binds as a homodimer to palindromically arranged NKE 
sites in the NPPA promoter (115). The HD itself consists of three α-helices connected 
by a loop (Figure 1.6 C). Thereby, helix α3 facilitates the majority of the HD-DNA 
interactions (115). The other helices seem to be important for the stability of the entire 
domain (115). Within helix α3, several residues are important for DNA-binding, but 
only a single tyrosine (Y191) is essential for the sequence-specific interaction (115). 
Consistently, a mutation of this residue (Y191C) is frequently associated with human 
heart diseases (125). Furthermore, this tyrosine is highly conserved among other Nk-2 
members, as illustrated in Figure 1.6 B. 
 
1.5.2. Nkx2.2 is important for neural development and a potential tumor suppressor 
protein 
The proper development of the central nervous system with its different classes of 
neurons and glia cells is very complex and requires a widespread, very accurately 
regulated network of signaling that turns certain transcription factors on or off at a 
precise time point and region during maturation of the different cell types.  
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In this context, Nkx2.2 has an essential function for the differentiation of 
oligodendrocyte progenitor cells, which is best studied for the development of the 
mouse and chicken spinal cord (126-133). During dorsal-ventral pattering of the neural 
tube, Nkx2.2 expression emerges in a defined ventral region of the ventricular zone as a 
response to Sonic Hedgehog (SHH) signaling (126, 127). Together with its adjacent 
region which is characterized by the expression of  the oligodendrocyte precursor-
specific factor Olig2, this most ventral region is the major region for oligodendrocyte 
linage determination in the developing spinal cord (132). Nkx2.2 and Olig2 collaborate 
to activate the final maturation program during late oligodendrocyte development (131, 
132, 134). In this regard, Nkx2.2 expression is inducible by Olig2 and Nkx2.2 also 
becomes a co-inducer of Olig2 during later maturation (131, 134), each probably in an 
indirect manner since both proteins are thought to act as transcriptional repressors 
during oligodendrocyte maturation (131).  
Nkx2.2 also prevents the premature expression of the myelin basic protein (MBP) gene 
by binding directly to the MBP promoter and by association with a repressor complex 
that includes histone deacetylase 1 (HDAC1) (135). On the other hand, Nkx2.2 is also 
able to induce the gene of the proteolipid protein (PLP) (129, 132). Both, MBP and 
PLP, are essential proteins for the formation of myelin sheaths by the mature 
oligodendrocytes. By a similar mechanism as shown for MBP, via recruiting HDAC1, 
Nkx2.2 negatively affects expression of Sirt2, a protein which belongs to the Sirtuin 
class III deacetylases (136). Sirt2 is another important factor during oligodendrocyte 
maturation since it associates with myelin (137, 138). Recently, it was also shown that 
Nkx2.2 represses Pdgfra via direct binding to its promoter (133). Pdgfra (Pdgf receptor 
α) and Pdgf signaling via its receptor is important for early oligodendrocytes lineage 
determination and an interruption of Pdgfra leads to a premature differentiation of the 
oligodendrocyte precursors (139, 140). After terminal differentiation, Nkx2.2 is down-
regulated in oligodendrocytes (128, 135). 
Besides its function in oligodendrocytes development in the spinal cord and in the brain 
(128, 129), Nkx2.2 is also essential for the generation of v3 interneurons in the spinal 
cord and serotonergic neurons in the developing hindbrain (126, 127, 141). 
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In 2010, it was furthermore reported that Nkx2.2 acts as a tumor suppressor for 
glioblastomas. For this study, Muraguchi et al. generated a transgenic mouse, which 
develops glioblastomas characterized by a human phenotype (142). These tumors 
showed only a weak Nkx2.2 expression (142).  Moreover, an overexpression of Nkx2.2 
in cancer stem cells of these tumors and in primary human glioblastoma cells negatively 
affected their ability for self-renewal as it led to a significant reduction of neurosphere-
like colonies (142). The overexpression in isolated glioblastoma cells from the 
introduced mouse model also resulted in a drastic decrease of Nestin and, consistently, 
in an elevation of mature oligodendrocytes markers such as NG2 (142). In addition, 
Muraguchi et al. also demonstrated a tumor suppressive effect of Nkx2.2 in vivo (142).  
Taken together, the findings by Muraguchi et al. turn the important developmental 
transcription factor Nkx2.2 to a interesting tumor suppressor candidate in glioblastoma 
biology. A de-regulation of this factor could be important for progression of this type of 
brain cancer.  
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The putative transcription factor CAMTA1 acts as a tumor suppressor for 
glioblastomas as well as for neuroblastomas. However, the exact mechanisms of how 
this protein carries out this function remains largely unknown. 
Hence, it was the aim of this thesis to characterize CAMTA1 in detail and to gain 
insight into which cellular network CAMTA1 is involved in to promote its tumor 
suppressive function. To achieve this, it was intended to establish tools for a functional 
characterization of CAMTA1, including antibodies or siRNAs. With these tools it 
should be further possible to examine which genes are regulated by CAMTA1 and 
which other proteins it interacts with. 
Based on previous findings about CAMTA proteins, a working model was developed 
for this thesis. As mentioned before, mammalian CAMTA2 interacts with Nkx2.5 in 
the heart to stimulate the expression of NPPA. Hence, it was assumed that a similar 
interaction might take place in neural cells between CAMTA1 and Nkx2.2. Moreover, 
both CAMTA1 and Nkx2.2 repress self-renewal and differentiation of glioblastoma 
CSCs. Therefore, one could speculate that these two proteins act in concert to suppress 
tumor formation and that a de-regulation of one or both proteins promotes 
glioblastoma progression. As mentioned before, CAMTA1 overexpression causes a 
significant elevation of NPPA mRNA levels. Remarkably, for the peptide hormone 
ANP (which arises from the precursor NPPA) an antiproliferative effect on 
glioblastoma cells was reported before (143) and, furthermore, NPPA expression 
correlates with survival of glioblastoma patients (53). Thus, it is likely that CAMTA1 
and Nkx2.2 might interact to stimulate NPPA expression, which finally causes a tumor 
suppressive effect. This working model is illustrated in Figure 1.7. 
Besides the investigation of a potential interaction between CAMTA1 and Nkx2.2, it 
was further intended to examine upstream and downstream pathways involving Nkx2.2 
in the context of glioblastoma biology.  
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Figure 1.7: Working model for this thesis. It is hypothesized that in the mammalian brain 
CAMTA1 acts in concert with Nkx2.2 to stimulate the promoter of NPPA (in a similar manner as 
CAMTA2 and Nkx2.5 interacts in cardiac myocytes). The expression of NPPA, which is the 
precursor of ANP, would in turn cause tumor suppression. Furthermore, de-regulated miR-9/9* 
would probably counteract this mechanism in glioblastoma CSCs by targeting the CAMTA1 
mRNA. It is assumed, that this maintains the stem cells character of these CSCs and promotes 
glioblastoma progression.  
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2. Results 
2.1. Characterization of CAMTA1 
CAMTA1 is a putative transcription factor, however less is known about its potential 
target genes and/or interaction partners. Therefore, in order to characterize the cellular 
function of CAMTA1, the generation and establishment of tools such as siRNAs and 
antibodies are essential. This is described in the following first two paragraphs of this 
chapter. 
 
2.1.1. Establishing of efficient CAMTA1 knockdown strategies 
SiRNA-mediated gene silencing provides a very effective tool to characterize proteins of 
interest in terms of their cellular functions. For the knockdown of CAMTA1, five 
siRNA oligonucleotides were designed. Each of these siRNAs targets a different exon 
and the target sites are distributed over the whole major CAMTA1 transcript, which 
encodes for the full-length CAMTA1 protein (Figure 2.1 A). Besides this major 
transcript, alternative transcripts with unknown function are predicted (illustrated in 
blue in Figure 2.1 A). In theory, all generated CAMTA1 siRNAs should also target 
these alternative transcripts except of siRNA4 with its target site in exon nine that is 
included only in the largest transcript. 
The efficiency of the generated siRNAs for CAMTA1 knockdowns was tested via 
qRT-PCR (Figure 2.1 B). Three different primer pairs were used to quantify the 
CAMTA1 mRNA levels. All primer pairs were designed to span exon-intron junctions. 
Primer pair 1 (CAMTA1 p1) spans exon three to five, CAMTA p2 exon three to four, 
and CAMTA1 p3 exon 20 to 21. Therefore, CAMTA1 p1 and p2 should only generate 
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their specific amplicon only from the major CAMTA1 transcript since exon four and 
five are exclusively found in the main transcript. As shown in Figure 2.1 B for a 
CAMTA1 knockdown in primary R11 glioblastoma cells, basically all siRNAs led to a 
decreased mRNA level of CAMTA1 (compared to the control siRNA). Notably, the 
highest knockdown efficiencies were observed for siRNA1 and siRNA2.  
 
Figure 2.1: Genomic locus of CAMTA1 and siRNAs against CAMTA1. A: Schematic 
illustration of the CAMTA1 locus (1p36.31 - 1p36.23). Vertical lines represent exons (E). The 
main transcript (coding for the complete CAMTA1 protein) is depicted in black, alternative 
transcripts are highlighted in blue. The particular exons targeted by the generated siRNAs are 
shown below. The illustration was drawn according to the genomic information available at the 
UCSC genome browser (http://genome.ucsc.edu/). B: Testing the functionality of the CAMTA1 
siRNAs. Primary R11 glioblastoma cells were transfected with the respective siRNAs [siRNA1 to 
5 and control siRNA (ctrl. siRNA)]. Total RNA extraction and cDNA synthesis were performed 
four days after transfection. The efficiency of the particular knockdowns was validated via qRT-
PCR using three different CAMTA1 primer pairs (p1, p2, and p3). SiRNA1 and siRNA2 showed 
the strongest knockdown of CAMTA1. 
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2.1.2. Polyclonal antibodies against CAMTA1 
Besides siRNAs, specific antibodies are also highly valuable tools to characterize the 
function of CAMTA1. Two polyclonal rabbit antibody sera against human CAMTA1 
were already available at the beginning of this thesis, named as "anti-CAMTA1 1886" 
and "anti-CAMTA1 1901" serum (shortened referred to as "1886" and "1901" in the 
following paragraphs). In order to test their functionality for detection of endogenous 
CAMTA1 in western blots, total protein lysates of the knockdown depicted in Figure 
2.1 B (see previous paragraph) were used. Both antibodies recognize bands with a 
molecular weight around 180 kDa (the theoretical weight for CAMTA1). Thereby, the 
band with the strongest signal intensity detected by the 1886 antibody ran slightly lower 
and the major band revealed by the 1901 antibody was slightly bigger than 180 kDa 
(Figure 2.2). However, for both antibodies, the signal intensities of these bands were 
unchanged in all lysate samples, including CAMTA1 knockdown samples. Therefore, it 
is questionable if these antibodies can indeed detect endogenous CAMTA1 in western 
blot. Alternatively, CAMTA1 might be highly stable and CAMTA1 mRNA changes 
might not impact immediately its cellular protein level (discussed in paragraph 3.1.2.).  
 
Figure 2.2: Testing the CAMTA1 antibodies 1886 and 1901 for their functionality to detect 
endogenous CAMTA1 in western blots. Protein samples of the CAMTA1 knockdowns shown in 
Figure 2.1 were used for western blot analysis. Of each particular knockdown (siRNA1 to 5) and 
knockdown control (ctrl.), 100 μg total protein lysate was loaded for each western blot [equal 
loading was controlled by western blot against α-Tubulin (lower panels)]. The respective detection 
pattern of both antibodies was basically unchanged for each of the individual knockdown samples. 
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Since it was not sure, whether the detected bands represent indeed endogenous 
CAMTA1, the antibodies 1886 and 1901 were tested for detection of overexpressed 
CAMTA1 with an N-terminally myc-tag CAMTA1 (mycCAMTA1). For this 
purpose, mycCAMTA1 was overexpressed in HEK293-T cells and subsequently 
knocked down by using siRNAs 1, 2, and 3 after 48 hours of overexpression. After 
further cultivation of again 48 hours, cells were harvested and split for total RNA 
extraction in order to validate the knockdown on the mRNA level (Figure 2.3 D) and 
for total protein lysates subsequently used for western blot analysis. The detection 
patterns of the CAMTA1 antibodies were observed and compared to an anti-myc 
antibody. This antibody detected mainly two bands: One band bigger than 250 kDa and 
a second band running slightly lower than 180 kDa. Since the signal intensity of both 
bands was clearly reduced by the used CAMTA1 siRNAs, it can be assumed that both 
bands were indeed mycCAMTA1 (Figure 2.3 C). The same bands were also detected 
by the 1886 and 1901 antibody (Figure 2.3 A and B), but with different signal 
intensities. Nonetheless, this leads to the conclusion that both antibodies can in 
principle detect myc-tagged CAMTA1. However, both antibodies also visualized 
prominent protein bands which ran different than mycCAMTA1 and were also present 
in the empty vector control: The 1886 antibody detected a band between 130 and 180 
kDa, whereas 1901 showed a band with a strong signal running slightly bigger than 180 
kDa. These bands were also detected in the western blots with CAMTA1 knockdown 
samples (Figure 2.2). Consistent with these western blots, the intensities of the bands 
detected around 180 kDa were here also not affected by the CAMTA1 siRNAs (Figure 
2.3 A and B). Hence, the identities of these bands are indistinct. 
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Figure 2.3: The CAMTA1 antibodies 1886 and 1901 can both detect overexpressed 
mycCAMTA1. Overexpressed (o.e.) mycCAMTA1 (in HEK293-T cells) was knocked down 
with the indicated CAMTA1 siRNAs or control siRNA (ctrl. siRNA) after 48 hours 
overexpression. Total RNA extraction for qRT-PCR validation and lysis for western blot analyses 
were performed 48 hours after siRNA transfection. For the western blot analysis 80 μg of each 
protein lysate was loaded (equal loading for the mycCAMTA1 knockdown samples was controlled 
by western blots for α-Tubulin). Both antibodies (A: 1886, B: 1901) were able to detect 
overexpressed mycCAMTA1 as the comparison with the western blot against the myc-tag (C) 
showed. D: Knockdown validation of mycCAMTA1 by qRT-PCR. 
 
It was further tested if both sera can be used for anti-CAMTA1 immunoprecipitations 
(IPs). However, no clear enrichment of endogenous CAMTA1 was seen for IPs using 
these antibodies (data not shown).  
Taken together, the utility of the two CAMTA antibodies 1886 and 1901 to 
characterize endogenous CAMTA1 via western blot analysis and/or IPs remains 
doubtful: Although both antibodies are at least able to detect overexpressed 
mycCAMTA1 in western blots, the identities of the most prominent protein bands 
detected around 180 kDa by these antibodies could not be clarified. Moreover, these 
antibodies showed also negative results for IPs of endogenous CAMTA1. For these 
reasons, a new set of antibodies against CAMTA1 was generated to further study the 
function of the endogenous protein. 
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The two CAMTA1 fragments (fragment 1 and 2) used as antigens for immunization of 
rabbits to produce the antibody sera 1886 and 1901 are schematically shown in Figure 
2.4 A. For the generation of new polyclonal antibodies, a CAMTA1 fragment located 
in the linker region between the ankyrin repeats and the C-terminal IQ domain was 
used (fragment 3 in Figure 2.4 A). This fragment was N-terminally fused to GST for 
purification and stabilization ("GST-CAMTA1-F3"). Additionally, a TEV protease 
recognition site was introduced between GST and fragment 3. The GST-fragment 3 
construct was recombinantly expressed in a Rosetta Escherichia coli strain. After 
determination of the optimal expression conditions (at 25°C for five hours), the fusion 
protein was purified in large scale (4 l culture volume) via fast protein liquid 
chromatography (Figure 2.4 B).  
To get GST-CAMTA1-F3 as pure as possible for immunization, a subsequent anion 
exchange chromatography was necessary. Figure 2.4 B (right panel, lane 1) shows GST-
CAMTA1-F3 after the final purification step. The purified GST-tagged peptide was 
used to immunize two rabbits for antibody production (Eurogentec, Liège, Belgium). 
This resulted in the generation of two additional anti-CAMTA1 antibody sera, termed 
as "anti-CAMTA1 SY6160" and "anti-CAMTA1 SY6161" (shortened referred to as 
"SY6160" and SY6161" in the following paragraphs). 
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Figure 2.4: Generation of new CAMTA1 antibodies. A: Position of the particular fragments used 
for the production of antibodies within the CAMTA1 protein. Fragment 1 and 2 were used to 
generate the antibody sera 1886 and 1901. Fragment 3 was purified (as GST fusion protein) in 
this thesis to produce additional antibody sera. B: Purification of GST-CAMTA1-F3. Left panel: 
Elution peak of the glutathione SepharoseTM purification step (about 0.1 % of each fraction was 
loaded on a 15 % PA gel). Right panel: GST-CAMTA1-F3 after final purification via anion 
exchange chromatography (15 % PA gel). Purity was controlled by cleaving off the GST-tag by 
TEV protease (about 10 μg of the purified protein was used for TEV cleavage). 
 
These new sera were first tested for their functionality in western blots using different 
mycCAMTA1 constructs overexpressed in HEK293-T cells (Figure 2.5 A). These 
constructs represent truncated versions of the CAMTA1 wildtype protein. In the case 
of the CAMTA1 ΔN construct, the N-terminus (including the CG1 domain) is 
completely deleted. The other constructs are depicted schematically in Figure 2.15 A 
(see page 47). As clearly shown in Figure 2.5 A, both new antibody sera detected the 
mycCAMTA1 constructs except of mycCAMTA1 ΔC, which lacks the entire C-
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terminus (including the ankyrin repeats). This detection pattern is not surprising 
because the antigen used for the generation of the new sera is located in a region next to 
the C-terminus, which is not present in mycCAMTA1 ΔC. 
 
Figure 2.5: Testing and purifying the generated CAMTA1 antibody sera. A: Both antibody sera 
(SY6160 and SY6161) detected several mycCAMTA1 constructs (overexpressed in HEK293-T), 
but not mycCAMTA1ΔC, which lacks the antigen (about 2 % of each lysate was loaded for the 
western blots). B: Purification of the sera via affinity chromatography. About 1 % of each elution 
peak fraction (f.) was loaded. To estimate the particular concentrations of the purified antibodies, 
serial diluted BSA was also loaded (lanes 5 - 8). [Purification of SY6160 was carried out by 
Martina Tremmel (B.Sc.) under supervision of Ludwig Wankerl]. 
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Since the two new sera indeed detect mycCAMTA1, these sera were further purified by 
affinity chromatography using the antigen GST-CAMTA1-F3 (Figure 2.5 B). The 
purified antibodies were then tested if they are capable to detect endogenous 
CAMTA1.  
For this purpose, CAMTA1 was knocked down in stable T98G glioma cells using the 
efficient CAMTA1 siRNA 1 (transected twice with 48 hours of incubation in between) 
(Figure 2.6). Although the knockdown was efficient on mRNA level (Figure 2.6 B), the 
signal intensities of the bands detected by the two purified antibodies were in both cases 
not decreased in the knockdown sample (compared to the siRNA control sample). 
Notably, the purified SY6161 antibody detected in both the knockdown and the control 
sample a band running slightly higher than 180 kDa. This protein band probably 
matches with the most prominent band detected by the 1901 CAMTA1 antibody (see 
e.g. Figure 2.2). The possibility whether this band represents endogenous CAMTA1 is 
discussed in paragraph 3.1.2.   
 
Figure 2.6: Testing the purified new CAMTA1 antibodies for their functionality to detect 
endogenous CAMTA1. Endogenous CAMTA1 was knocked down in T98G cells using 
CAMTA1 siRNA1 (transfected twice). A: Western blot analyses using the two purified (purf.) 
antibodies (100 μg of each protein lysate was loaded; equal loading controlled by western blots for 
α-Tubulin). The individual detection patterns of both antibodies were not affected by the 
knockdown. B: Knockdown validation via qRT-PCR. 
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Analogous to the antibody tests of the "old" sera (1886 and 1901), it was also examined 
if the new antibodies can be used to immunoprecipitate endogenous CAMTA1. For the 
IPs3 total protein lysates of HEK293-T and stable T98G glioma cells were used. The 
western blot analysis of the IP eluates revealed that the purified CAMTA1 antibody 
SY6161 clearly precipitated a protein with the expected molecular weight of CAMTA1 
from the HEK293-T as well as from the T98G lysate (Figure 2.7). Since this protein 
has the expected molecular weight and was not detected in the IP control with rabbit 
IgG, it can be assumed that the precipitated protein is indeed endogenous CAMTA1. 
 
Figure 2.7: Immunoprecipitation of endogenous CAMTA1 from HEK293-T and T98G cells via 
the generated antibodies. The purified (purf.) antibody SY6161 precipitated CAMTA1 from 
HEK293-T and T98G total protein lysates. A: Western blot analysis of the IPs using the purified 
SY6160 antibody for CAMTA1 detection. For each IP, material form three 15-cm culture dishes 
were lysed (about 1 % IP-input and 50 % IP-eluate were loaded). B: Western blot result using the 
SY6161 CAMTA1 antibody (of each sample the same amount as in A was loaded).   
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2.1.3. Localization of CAMTA1 
The nuclear localization for atCAMTA1 (59, 60), dmCAMTA (68) as well as for 
mammalian CAMTA2 (61) was already shown previously. Hence, it was assumed that 
human CAMTA1 should also mainly be localized in the nucleus.  
To investigate the subcellular localization of human CAMTA1, all polyclonal 
antibodies motioned in paragraph 2.1.2. were used for immunofluorescence (IF) 
staining of CAMTA1. A first screening using different cell lines (HEK293-T as well as 
the stable glioma cell lines LNT229 and T98G) revealed that for all antibodies the 
strongest signal intensity was observed in T98G cells (data not shown). Therefore, these 
cells were used to further examine the localization of CAMTA1 and to confirm that the 
observed signals indeed originate from endogenous CAMTA1. For this purpose, 
CAMTA1 was knocked down in these cells using CAMTA1 siRNA1 and siRNA2. 
The knockdown was also validated on mRNA level via qRT-PCR resulting in an 
approximately 50 % decrease of the CAMTA1 mRNA level for siRNA 1 (compared to 
the control siRNA). However, no knockdown was measured on mRNA level in the case 
of siRNA 2 (data not shown). In the IFs, the antibodies showed clearly different 
detection patterns. For the 1886 antibody a nuclear signal was detected, which was also 
decreased in the cells transfected with siRNA 1 (Figure 2.8). In contrast, the 1901 
antibody caused a signal that was distributed over the whole cell (Figure 2.9, page 39). 
The intensity of this signal was not reduced in the siRNA1-knockdown cells. The 
antibodies SY6160 and SY6161 which were generated in this thesis show similar 
detection patterns: Here, the strongest signal was observed in a region adjacent to the 
nucleus. However, this signal was not changed by the knockdown [see Figure 2.10 
(page 40) for SY6160 and Figure 2.11 (page 41) for SY6161]. Besides this signal, for 
both antibodies a faint nuclear signal was also observed, but it was difficult to determine 
if this signal is indeed reduced within the cells when CAMTA1 was knocked down. 
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Figure 2.8: Immunofluorescence of endogenous and knocked down CAMTA1 using the 1886 
antibody. Knockdown for subsequent IF was performed in T98G cells transfected twice with the 
indicated siRNAs. The 1886 antibody showed a clear nuclear signal which was decreased for 
CAMTA1 siRNA1 [for this knockdown also a reduction of CAMTA1 mRNA of approximately 
50 % compared to control siRNA (ctrl. siRNA) was measured via qRT-PCR; data not shown]. 
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Figure 2.9: Immunofluorescence of endogenous and knocked down CAMTA1 using the 1901 
antibody. This IF reflects the same CAMTA1 knockdown as depicted in Figure 2.8. In contrast 
to the 1886 antibody, the 1901 antibody showed no specific nuclear signal and also no signal 
decrease for CAMTA1 siRNA1-transfected cells. 
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Figure 2.10: Immunofluorescence of endogenous and knocked down CAMTA1 using the 
purified SY6160 antibody. This IF reflects the same CAMTA1 knockdown as depicted in Figure 
2.8. For this antibody, the strongest signal was observed close to nucleus, whereas the nuclear 
signal was only faint. However, basically no change of the signal intensities was observed for the 
CAMTA1-knockdown cells. 
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Figure 2.11: Immunofluorescence of endogenous and knocked down CAMTA1 using the 
purified SY6161 antibody. This IF reflects the same CAMTA1 knockdown as depicted in Figure 
2.8. The SY6161 antibody had a similar detection pattern as the SY6160 antibody. However, the 
overall signal intensity observed was stronger compared to SY6160. Also for this antibody a (weak) 
nuclear signal was detected. This signal seemed to be reduced in siRNA1-knockdown cells. 
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It was also investigated if CAMTA1 shows nuclear localization in western blots using 
subcellular fractions. Therefore, nuclear extracts were prepared from HEK293-T and 
HeLa cells.  
As before, the previously described CAMTA1 antibodies showed different detection 
patterns in western blots of cytoplasmic and nuclear fractions from HEK293-T cells 
(Figure 2.12). The 1886 antibody detected a band running at 180 kDa, which had the 
same intensity in cytoplasmic and nuclear fractions. In the nuclear fraction the most 
intense signal, however, was a double band slightly lower than 180 kDa. This double 
band was less intense in the cytoplasmic fraction (Figure 2.12 A, left panel, lane 1). In 
contrast, the band with the strongest signal visualized by the 1901 antibody (slightly 
bigger than 180 kDa) was equally intense in cytoplasmic and nuclear fractions (Figure 
2.12 A, right panel). In the case of the SY6160 antibody, several bands appeared in the 
nuclear fraction. Among these, a band slightly bigger than 180 kDa was most intense 
and was detected with lower intensity in the cytoplasmic fraction (Figure 2.12 B, left 
panel, lane 1). The SY6161 antibody visualized a band around 180 kDa, which was 
equally strong in both fractions, similar to the detection pattern of the 1901 antibody 
(Figure 2.12 B, right panel). Additionally, this antibody detected also a band running a 
little bit lower than 180 kDa, that appeared exclusively in the nuclear fraction (Figure 
2.12 B, right panel, lane 2).  
The newly generated antibodies (SY6160 and SY6161) were also used in western blots 
with subcellular fractions of HeLa-S3 suspension culture cells. For the preparation of 
these fractions, the raw nuclear fraction was further purified resulting in a soluble and 
insoluble nuclear fraction. In case of the SY6160 antibody, several bands appeared 
(Figure 2.13 A, page 44). One band around 180 kDa was detected in the whole cell 
lysate (lane 1) as well as in the cytoplasmic (lanes 2 and 3) and nuclear fraction (lanes 4 
and 5). Also a smaller band (between 130 and 180 kDa) was observed in the nuclear 
fraction (lanes 4 to 6), but not in the cytoplasmic fraction. The SY6161 antibody 
showed a similar result, however the detection pattern for this western seems to be more 
specific compared to the SY6160 antibody (Figure 2.13 B). Interestingly, the detected 
band running slightly lower than 180 kDa was observed within the nuclear fraction 
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mainly in the raw nuclear extract and in the sample containing the insoluble parts of the 
nucleus, but was not present in the cytoplasmic fraction (Figure 2.13 B). 
 
Figure 2.12: Subcellular fractionation of HEK293-T cells for CAMTA1 localization. For the 
fractionation, material form eight 15-cm cell culture dishes were lysed. Comparable amounts of 
cytoplasmic (cyt.) and nuclear fraction (nuc.) were loaded for the particular western blots. A: 
Western blot results using the CAMTA1 antibodies 1886 (left panel) and 1901 (right panel). The 
(double) band with strongest signal detected by the 1886 antibody ran slightly lower than 180 kDa 
and was more intense in the nuclear fraction. Using the 1901 antibody, a band running higher 
than 180 kDa was detected with high intensity (equal in both fractions). B: Western blot analyses 
with the new generated, purified (purf.) CAMTA1 antibodies. Multiple bands in cyt. and nuc. 
fractions were detected by the SY6160 antibody. In contrast, the SY6161 antibody showed a 
similar detection pattern as the 1901 antibody. C: Purity of the cyt. and nuc. fraction was 
controlled by western blots for lamin A/C (left panel) and α-Tubulin (right panel). 
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Figure 2.13: Subcellular fractionation of HeLa-S3 suspension culture cells to detect endogenous 
CAMTA1 by the generated antibodies. Comparable amounts of each fraction was loaded for the 
particular western blots. A: Western blot analysis using the purified (purf.) SY6160 antibody: 
SY6160 detected a band around 180 kDa, which was observed in the whole cell lysate (WCL; lane 
1), the cytoplasmic (cyt.) fractions (lane 2 and 3), as well as in the total (lane 4) and soluble (lane 
5) nuclear (nuc.) fractions. The same band was also detected by the SY6161 antibody (B). 
However, this antibody visualized also a band slightly lower than 180 kDa, which was exclusively 
found (besides the WCL) in the total and insoluble nuc. fractions (lanes 4 and 6). C: Purity of the 
cyt. and nuc. fractions was controlled by western blots for lamin A/C (left panel) and α-Tubulin 
(right panel). 
 
 
2.1.4. A potential CAMTA1 interaction partner: Nkx2.2 
As pointed out in the working model for this thesis (see paragraph 1.6), we 
hypothesized that Nkx2.2 could be an interaction candidate for CAMTA1. It was 
thought, that this potential interaction is similar to the interaction between Nkx2.5 and 
CAMTA2 in the heart, which was reported previously (61). 
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To provide first evidences for an interaction between both proteins, mycCAMTA1 and 
N-terminally FLAG/HA-tagged Nkx2.2 (FH-Nkx2.2) were simultaneously 
overexpressed in HEK293-T cells. After 48 hours of overexpression, mycCAMTA1 
was immunoprecipitated using anti-myc Sepharose® beads. In subsequent western blot 
analysis of the eluate, the co-precipitation of FH-Nkx2.2 was examined. As controls, 
N-terminally myc-tagged constructs of wildtype human Dicer, Exportin 5 (XPO5), 
Argonaute 2 (Ago2), and Target of EGR1 protein 1 (TOE1) were used. Additionally, 
instead of FH-Nkx2.2, FH-GFP was overexpressed together with each of the above 
mentioned myc-tagged proteins. As shown in Figure 2.14, FH-Nkx2.2 was detected in 
the eluate of the mycCAMTA1 precipitation (lane 6 of the anti-HA western blot) but 
not for the immunoprecipitations of the other myc-tagged proteins (lanes 7 to 10 of the 
anti-HA western blot). 
 
Figure 2.14: Interaction between mycCAMTA1 and FLAG/HA-Nkx2.2. The indicated myc-
tagged proteins were overexpressed either together with FH-Nkx2.2 or with FH-GFP. Lane 6 of 
the anti-HA western blot (lower panel) showed a distinct signal for FH-Nkx2.2, which was co-
immunoprecipitated by mycCAMTA1 (anti-myc western blot, upper panel). For western blot 
analysis about 1 % IP-input and 20 % IP-eluate was loaded.  
 
 
46 2. Results  
 
 
This interaction was studied more in detail by mapping CAMTA1 for a potential 
Nkx2.2 interaction region. Therefore, several deletion mutants or truncated versions of 
CAMTA1 (all N-terminally myc-tagged) were generated as illustrated schematically in 
Figure 2.15 A. For CAMTA2 it was reported before that the CG-1 domain, which is 
located in close proximity to the N-terminus, is responsible for interaction with Nkx2.5 
and that the TAD probably stabilizes this interaction (61). Accordingly, the 
corresponding region of CAMTA1 was completely deleted resulting in a truncated 
CAMTA1 version lacking the amino acids from 1 to 600. This construct was termed as 
"CAMTA1 ΔN600". In another construct ("CAMTA1 ΔC") the complete C-terminus 
was deleted including the ankyrin repeats. Further constructs were "CAMTA1 N+C", 
which is characterized by the fusion of the N- and C-terminus and lacks the region 
between amino acid 600 and 1054, "CAMTA1 M" consisting exclusively of the middle 
region of CAMTA1 bearing the TIG domain, and "CAMTA1 C", which is basically 
the CAMTA1 C-terminus including the ankyrin repeats. 
Each of the mycCAMTA1 constructs was overexpressed in HEK293-T cells either 
together with FH-Nkx2.2 or with FH-GFP, followed up by anti-myc IPs. The eluate 
of each IP was analyzed via western blot for detection of FH-Nkx2.2 [Figure 2.15 
B(2)]. Remarkably, FH-Nkx2.2 was co-precipitated for every CAMTA1 construct. 
However, minor differences in the signal intensity were observed: The co-IP by 
mycCAMTA1 M construct showed the strongest signal for FH-Nkx2.2 in western 
blots [Figure 2.15 B(2), lane 10], whereas the FH-Nkx2.2 signal was weakest for 
mycCAMTA1 C. FH-Nkx2.2 was detected with similar signal intensity in each eluate 
of the co-IPs with the other mycCAMTA1 constructs (wildtype CAMTA1, 
CAMTA1 ΔN600, CAMTA1 N+C, and CAMTA1 ΔC).  
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Figure 2.15: Mapping the interaction between CAMTA1 and Nkx2.2. A: Schematic illustration 
of the different mycCAMTA1 constructs to reveal a potential interaction site. B: The indicated 
constructs were overexpressed in HEK293-T cells together either with FH-Nkx2.2 or FH-GFP. 
(1) Western blot against myc-tag (about 1 % IP-input and 20 % IP-eluate was loaded). (2) 
Western blot against HA-tag (1 % IP-input and 30 % IP-eluate was loaded). FH-Nkx2.2 was 
detected for basically all mycCAMTA1 constructs. However, the signal for FH-Nkx2.2 was 
strongest in the mycCAMTA1 M co-IP (lane 10) and only weak in the mycCAMTA1 C co-IP 
(lane 12). 
 
For the above-mentioned studies, interactions between overexpressed (tagged) proteins 
were examined. To further prove a potential CAMTA1/Nkx2.2 interaction, it was 
investigated if also the endogenous proteins form a complex that can be 
immunoprecipitated. Since stable LNT229 glioma cells show a strong nuclear signal for 
endogenous Nkx2.2 in immunofluorescence (see paragraph 2.2.1.), these cells were used 
for the endogenous co-immunoprecipitations. 
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Figure 2.16 shows the western blot result for a co-IP of endogenous CAMTA1. Since 
the purified CAMTA1 antibody SY6161 was efficient to immunoprecipitate 
endogenous CAMTA1 from total cell lysates of HEK293-T and T98G (Figure 2.7.), 
this antibody was used for the CAMTA1 co-IP. Moreover, the subsequent western blot 
analysis for CAMTA1 was also performed with this antibody. For the co-IP, LNT229 
cells were lysed using IP-lysis buffer 1 (containing sodium deoxycholate, see also 
paragraph 4.2.3.2.), which was supplemented with a nuclease (Benzonase®). 
 
Figure 2.16: Immunoprecipitation of endogenous CAMTA1 to investigate a potential interaction 
with Nkx2.2 in LNT229 cells. The IP of endogenous CAMTA1 was performed using the purified 
(purf.) SY6161 CAMTA1 antibody. Western blot analysis of the IPs was performed with the 
SY6161 antibody (upper panel) and a Nkx2.2 specific antibody (lower panel). CAMTA1 was 
immunoprecipitated (lane 2, upper panel) but endogenous Nkx2.2 was not co-precipitated (lane 2, 
lower panel). For the IP and the IP-control (IgG ctrl.) material from ten 15-cm cell culture plates 
were used each; about 0.2 % IP-input/IP-supernatant (SN) and 50 % IP-eluate were loaded. 
 
By using a monoclonal antibody against Nkx2.2 in the western blot analysis, the 
endogenous protein was only detected in the input and IP-supernatant samples, but not 
in the IP-eluate (Figure 2.16, lower panel). 
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When endogenous Nkx2.2 was immunoprecipitated, an interaction between the two 
endogenous proteins was also not observed (Figure 2.17). Thereby, the co-IP eluates 
were analyzed for CAMTA1 co-immunoprecipitation via western blots using both 
newly generated CAMTA1 antibodies (SY6160 and SY6161). Since it was believed 
that sodium deoxycholate has possibly a negative effect on the interaction, the lysis 
conditions were changed for this co-IP. Here, cells were lysed by hypotonic treatment 
(with IP-lysis buffer 2) and the nuclear proteins were extracted by adding NaCl 
afterwards (see also paragraph 4.2.3.2.). Moreover, the lysis for this co-IP was carried 
out without using any nuclease since it was thought that DNA is maybe required for a 
stable interaction of CAMTA1 and Nkx2.2.  
 
Figure 2.17: Immunoprecipitation of endogenous Nkx2.2 to investigate a potential interaction 
with CAMTA1 in LNT229 cells. The IP of endogenous Nkx2.2 was performed using a Nkx2.2 
specific antibody. A: Western blot analysis of the IPs using the purified (purf.) CAMTA1 
antibody SY6160. B: Western blot analysis with the purified SY6161 antibody. In both western 
blots, CAMTA1 was not detected in Nkx2.2-IP samples. C: The IP was validated by western blot 
analysis for Nkx2.2. For the IP and the beads only-control (beads ctrl.) material from ten 15-cm 
cell culture plates was used each; about 0.2 % IP-input/IP-supernatant (SN) and 50 % IP-eluate 
were loaded. 
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2.2. Characterization of Nkx2.2 
The transcription factor Nkx2.2 was identified as a potential CAMTA1 interaction 
factor (as described in the previous chapter) and is known as a tumor suppressor 
candidate for glioblastomas. This chapter points out the further biochemical and 
functional characterization of Nkx2.2. 
  
2.2.1. Nuclear localization of Nkx2.2 
Hessabi et al. reported before that (overexpressed) Nkx2.2 showed nuclear localization 
and its HD contains two functional nuclear localization signals (NLS) (144). Both NLS 
are necessary for an efficient nuclear import (144).  
Since it was thought that Nkx2.2 act as a transcription factor in glioma pathogenesis, 
the nuclear localization of the endogenous protein was analyzed in several different 
glioma-derived cell lines. This was assayed via IFs using a monoclonal antibody against 
endogenous Nkx2.2. Thereby, Nkx2.2 localization was investigated for the stable 
glioma cell lines T98G and LNT229 in comparison to the non-glioma-related cell line 
HEK293-T. Whereas in T98G cells, Nkx2.2 was barely detectable, HEK293-T 
showed a faint and LNT229 a strong nuclear fluorescence signal for Nkx2.2 (data not 
shown). Using an siRNA-mediated knockdown of endogenous Nkx2.2 in LNT229 
cells it was proven that the detected signal originates from endogenous Nkx2.2 (Figure 
2.18). 
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Figure 2.18: Nuclear localization of endogenous Nkx2.2 in LNT229 cells. For the IF, Nkx2.2 was 
knocked down using an siRNA targeting Nkx2.2. The IF was performed 48 h after siRNA 
transfection with a Nkx2.2-specific antibody. The IF showed a clear decrease of the nuclear 
Nkx2.2 signal. 
 
2.2.2. Nkx2.2 interaction partners 
In paragraph 2.1.4. it was comprehensively illustrated that CAMTA1 was considered to 
be a potential interaction partner for Nkx2.2. To validate this and to identify other 
putative interaction partners, overexpressed FH-Nkx2.2 was immunoprecipitated and 
co-immunoprecipitated proteins were analyzed using mass spectrometry. As negative 
controls, the empty expression vector and a FH-GFP encoding plasmid were used. 
Immunoprecipitation was performed with pre-coupled anti-FLAG agarose. The IP 
efficiency was controlled by western blot with 20 % of each eluate (Figure 2.19 A, page 
53). Afterwards, 50 % of each eluate was used for a second SDS-polyacrylamide gel 
electrophoresis. This gel was then stained with silver nitrate until specific bands were 
clearly visible (Figure 2.19 B). Finally, several bands that appeared exclusively in the 
eluate of the FH-Nkx2.2 IP (named a to n in Figure 2.19 B) were cut out and analyzed 
by mass spectrometry. To identify proteins, mass spectrometric raw data were 
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interpreted using the Mascot software tool (see paragraph 4.2.3.8.). Table 2.1 (page 54) 
shows for each band the identified protein that appears at the first position with the 
highest Mascot protein score. In general, the higher the score value is, the more 
peptides were identified from a particular protein, which correlates with the significance 
of a match for a distinct protein. A complete list for mass spectrometric analysis of the 
FH-Nkx2.2 IP can be found in the appendix (see page 151).  
In band k to n, Nkx2.2 was identified at top position, indicating a clear enrichment of 
FH-Nkx2.2 by the IP. This is also reflected by the western blot analysis of the IP 
(Figure 2.19 A). Interestingly, band m and n contain also Nkx2.3 (another Nk-2 class 
protein) with a relative high score (around 200). However, neither CAMTA1 nor 
previously reported Nkx2.2 interaction partners such as histone deacetylase I (135) or 
Olig2 (145) were detected for this co-IP. Among the other proteins identified are some 
nuclear proteins (e.g. Structural maintenance of chromosomes protein 1A), but it is 
difficult to determine if indeed specific Nkx2.2 interaction partners were co-
immunoprecipitated. Yet, based on the identities and functions (if known) of these 
proteins as well as on the knowledge about previously studied cellular processes 
involving Nkx2.2, none of these was considered to be a reasonable candidate for Nkx2.2 
interaction.  
Although the IP of FH-Nkx2.2 was successful, the other proteins identified by mass 
spectrometry were most likely non-specifically co-precipitated, with the exception of 
Nkx2.3. This co-IP of Nkx2.3 was presumably a result of a heterodimerization between 
FH-Nkx2.2 and Nkx2.3 (discussed in paragraph 3.2.1.). 
2.2. Characterization of Nkx2.2 53 
 
 
 
Figure 2.19: Screening for potential Nkx2.2 interaction partners. FLAG/HA-tagged Nkx2.2 
(FH-Nkx2.2) was overexpressed in HEK293-T cells and subsequently precipitated (anti-FLAG 
IP). For each IP transfected cells from three 15-cm cell culture plates were used. A: Western blot 
control of the IPs using an antibody against the HA-tag (upper panel) and a Nkx2.2 specific 
antibody (lower panel). [About 1 % of the IP-inputs (lanes 1 to 3) and 20 % of each IP-eluate 
(lanes 4 to 6) were loaded]. B: PAGE and subsequent silver straining to identify unique protein 
bands (a to n) in the eluate of the FH-Nkx2.2 IP (lane 2). The particular bands were cut out and 
analyzed via mass spectrometry (for the PAGE, 50 % of each IP-eluate was loaded) 
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Table 2.1: Results of the mass spectrometric analysis of  the FH-Nkx2.2 IP (shown in Figure 
2.19). Only proteins with the highest Mascot score identified in the particular bands (a to n) were 
listed here. For a full list, see appendix (page 151). 
band  protein identified at top position molecular
weight [kDa] 
score 
a Myosin-9 226.4 842.1 
b Structural maintenance of chromosomes protein 1A 143.1 257.4  
c Heterogeneous nuclear ribonucleoprotein U 90.5 678.2  
d Kinesin-like protein KIF11 119.1 981.8  
e Importin subunit beta-1  97.1 475.9  
f X-ray repair cross-complementing protein 5 82.7 1495.8 
g 78 kDa glucose-regulated protein 72.3 2489.4 
h Heat shock 70 kDa protein 1A/1B 70.0 2695.2 
i Tubulin beta chain  49.6 1245.6 
j Elongation factor Tu, mitochondrial 49.5 1293.7 
k Homeobox protein Nkx-2.2 30.1 1046.9 
l Homeobox protein Nkx-2.2 30.1 2075.1 
m Homeobox protein Nkx-2.2 30.1 3899.2 
n Homeobox protein Nkx-2.2 30.1 2982.4 
 
 
2.2.3. Investigation of a putative regulation by microRNAs 
As outlined before, miRNAs play an important role during cancer development and 
progression (oncomiRs). In gliomas, respectively glioblastomas, several onocmiRs were 
identified previously (see paragraph 1.3.2.). Hence, if Nkx2.2 is really a tumor 
suppressor protein in glioma biology, one could speculate that it is potentially down-
regulated by certain oncomiRs. To support this hypothesis, the 3'-UTR of Nkx2.2 was 
analyzed using microRNA.org and TargetScan 6.2 to search for predicted miRNA 
binding sites. Remarkably, the 3'-UTR contains a predicted target site for miRNAs, 
which have the same seed sequence and arise from the miR-17~92 cluster or its paralogs 
(Figure 2.20 A). Since miR-17 and miR-106b are specifically enriched in CD133-
positive cells (see paragraph 1.3.2.), this thesis investigated more closely if Nkx2.2 is 
indeed a target for miR-17 and/or miR-106b. 
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To validate the predicted miR-17/-106b target site, the Nkx2.2 3'-UTR was fused to 
firefly luciferase. The construct was expressed from a reporter vector also coding for 
renilla luciferase (constant renilla activity was used for normalization of the firefly 
activity). As negative control, the seed sequence of the miR-17/-106b target site was 
mutated into a BamHI restriction site. Furthermore, positive controls were generated by 
cloning the fully complementary sequences of miR-17 and miR-106b into the luciferase 
reporter vector. The target site validation was assayed by co-tansfecting stable T98G 
glioma cells with the dual luciferase reporter plasmid and 2'-O-methylated antisense 
inhibitors against miR-17 or miR-106b. These chemically modified RNA antisense 
oligonucleotides inhibit endogenous miRNAs in a very efficient way (146). Therefore, if 
the Nkx2.2 3'-UTR is regulated by miR-17 and/or miR-106b, the normalized firefly 
activity should be significantly higher in comparison to a control inhibitor (de-
repression). Here, the inhibitor of the liver-specific miR-122 was used as control. 
Figure 2.20 B and C show the specific inhibition of either miR-17 or mir-106b. In both 
cases, the normalized activity of the firefly luciferase fused to the wildtype Nkx2.2 3'-
UTR shows no obvious difference compared to the firefly luciferase with the mutated 
3'-UTR. This was also observed when both miRNAs were inhibited at once (Figure 
2.20 D).  
The assays were repeated several times, also using other cell lines such as LNT229 cells, 
resulting in basically the same outcome as shown in Figure 2.20 for one assay with 
T98G cells. Furthermore, the validation of the miR-17/-106b target site was also 
assayed in  a different way  by miR-17 and/or miR-106b overexpression using plasmids 
that encode for the corresponding miRNA precursors, or by co-transfection of a pre-
annealed miR-17 and/or miR-106b duplex mimics. Also in these assays, the firefly 
luciferase with the Nkx2.2 3'-UTR was not affected significantly by elevated miR-17 or 
miR-106b concentrations, whereas the positive controls (fully complementary sequences 
of miR-17 and miR-106b fused to firefly luciferase) clearly responded upon the elevated 
concentrations of these miRNAs (strong reduction of the firefly luciferase activity) (data 
not shown). 
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Figure 2.20: Nkx2.2 as a potential target for miR-17-5p and miR-106b. A: Nkx2.2 3'-UTR 
illustrated schematically. Analysis via miRNA.org TargetScan 6.2 revealed a target site for miR-
17-5p and miR-106b within the 3'-UTR. B to D: Dual luciferase reporter assays using T98G 
cells. For the assays the following constructs fused to firefly luciferase were used: wildtype 3'-UTR 
of Nkx2.2 (Nkx2.2), miR-17/106b target site mutated Nkx2.2-3'-UTR (Nkx2.2[mut]), full 
complementary (artificial) target sites of miR-17 or miR-106b (miR-17 or miR106b site). The 
particular miRNAs were specifically depleted as indicated: miR-17-5p (B), miR-106b (C), and 
simultaneous inhibition of miR-17/106b (D); a liver-specific miR-122 inhibitor was used as 
control (ctrl.). For all assays no significant de-repression of the Nkx2.2-3'-UTR reporter was 
observed. 
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Taken together, the results of the different reporter assays for the validation of the 
predicted miR-17/-106b target site in the Nkx2.2 3'-UTR suggest that Nkx2.2 is 
presumably not regulated by miR-17 or miR-106b.  
To further investigate the general regulation of the Nkx2.2 3'-UTR by miRNAs, a key 
factor of the miRNA-directed regulation mechanism, the Ago protein, was prevented 
from carrying out its function as mediator of silencing. This was achieved by 
overexpression of a 85 amino acid long peptide which binds Ago proteins with high 
affinity (Hauptmann et al., unpublished data). This strong binding affinity of the 
peptide (termed "T6B") is due to the fact that T6B consists basically of an interaction 
motif of TNRC6B, which is part of the TNRC6B Ago binding region (147). Hence, 
the T6B competes with full-length endogenous TNRC6B for Ago binding.  Because of 
the high concentration of T6B upon overexpression, most of the Ago proteins are 
bound by T6B and are thus prevented for interaction with endogenous TNRC6B (and 
probably other TNRC6 proteins) (Hauptmann et al., unpublished data). It can be 
assumed that this makes miRNA-guided silencing virtually inoperable. Therefore, this 
peptide can be used to investigate a general miRNA-directed regulation of distinct 
transcripts.   
For the dual luciferase assays using T6B, the expression plasmid coding for T6B with an 
N-terminal FLAG/HA-tag and a C-terminal GFP-tag was co-transfected into cells 
together with the reporter plasmids. In addition to reporter plasmid containing the 
wildtype Nkx2.2 3'-UTR, plasmids with the mutated Nkx2.2 3'-UTR (miR-17/-106b 
seed sequence mutated), the CAMTA1 3'-UTR, the HMGA2 3'-UTR, the mutated 
HMGA2 3'-UTR, and with the empty multiple cloning site were used as controls. 
Thereby, the mutated HMGA2 3'-UTR is characterized by the mutation of all seven 
let-7 target sites [according to (148)]. The normalized firefly activities of the 
corresponding constructs were analyzed in comparison to GFP overexpression. As a 
control, a mutated version of the peptide was co-transfected together with each of the 
reporter constructs. This mutant is characterized by lacking all tryptophan residues and 
can thus not interact with Ago proteins (Hauptmann et al., unpublished data). 
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Figure 2.21 A (left panel) shows a "T6B-assay" carried out with HeLa cells. Here, 
firefly luciferase-CAMTA1 3'-UTR and firefly luciferase-HMGA2 3'-UTR clearly 
responded to T6B overexpression (compared to GFP). In contrast, the activity of the 
firefly luciferase fused to the Nkx2.2 3'-UTR showed no change upon overexpression of 
T6B. When the mutated T6B was overexpressed (Figure 2.21 A, right panel), no firefly 
luciferase construct was de-repressed, indicating that the assay was successful.  
The assay was also repeated in stable T98G glioma cells (Figure 2.21 B) resulting in a 
similar outcome as observed for HeLa cells, although the de-repression of the firefly 
luciferase-CAMTA1-3'-UTR and firefly luciferase-HGMA2-3'-UTR constructs was 
not as strong as in the assays with HeLa cells. 
 Since the T6B-assays using the Nkx2.2 3'-UTR reporter construct resulted in no clear 
de-repression, the general question emerged whether Nkx2.2 is regulated by miRNAs at 
all. This is discussed more closely in paragraph 3.2.2. 
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Figure 2.21: Investigation via dual luciferase reporter assays if Nk2.2 is generally regulated by 
miRNAs in HeLa and T98G cells. For the assays the following constructs fused to firefly 
luciferase were used: The wildtype 3'-UTR of Nkx2.2, CAMTA1, and HMGA2 as well as the 
mutated 3'-UTRs of Nkx2.2 (Nkx2.2[mut]; miR-17/106b target site mutated) and HMGA2 
(HMGA2[mut]; all let-7 sites mutated). Additionally, the T6B peptide, which disrupts Ago 
function, or the mutated peptide (T6B-peptide[m]) were overexpressed, as indicated. A: Assay 
performed in HeLa cells. Overexpression of T6B caused a significant de-repression of the 
CAMTA1-3'-UTR as well as the HMGA2-3'-UTR  but had basically no effect on the Nkx2.2-
3'-UTR (left panel). In contrast, no de-repression at all was observed when the mutated T6B was 
overexpressed (right panel). B: The assay using T98G cells showed a similar outcome as the assay 
with HeLa cells. In A and B significance was assessed by two-sided Student's t-test (** P < 0.01, 
*** P < 0.001)   
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2.2.4. The effect of Nkx2.2 on glioma tumor biology 
2.2.4.1. Nkx2.2 overexpression leads to decreased neurosphere formation of primary 
glioblastoma cells 
As mentioned before, isolated primary glioblastoma cells show neurosphere-like growth 
when they are cultivated under stem cell conditions. Muraguchi et al. reported 
previously that Nkx2.2 overexpression led to significantly reduced neurosphere 
formation of mouse and human primary glioblastoma cells (142). In order to examine if  
this effect is reproducible for other human primary glioblastoma cell lines, Nkx2.2 was 
overexpressed in R11 and ZH161 primary glioblastoma cells. A negatively affected 
neurosphere formation upon Nkx2.2 overexpression of these cells would further support 
the role of Nkx2.2 as tumor suppressor for glioblastomas. Indeed, a reduced 
neurosphere formation due to Nkx2.2 overexpression was observed for both R11 and 
ZH161 cells (Figure 2.22, page 62). For R11 cells the combined results of two 
biological replicates is shown in Figure 2.22 A. Thereby, the significance of the effect 
caused by Nkx2.2 was not that strong (P = 0.07) as observed for ZH161 cells (Figure 
2.22 B). Here, the diagramed result arises from four biological replicates and it shows a 
significantly reduced neurosphere formation in response to Nkx2.2 overexpression. 
It was also investigated in this thesis if the deletion or the mutation of one critical 
residue of the Nkx2.2 homeobox binding domain has an effect on neurosphere 
formation. For the exchange of one single amino acid in the DNA binding domain, 
structural information preciously published for Nkx2.5 was used (115). As mentioned 
before, tyrosine 191 of Nkx2.5 is essential for sequence specific recognition of the NK-
response element (NKE) by the homeobox binding domain (115). Since this domain is 
highly conserved among Nk-2 family members, the corresponding tyrosine of Nkx2.2 
(Y181) was mutated to cystein (referred to as "Nkx2.2Y181C"). In theory, both the 
homeobox deletion mutant (referred to as "Nkx2.2ΔHD") and Nkx2.2Y181C should 
not be able to bind DNA. This disrupts most likely the function of these mutants to act 
as transcription factors. It was further hypothesized that thus these mutants probably 
lose the capability to trigger a tumor suppressive effect. Such loss-of-function mutants 
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would in turn lead to a neurosphere formation similar to the negative control when 
these constructs are overexpressed in primary glioblastoma cells. However, both 
Nkx2.2Y181C and Nkx2.2ΔHD were still able to reduce the number of spheres in 
comparison to the control (Figure 2.23, page 63). Here, it appears that the 
overexpression of the deletion mutant (Nkx2.2ΔHD) had a milder effect, while 
Nkx2.2Y181C and the wildtype strongly reduced the formation of neurosphere-like 
colonies. Yet, this effect was not significant compared to the wildtype (this is 
presumably also due to the fact that this result was gained from only two biological 
replicates). 
Summing up, the effect of Nkx2.2 on neurosphere formation reported previously was 
confirmed in this thesis. This further supports the idea of Nkx2.2 as a tumor suppressor 
for glioblastomas. Regarding the mutants, one would expect a loss of function reflected 
by a neurosphere formation similar to the control. This was not the case, in particular 
for Nkx2.2Y181C. A possible explanation for this is discussed in paragraph 3.2.3. 
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Figure 2.22: Nkx2.2 reduces the formation neurosphere-like colonies. Nkx2.2 was overexpressed 
in primary glioblastoma cells. A: Neurosphere assay using R11 cells. The box blot shows combined 
results from two biological replicates (n: total number of wells). B: Neurosphere formation of 
ZH161 was significantly repressed by Nkx2.2 overexpression. For the box blot results from four 
biological replicates were combined (n: total number of wells). In A and B significance was 
assessed by two-sided Student's t-test (** P < 0.01).   
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Figure 2.23: Effect of a mutated or deleted Nkx2.2 homeobox-binding domain on neurosphere 
formation of ZH161 cells. Overexpression of Nkx2.2Y181C (point mutation in the HD) and 
Nkx2.2ΔHD (deletion of the entire HD) still reduced the formation of neurosphere-like colonies 
(compared to the empty vector control). The box blot shows combined results from two biological 
replicates (n: total number of wells). Significance was assessed by two-sided Student's t-test (* P < 
0.05).   
 
2.2.4.2. Nkx2.2 expression correlates with glioma outcome 
To further support the previous findings that suggest a role for Nkx2.2 as a tumor 
suppressor in glioblastomas, Nkx2.2 expression data from glioma patients were 
analyzed. These datasets were obtained from the Repository of Molecular Brain 
Neoplasia Data (REMBRANDT) database, which is provided by the U.S. National 
Cancer Institute. Nkx2.2 expression levels from patients diagnosed with all types of 
gliomas (low-grade as well as high-grade such as glioblastomas) were correlated to 
patient survival and plotted as Kaplan-Meier survival curve in Figure 2.24 A (page 65). 
Strikingly, patients characterized by a higher Nkx2.2 expression survived significantly 
longer than patients with low or intermediate expression. Moreover, data from patients 
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exclusively suffering from glioblastomas were also analyzed in terms of survival. 
Accordingly, also glioblastoma patients with up-regulated Nkx2.2 expression showed a 
longer survival. However, this higher survival rate is statistically not significant due to 
the low number of samples in this study (data not shown). 
The REMBRANDT database provides also Affymetrix microarray data derived from 
patients with low-, medium-, or high-grade gliomas. These microarray data were used 
to analyze the mRNA expression level of Nkx2.2 in astrocytoma (low-grade glioma) and 
glioblastoma (high-grade glioma) in contrast to samples originating from non-tumor 
brain tissue. As diagrammed in Figure 2.24 B (left panel), Nkx2.2 shows no differences 
concerning its expression pattern for astrocytoma, glioblastoma or non-tumor tissue. 
For comparison, CAMTA1 expression is strongly decreased in astrocytoma and 
glioblastoma tumor samples (Figure 2.24 B, right panel). This expression pattern of 
CAMTA1 was observed and published before (53). 
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Figure 2.24: Nkx2.2 expression correlates with survival of glioma patients. A: Kaplan-Meier 
survival plot for patients (suffering from all types of gliomas) characterized by high (red curve), 
intermediate (green curve), or low (blue curve) Nkx2.2 expression. B: Nkx2.2 expression (left 
panel) in low- (astrocytomas) and high-grade gliomas (glioblastomas; GBM) in comparison to 
CAMTA1 expression (right panel) in low- and high-grade gliomas. In contrast to CAMTA1, 
Nkx2.2 showed similar expression levels in low- and high-grade gliomas as well as in normal brain 
tissue (non-tumor). Expression analysis was performed using the indicated Affymetrix probes on a 
U-133A microarray (n: number of samples). Data for A an B was obtained from the 
REMBRANDT database. 
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2.2.4.3. Nkx2.2 overexpression shows an antiproliferative effect on stable glioma cells 
Since overexpression of Nkx2.2 showed a negative effect on neurosphere formation in 
this thesis and Nkx2.2 was suggested as a tumor suppressor candidate in glioblastomas 
before (142), it was also investigated if Nkx2.2 triggers a potential antiproliferative 
effect. 
To examine the effect of Nkx2.2 overexpression on cell proliferation, stable LNT229 
glioma cells were transfected and the assays were performed as described in paragraph 
4.2.4.3. The effect of Nkx2.2 overexpression was observed in comparison to the 
overexpression of negative controls, namely the Nkx2.2 mutants Nkx2.2Y181C and 
Nkx2.2ΔHD as well as GFP. Cell proliferation was monitored for four subsequent days 
and an effective overexpression of wildtype Nkx2.2 and the mutants was confirmed by 
western blot at the end of the experiment [whereas an efficient expression of GFP was 
verified by fluorescence microscopy (data not shown)]. 
The results were reproduced in three independent experiments. Thereby, Nkx2.2 had a 
striking negative effect on cell proliferation compared to GFP (Figure 2.25 shows the 
result of one experiment). This is consistent with the neurosphere assays. Notably, in 
contrast to the neurosphere assays, the overexpression of Nkx2.2ΔHD showed a clear 
loss-of-function-phenotype reflected by a much higher cell proliferation compared to 
the wildtype protein (Figure 2.25 A). Although the phenotype caused by Nkx2.2Y181C 
was never as strong as observed for Nkx2.2ΔHD, the proliferation rate observed for this 
mutant was still higher than for the wildtype (Figure 2.25 A). 
As described in the working model for this thesis (see paragraph 1.6.), it was assumed 
that Nkx2.2 is able to activate the NPPA gene in the same way as Nkx2.5 does in the 
heart. Moreover, since for ANP an antiproliferative effect was reported before (143), it 
was further hypothesized that the antiproliferative effect observed for Nkx2.2 was 
mediated by NPPA induction. To prove this assumption, total RNA was isolated after 
the proliferation-experiment shown in Figure 2.25 had been performed. Subsequently, 
the mRNA levels of NPPA and its main receptor NPR-A were quantified via qRT-
PCR. An overexpression of Nkx2.2 led indeed to up-regulated mRNA levels of NPPA 
(compared to GFP overexpression), but not of NPR-A (Figure 2.25 C). However, 
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Nkx2.2Y181C resulted also in an elevated NPPA mRNA level although it is not as 
high as caused by overexpressing the wildtype. In contrast, the effect of the deletion 
mutant Nkx2.2ΔHD on NPPA mRNA level is only weak (Figure 2.25 C). 
It was also investigated, if the CAMTA1 mRNA level was affected by the 
overexpression of Nkx2.2 wildtype or the mutants. This was not the case as the qRT-
PCR quantification revealed (Figure 2.25 C). 
 
Figure 2.25: Nkx2.2 causes an antiproliferative effect and elevates the expression of NPPA. A: 
The indicated proteins were overexpressed in LNT229 cells and the cell proliferation was observed 
for four subsequent days. Nkx2.2 overexpression has a clear antiproliferative effect on LNT229 
cells, in contrast to the Nkx2.2ΔHD mutant. Overexpression of Nkx2.2Y181C showed a less 
strong phenotype in comparison to Nkx2.2ΔHD. B: Overexpression was controlled by western 
blot analysis using a Nkx2.2 specific antibody (70 μg of each lysate was loaded). C: Nkx2.2 
overexpression resulted in an increase of the NPPA mRNA-levels, but had no effect on the 
expression of the ANP receptor A (NPR-A) or CAMTA1. 
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2.2.5. NPPA as a potential Nkx2.2 target gene: Only Nkx2.2 with an intact homeobox 
binding domain induces the NPPA promoter 
As already mentioned before, Nkx2.5 regulates the NPPA gene in the heart via binding 
to the NKE sites of the NPPA promoter as a homodimer (115). The same mode of 
action was assumed for Nkx2.2 in the brain.  
In the previous paragraph it was shown that an Nkx2.2 overexpression leads to an 
elevated NPPA mRNA level. This result turns NPPA into a candidate as Nkx2.2 target 
gene. Therefore, it was investigated in this thesis if Nkx2.2 is able to induce the NPPA 
promoter. For this purpose, a firefly luciferase vector containing a 1.5 kb-long DNA 
fragment bearing the distal and proximal NPPA promoter region was used to validate 
the regulation of the NPPA promoter by Nkx2.2 using dual luciferase reporter assays. 
For this assays, HEK293-T cells were used for high transfection efficiency as well as for 
high firefly and renilla expression levels. Thereby, the reporter plasmid was co-
transfected together with an Nkx2.2 expression vector and a renilla luciferase encoding 
plasmid for normalization.  
Remarkably, Nkx2.2 overexpression leads to strongly increased firefly activity compared 
to the empty vector control (three-fold higher activity, cf. Figure 2.26). Moreover, it 
was also examined if the mutants Nkx2.2Y181C and Nkx2.2ΔHD (extensively 
described in the previous paragraph) can still induce the NPPA promoter. As clearly 
depicted in Figure 2.26, both mutants show no effect on firefly activity, which means 
they are not capable of regulating the NPPA promoter anymore.  
In summary, this leads to the conclusion that an intact (wildtype-)HD of Nkx2.2 is 
necessary to induce the promoter of its potential target gene NPPA. In particular, the 
highly conserved tyrosine Y181 is obviously essential for this stimulation (as it is also the 
case for the corresponding tyrosine of Nkx2.5, see paragraph 1.5.1.). It was further 
thought that the induction of NPPA mainly triggers the tumor suppressive effect of 
Nkx2.2 (discussed in paragraph 3.2.3.). 
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Figure 2.26: Nkx2.2 is able to induce the NPPA promoter. Promoter activation was examined via 
dual luciferase assays. The firefly luciferase reporter containing the NPPA promoter was co-
expressed in HEK293-T cells with the indicated constructs. Only wildtype Nkx2.2 characterized 
by an intact HD caused an induction of the NPPA promoter. Significance was assessed by two-
sided Student's t-test (*** P < 0.001).   
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3. Discussion 
3.1. Characterization of CAMTA1 
In this thesis, siRNAs and antibodies against CAMTA1 were generated and established 
as tools to study CAMTA1 in detail. The characterization of CAMTA1 involved the 
investigation of potential target genes and interaction partners. In this regard, an 
interaction between CAMTA1 and Nkx2.2 was investigated. 
 
3.1.1. Establishment of an siRNA-mediated CAMTA1 knockdown and a potential 
function for alternative CAMTA1 transcripts 
All siRNAs against CAMTA1 generated, led to a reduction of the CAMTA1 mRNA 
level. Thereby, siRNA1, 2, and 3 were the most efficient ones. The target sites for the 
particular siRNAs are distributed over the whole CAMTA1 mRNA. However, besides 
this main CAMTA1 transcript, which encodes for the full-length CAMTA1 protein, 
also several alternative transcripts are predicted. These, much shorter transcript variants, 
share either certain 5'-exons or 3'-exons with the main transcript (see also Figure 2.1. 
A), hereinafter termed 5'- or 3'-alternative transcripts. Additionally, most of the 
alternative transcripts carry unique exons. The siRNAs 1, 2, and 3, which caused the 
strongest decrease of the CAMTA1 mRNA level, should also target such 3'-alternative 
transcripts that include the respective exons 16, 17, and 20 of the main transcript (see 
also Figure 2.1. A). 
Yet, it remains unclear if these alternative transcripts have any functional relevance. The 
alternative transcripts can probably emerge by alternative transcription or splicing 
events. Some of these transcript are predicted to encode for CAMTA1 isoforms 
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[according to www.uniprot.org (Q9Y6Y1) or to the UCSC genome browser]. Other  
transcript variants might be long non-coding RNAs since no coding sequence could be 
identified within these transcripts [e.g. CAMTA1 transcript variant 4 (NCBI accession 
number: NR_038934)].  
The 3'-alternative transcripts containing also the last exon (exon 23) of the major 
transcript are of particular interest since this exon encodes for the CAMTA1-3'-UTR. 
The 3'-UTR of CAMTA1 bears several target sites for miR-9/9*, miR-17-5p, and 
miR-106b (53). Alternative transcripts involving this exon contain most likely the same 
functional miRNA target sites as the 3'-UTR of the main transcript. Assuming that 
such alternative CAMTA1 transcripts are indeed expressed, they could function as so-
called "competitive endogenous RNAs" ("ceRNAs") for the above-mentioned miRNAs 
(and others). Such ceRNAs compete for the same set of miRNAs with other RNAs 
having the same miRNA target sites (149). For the tumor suppressor PTEN it was 
shown that a pseudogene called PTENP1 is targeted by the same set of miRNAs since 
the 3'-UTRs of both transcripts are partly identical (150). In this regard, the 3'-UTR of 
PTENP1 functions as a decoy for miRNAs that repress PTEN (150). By this de-
repression mechanism of PTEN, the PTENP1 3'-UTR itself acts as a tumor suppressor 
(150). It has been suggested that almost any kind of RNA sharing common miRNA 
binding sites with another RNA can in principle function as a ceRNA (149). Hence, it 
is conceivable that some of the alternative CAMTA1 transcripts bearing the same 3'-
UTR as the main mRNA act as decoy for the CAMTA1-targeting miRNAs. This 
would be interesting to investigate in the context of glioblastoma progression and, in 
particular, of glioblastoma CSCs genesis. One could speculate that these alternative 
transcripts might be less abundant in glioblastoma CSCs, which would, in turn, increase 
the repression of the CAMTA1 tumor suppressor by certain oncogenic miRNAs such 
as miR-9/9*. 
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3.1.2. Functionality of the polyclonal antibodies against CAMTA1 
Two sets of antibodies against CAMTA1 were extensively tested regarding their 
functionality in western blot, immunoprecipitation, and immunofluorescence. In 
general, all antibodies can detect overexpressed mycCAMTA1 in western blot analyses. 
In contrast, it is rather difficult to determine if these antibodies can indeed detect 
endogenous CAMTA1 since basically no decrease of putative CAMTA1 bands was 
observed for the CAMTA1 knockdown samples. However, all knockdowns were 
proven to be effective on mRNA level via qRT-PCR. Therefore, one could speculate 
that either simply all antibodies cannot detect endogenous CAMTA1 in western blot 
analyses or that CAMTA1 is a very stable protein. The mRNA level generally reflects 
the real protein level only to a certain extent since protein stability also depends on post-
translational modifications such as ubiquitination or SUMOylation. It could be that a 
relatively stable endogenous CAMTA1 protein pool exists which is not affected by an 
siRNA-mediated knockdown immediately (even when the cells were transfected with 
siRNAs twice, as performed for several CAMTA1 knockdowns in this thesis). 
However, the IF using the 1886 antibody (and probably also the IF with the purified 
SY6161 antibody) argues against this hypothesis since it shows a clear reduction of the 
detected nuclear signal in cells with knocked down CAMTA1.  
Western blot, IF and IP are different experimental methods and an antibody which is 
useful for one of these applications is not likewise suitable for the other. In this regard, 
the 1886 antibody turned out to be the best antibody valuable for IFs. In contrast, the 
purified SY6161 antibody is probably more useful for immunoprecipitations of 
endogenous CAMTA1 since it precipitated CAMTA1 from HEK293-T, T98G, and 
LNT229 total cell lysates. Moreover, this antibody also detected enriched endogenous 
CAMTA1 in western blot analyses of IP samples. Furthermore, western blot analyses of 
HEK293-T and HeLa subcellular fractions using this antibody also revealed a band, 
which ran slightly lower than 180 kDa (the theoretical molecular weight of CAMTA1) 
and originated from the nuclear fractions of HEK293-T and HeLa cells. This is 
consistent with previously published western blot analyses of subcellular fractions of 
Arabidopsis aerial tissues, which showed clearly that atCAMTA1 was only present in the 
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nuclear fraction (60). The purified SY6161 antibody visualized also a band running 
slightly higher than 180 kDa which was present in the cytoplasmic and nuclear fractions 
of HEK293-T and HeLa cells. This band was also detected by the 1901 antibody with 
strong intensity in western blot analysis of subcellular HEK293-T fractions (and in 
western blot analyses of total lysates from other cell lines such as R11). It is possible that 
this band represents CAMTA1 which is post-translationally modified and thus is also 
associated with the cytoplasmic fraction. However, this is rather speculative and has to 
be further examined.  
 
3.1.3. Interaction between CAMTA1 and Nkx2.2 
It was shown in this thesis, that mycCAMTA1 clearly interacted with FH-Nkx2.2 
when both proteins were simultaneously overexpressed in HEK293-T cells (Figure 
2.14). This supports the hypothesis of an interaction between both proteins as pointed 
out in the working model (see paragraph 1.6.). To further identify an interaction motif, 
mycCAMTA1 was truncated. However, FH-Nkx2.2 was co-immunoprecipitated in 
basically all IPs with these constructs. For the interaction between CAMTA2 and 
Nkx2.5 it was shown that the interaction is mediated by the CG-1 domain and 
stabilized by the TAD of CAMTA2 (61). The corresponding region was deleted in the 
mycCAMTA1ΔN600 construct, but this construct still interacted with FH-Nkx2.2. 
Remarkably, the strongest signal observed for co-precipitated FH-Nkx2.2 was detected 
in western blot analysis for the co-IP by mycCAMTA1 M. In contrast, the weakest 
FH-Nkx2.2 signal was detected for co-IP by the mycCAMTA1 C (Figure 2.17). The 
mycCAMTA1 M construct consists essentially of the TIG domain only, whereas 
mycCAMTA1 C bears exclusively the ankyrin repeats, the CaMBD, and the IQ 
domain. The results of these interaction studies suggest that the TIG domain is possibly 
involved in the interaction between CAMTA1 and Nkx2.2 in contrast to the C-
terminal CAMTA1 domains. This is further supported by previous reports for the TIG 
domain of NF-κB family members, which showed that this domain is also responsible 
for dimerization of these proteins (71-74). Furthermore, the TIG domain of CAMTA2 
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is important for the co-activation of the NPPA promoter in the heart and thus it was 
suggested that this domain is essential for the association of CAMTA2 with Nkx2.5 at 
the NPPA promoter (61). 
However, the CAMTA1 and Nkx2.2 interaction mapping experiments must be 
interpreted with caution. These truncated, tagged constructs are rather artificial and it is 
unpredictable how these will fold within the cells. It is possible that truncated 
CAMTA1 variants expose certain residues or motifs which are not accessible for 
protein-protein interaction in the native protein. This could cause false positive co-IP 
results. To overcome this problem, separated units of CAMTA1 with known folding 
could be used for further interaction experiments. For example, the folding of the TIG 
domain (71, 72) or ankyrin repeats (75, 78, 151) was revealed previously. Moreover, for 
complementation of these interaction studies it should also be considered to include 
mutated versions and/or folding units of Nkx2.2. Point mutations or deletions in the 
particular Nkx2.2 domains affecting the potential interaction between Nkx2.2 and 
CAMTA1 would be interesting to examine. 
Furthermore, the interaction of the endogenous proteins was investigated. These studies 
using LNT229 cells revealed that CAMTA1 and Nkx2.2 could not be co-
immunoprecipitated for the lysates of these cells, regardless of which protein was 
immunoprecipitated. Several reasons for this result are conceivable: It could be possible 
that both transcription factors associate only with chromatin in a certain state. 
Interestingly, Song et al. pulled down a complex of (in vitro translated) CAMTA2 and 
GST-Nkx2.5 with a DNA-oligonucleotide containing the NK-response element 
(NKE) (61). This indicates that DNA might be necessary for the formation of a stable 
interaction between both proteins. Moreover, the interaction could be dependent on 
additional interaction factors which are either lost during IP or are less abundant in 
these LNT229 cells. Latter is indeed possible since these cells are glioma-derived cells 
in which the interaction between CAMTA1 and Nkx2.2 could be directly or indirectly 
disrupted to suppress antiproliferative effects. Nonetheless, the interaction studies were 
performed with these cells since LNT229 cells showed a strong nuclear signal for 
Nkx2.2 (see also paragraph 3.2.1.). 
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3.2. Characterization of Nkx2.2 
Besides its potential interaction with CAMTA1, Nkx2.2 was further characterized 
regarding its subcellular localization in glioblastoma cells, the identification of other 
interaction partners, and the possible regulation by miRNAs. Moreover, this thesis 
provides further evidences that Nkx2.2 acts as a tumor suppressor for glioblastomas. 
The tumor suppressive function of Nkx2.2 and its relevance for other gliomas is more 
closely discussed in the last paragraph of this chapter.   
 
3.2.1. Nuclear localization of Nkx2.2 and identification of interaction partners 
Nuclear localization of Nkx2.2 
Nkx2.2 is clearly localized in the nucleus of LNT229 glioma cells. This is in line with 
the role of Nkx2.2 as a transcription factor that localizes via its internal NLS into the 
nucleus (144). The localization of Nkx2.2 was also investigated for another glioma-
derived cell line, T98G. In these cells Nkx2.2 was also detected exclusively in the 
nucleus, but this signal was very faint in contrast to the strong nuclear Nkx2.2 signal 
observed for LNT229 cells (data not shown). It needs to be further investigated, if the 
different expression of Nkx2.2 is due to a different linage origin of these cell lines. As 
discussed below, Nkx2.2 expression indeed varies between certain types of gliomas. 
 
Search for Nkx2.2 interaction partners  
To gain further insights into the cellular network, into which Nkx2.2 is probably 
integrated, it was intended to identify Nkx2.2 interaction partners via biochemically 
complex isolation, followed by mass spectrometry. However, the mass-spectrometric 
analysis of FH-Nkx2.2 (co-)immunoprecipitates revealed no reasonable candidate for 
Nkx2.2 interaction which could be further investigated (see appendix, page 151). 
Furthermore, neither known Nkx2.2 interaction partners nor the potential interaction 
partner CAMTA1 were identified in this mass spectrometry analysis. Regarding the 
identified proteins, it was thought that these proteins were non-specifically co-
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precipitated (e.g. by an unspecific binding to the used anti-FLAG agarose). Hence, the 
washing conditions and/or the elution procedure probably need to be further optimized 
for this IP. Furthermore, co-IPs using nuclear extracts might be valuable for a more 
selective identification of Nkx2.2-specific interaction partners. 
Nevertheless, the mass spectrometric analysis showed that Nkx2.3 was co-
immunoprecipitated. Thereby, the identified peptides for Nkx2.3 were clearly 
distinguishable, which excludes the possibility that this result was a mass spectrometric 
artifact. The co-IP of Nkx2.3 is not surprising since it was reported previously that Nk-
2 class protein can form heterodimers. For Nkx2.5 a heterodimerization with other Nk-
2 class proteins such as Nkx2.6 and Nkx2.3 was reported before (152). Therefore, the 
identified Nkx2.3 probably resulted from heterodimerization of exogenous, 
overexpressed FH-Nkx2.2 and endogenous Nkx2.3 of HEK293-T cells. 
 
3.2.2. Is Nkx2.2 regulated by miRNAs? 
A computational analysis of the 3'-UTR of Nkx2.2 revealed a binding site for miR-17-
5p and miR-106b, related miRNAs which have an identical seed sequence (see Figure 
2.20 A and Figure 3.1). These miRNAs arise from paralogous miRNA-clusters: miR-
17~92 and miR-106b~25 (50). As already mentioned, both miRNAs are specifically 
enriched in CD133-positive glioblastoma cancer stem cells (53). Hence, it was 
hypothesized in this thesis that Nkx2.2 is potentially repressed by these miRNAs in 
glioblastoma CSCs and that this negative regulation is in turn important for the 
maintenance of these cancer stem cells, as it was previously reported for CAMTA1 by 
Schraivogel et al. (53). 
However, the validation of the miR-17-5p/miR-106b target site in the Nkx2.2 3'-UTR 
via dual-luciferase assay was negative since a specific inhibition of endogenous miR-17-
5p, miR-106b, or both showed no de-repression of the firefly-Nkx2.2 3'-UTR reporter 
construct in T98G stable glioblastoma cells. Although the assay was performed in 
various other cell lines, a clear de-repression effect was never observed upon depletion of 
these particular miRNAs. Vice versa, an exogenous elevation of miR-17-5p and/or miR-
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106b concentrations showed for the Nkx2.2. 3'-UTR reporter construct no decrease of 
the firefly-luciferase activities, in contrast to the positive controls (data not shown). 
Taken together, these results indicate that the 3'-UTR of Nkx2.2 is neither targeted by 
miR-17-5p nor by miR-106b. 
Thus, the question was raised whether Nkx2.2 is regulated by miRNAs at all. To 
address this, the function of Ago proteins as key mediators of miRNA-induced gene 
silencing was disrupted by overexpression of a short peptide derived from TNRC6B 
("T6B"). This leads to a de-repression of the reporter constructs, when they are co-
expressed with T6B. 
Remarkably, it was shown that the two firefly-reporter constructs bearing the 
CAMTA1 3'-UTR or the HMGA2 3'-UTR are both clearly de-repressed when T6B is 
overexpressed. The regulation of the CAMTA1 mRNA by miR-9/9* (and potentially 
also by miR-17-5p) was shown by Schraivogel et al. (53) and also the repression of 
HMGA2 by the miRNA let-7 was demonstrated previously (148, 153). The 
effectiveness of this reporter assay was on the one hand controlled by the use of a 
reporter construct where all let-7 sites of the HMGA2 3'-UTR were mutated. On the 
other hand, a mutated T6B peptide, which does not bind Ago was overexpressed. 
Strikingly, in both cases basically no de-repression of the reporter constructs was 
observed.  
In contrast to the CAMTA1 or HMGA2 3'-UTR, the effect of the overexpressed 
peptide on the Nkx2.2-3'-UTR reporter construct was only weak, but not significant. 
This would imply that Nkx2.2 is not regulated by miRNAs. However, although the 
performed T6B peptide-assay seems to be very effective, it allows only to address the 
effect of endogenously expressed miRNAs of the used cell lines. In this thesis, the T6B 
peptide-assay was carried out with HeLa (and T98G cells). Both miR-17-5p and miR-
106b, which have a predicted target site within the Nkx2.2 3'-UTR are overexpressed in 
HeLa cells (154). Hence, if these miRNAs target Nkx2.2, a de-repression of the 
Nkx2.2-3'-UTR reporter construct should be observed in the T6B peptide-assay with 
HeLa cells, which was not the case. 
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Interestingly, further examination of the Nkx2.2-3'-UTR by TargetScan 6.2 for 
additional miRNA binding sites also revealed potential binding sites for miR-26a and 
for miR-182 (Figure 3.1). These two miRNAs play also a role in glioblastoma 
progression. MiR-26a was already introduced in paragraph 1.3.2. as an oncogenic 
miRNA targeting the tumor suppressor PTEN (48). Thus, the predicted binding site 
also in the Nkx2.2 3'-UTR turns this miRNA to an interesting candidate for Nk2.2 
regulation. An oncogenic function in glioblastomas was also reported for miR-182. This 
miRNA is abundant in high-grade glioblastomas and targets CYLD deubiquitinase, 
which is a negative regulator of the NF-κB signaling pathway (155, 156). In 
glioblastomas, this particular pathway is important for mediating the (de-regulated) 
EGFR signaling (157). 
It was reported previously that miR-26a and miRNA-182 are highly expressed in HeLa 
as well as T98G cells (154, 155, 158, 159). Therefore, these particular miRNAs were 
presumably already included by the T6B assays performed with HeLa and T98G cells 
in this thesis. Still, the Nkx2.2-3'-UTR reporter was only slightly affected by the T6B 
overexpression in T98G cells and showed no tendency of a de-repression in HeLa, as 
already mentioned. However, to interpret the influence of certain miRNAs in the T6B 
peptide-assay, it is also important to consider that miRNA expression profiles may vary 
due to culture conditions or passage number of the used cell lines. Hence, the expression 
of particular miRNAs under assay conditions has to be experimentally assessed (e.g. by 
northern blot analysis). 
 
Figure 3.1: The 3'-UTR of Nkx2.2 has additional binding sites for miR-26a and miR-182. Both 
miRNAs act as oncogenes for glioblastomas. Illustration based on analysis via TargetScan 6.2. 
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To conclude, the results of the T6B peptide assay must be construed carefully. On the 
one hand this reporter assay is efficient, but on the other hand it is to some extent 
artificial and provides no information about the identities of the targeting miRNAs. 
Moreover, due to the overexpression of the reporter, a potential regulation by 
endogenously low expressed miRNAs can hardly be detected by de-repression reporter 
assays.  
An alternative, more informative and sensitive approach to investigate a potential 
regulation of Nkx2.2 by miRNAs is the CLIP (cross-linking immunoprecipitation) 
method, in particular PAR-CLIP (photoactivatable-ribonucleoside-enhanced CLIP). 
For PAR-CLIP, nascent RNA molecules like mRNAs are labeled by photoactivatable 
ribonucleosides such as 4-thiouridine (4-SU) (160, 161). Thereafter, RNA-binding 
proteins such as Ago are crosslinked to the 4-SU labeled transcripts by UV-light. The 
crosslinked complexes are subsequently immunoprecipitated by Ago-specific antibodies, 
the RNA is recovered and used for the generation of cDNA libraries, which can be 
analyzed by deep sequencing. At the crosslinked site, a characteristic thymine to 
cytosine mutation can be observed frequently (160, 161). Finally, the sequencing reads 
can be aligned to a known sequence, in this case the Nkx2.2 3'-UTR. This method 
reflects the native status of a 3'-UTR of interest more accurately. It would be an 
alternative possibility to validate predicted miRNA binding sites in the Nkx2.2-3'-UTR 
and to identify new sites beyond these. However, this method is technically challenging 
and cost-intensive.  
 
3.2.3. Function of Nkx2.2 as a tumor suppressor for gliomas 
Nkx2.2 causes an antiproliferative effect 
As shown in the results, the overexpression of Nkx2.2 had a clear antiproliferative effect 
on LNT229 glioma cells. This further supports the assumption of Nkx2.2 as a tumor 
suppressor for glioblastomas. An intact HD of Nkx2.2 is obviously necessary to cause 
the observed antiproliferative effect, although the phenotype of the Nkx2.2Y181C 
mutant was not as strong as that of the Nkx2.2ΔHD, which lacks the entire HD. The 
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phenotype for the latter mutant is not surprising since it is most likely unable to bind 
DNA and can therefore not cause a transcriptional response. Furthermore, the HD of 
Nkx2.2 carries two nuclear localization signals, both of which are necessary for an 
efficient localization of Nkx2.2 into the nucleus (144). Therefore, the Nkx2.2ΔHD 
deletion mutant should not even enter the nucleus. In contrast, the Nkx2.2Y181C 
mutant can probably still localize to the nucleus since the two NLS are likely not 
affected by this point mutation. Yet, the highly conserved tyrosine Y181 of Nkx2.2 is 
presumably responsible for specific NKE recognition, as it was shown for the 
corresponding tyrosine of Nkx2.5 (115). Therefore, it was suggested that the 
transcriptional regulation of the Nkx2.2Y181C mutant is disrupted. 
However, for Nkx2.5 it is known that it binds as a homodimer to DNA (115, 152). 
This dimerization involves the HD and is also mediated by the C-terminus of Nkx2.5 
(152). Thereby, two conserved residues at the C-terminal end of the HD, K194 and 
R195, are essential for dimerization (152). Consistently, the Y181C mutation in HD of 
Nkx2.2 would most likely not impair a potential dimerization of Nkx2.2 because it does 
not affect the critical residues (K184 and R184 in Nkx2.2). Hence, it is conceivable that 
a dimerization can occur not only between two Nkx2.2Y181C mutants, but also 
between the mutant and endogenous Nkx2.2. This heterodimer is possibly capable to 
interact with NKE sites of target genes due to the intact HD of the endogenous 
protein. Moreover, other factors, which are required for target activation could still be 
recruited by this heterodimer. All in all, this might cause a transcriptional response, 
which would give a plausible explanation for the weaker phenotype observed for 
Nkx2.2Y181C in comparison to the deletion mutant. Furthermore, for Nkx2.2 an 
additional recognition sequence was reported (5'-GAGT-3') (111). It remains unknown 
if the mutation of the tyrosine, which is critical for the NKE binding also affects the 
recognition of this alternative target site.   
Interestingly, the antiproliferative effect of Nkx2.2 was recently also observed upon 
Nkx2.2 overexpression in mouse oligodendrocytes: The elevated Nkx2.2 levels 
significantly decreased cell proliferation of oligodendrocyte precursors in the developing 
spinal cord, but did not affect survival of these cells (133).  
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It would be of further interest to investigate how the other Nkx2.2 domains contribute 
to the observed antiproliferative phenotype. Therefore, the effect of mutations/deletions 
in the Nk-SD (which was suggested to be an interaction platform), in the TAD, and in 
the transcriptional repression domain (TD) should be examined. Latter would be of 
particular interest since several studies reported that Nkx2.2 acts as transcriptional 
repressor as well (131, 133, 135, 136, 141). Consistently, it has been suggested that the 
antiproliferative effect of Nkx2.2 on oligodendrocyte precursors is due to direct 
repression of Pdgfra (Pdgf receptor α), which impairs Pdgf signaling (133). 
However, in this thesis it was assumed that the antiproliferative phenotype of Nkx2.2 is 
caused by transcriptional activation, in particular by activation its potential target gene 
NPPA (cf. the working model in paragraph 1.6.). 
 
NPPA as a target gene of Nkx2.2  
Notably, an overexpression of Nkx2.2 in LNT229 glioma cells caused an elevation of 
the mRNA level of NPPA (Figure 2.25 C). Furthermore, a strong induction of the 
NPPA promoter by wildtype Nkx2.2 was demonstrated via dual luciferase assays in 
HEK293-T cells (Figure 2.26). In contrast, the Nkx2.2ΔHD deletion mutant and 
Nkx2.2Y181C did not activate the NPPA promoter anymore. For the deletion mutant 
this result is not surprising. However, for the Nkx2.2Y181C mutant is was speculated 
above that it possibly still can dimerize with endogenous Nkx2.2 and thus affect Nkx2.2 
targets to some extent. This was not observed in the luciferase reporter assays in 
HEK293-T cells, but is possibly reflected by the qRT-PCR quantification for NPPA 
mRNA levels upon Nkx2.2Y181C overexpression in LNT229 cells. The latter revealed 
that this mutant also elevated the NPPA mRNA levels, but less strong than the 
wildtype protein and in contrast to the deletion mutant. This is consistent with the 
observed weaker antiproliferative phenotype of this mutant compared to the deletion 
mutant.  
Nevertheless, this thesis further supports the hypothesis that NPPA is a potential target 
gene for Nkx2.2. As already mentioned before, NPPA encodes for the precursor of the 
atrial natriuretic peptide (ANP), which is a secreted peptide hormone (124, 162). ANP 
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is an essential hormone for the regulation of renal NaCl reabsorbtion. It is produced 
and secreted by the myoendocrine cells of the heart (124, 162). However, ANP acts not 
only as an endocrine hormone but is also an important autocrine/paracrine factor for 
heart (124) as well as for brain development and function (163-166). In particular, the 
expression of ANP and ANP receptors was also detected in various types of mammalian 
glia cells and it was suggested that ANP is relevant for glia cell biology (166). 
Interestingly, it was shown previously that ANP has an antiproliferative effect on 
mammalian astrocytes in vitro (167) and also on various types of human cancer cells like 
colon adenocarcinoma (168), prostate carcinoma (169), small-lung cancer (170), 
pancreatic cancer (171) as well as glioblastoma cells (143). ANP signaling is mainly 
transmitted via the receptor NPR-A, which is embedded in the plasma membrane and 
is characterized by an external ANP-binding and an internal guanylate cyclase domain. 
The activation of NPR-A results in the catalytic conversion of GTP to cyclic GMP 
(cGMP) by the intrinsic guanylate cyclase domain (162, 172). Cyclic GMP is a second 
messenger, which induces a signaling cascade involving the inhibition of certain 
signaling pathways within in the cell (172). In this regard, cGMP efficiently inhibits 
kinases of the Ras-MEK1/2-ERK1/2-signaling pathway, as previously shown for 
prostate cancer (173-175). Signaling via this pathway is also increased by overexpressed 
EGFR during the progression of glioblastomas (17). Besides the inhibition of the  Ras-
MEK1/2-ERK1/2-signaling pathway, ANP signaling via NPR-A and cGMP represses 
various other signaling pathways (or the crosstalk between certain pathways) which are 
often de-regulated in cancer, for example AKT- or STAT3-signaling (172). 
Interestingly, STAT3 was reported previously to be an important factor which 
maintains the stem cell abilities of glioblastoma CSCs (176). Therefore, it is conceivable 
that ANP-signaling also has a negative effect on these cancer stem cells.  
In this thesis, an increase of the NPR-A mRNA level upon Nkx2.2 overexpression in 
LNT229 cells was not observed. However, it was shown by Schraivogel et al. that 
CAMTA1 overexpression in LNT229 caused a drastic elevation of the NPR-A 
expression (53). Moreover, this overexpression increased also the NPPA mRNA levels 
(53) to a similar extent as measured in this thesis for Nkx2.2 overexpression. This 
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suggests a collaborative network between both proteins in which they interact to activate 
NPPA and CAMTA1 additionally leads to an increased expression of the ANP 
receptor. Such a collaboration is possibly required for efficient ANP signaling to cause a 
tumor suppressive effect and needs to be further investigated. 
 
Nkx2.2 in cancer biology: A two-sided protein? 
The data of this thesis confirm the previous results of Muraguchi et al. showing that 
Nkx2.2 can significantly repress the formation of neurosphere-like clones when it is 
overexpressed in primary glioblastoma cells. However, the mutants Nkx2.2Y181C and 
Nkx2.2ΔHD also reduced the neurosphere formation of ZH161 cells to some extent 
(Figure 2.23). Thereby, Nkx2.2ΔHD reduced neurosphere-like colonies less than the 
wildtype and the Nkx2.2Y181C mutant. Since this result reflects only two biological 
replicates, it is not significant and does not allow a final conclusion. Hence, the 
neurosphere assays including these Nkx2.2 mutants need to be continued to get a 
statistically more reliable result. As for the proliferation assay, one would expect no 
phenotype for the Nkx2.2ΔHD since it cannot (most likely) localize to the nucleus, 
bind DNA, and should therefore not cause any transcriptional response. In contrast, the 
Nkx2.2Y181C mutant possibly still causes a reduction of neurosphere formation, which 
might arise from the same effect already discussed for the proliferation assays.  
The idea of Nkx2.2 as tumor suppressor in glioma biology was further supported by the 
analysis of patient survival data obtained from the REMBRANDT database. Strikingly, 
this analysis revealed a significantly higher survival rate for glioma patients with 
increased Nkx2.2 expression (Figure 2.24 A).  
However, the relevance for Nkx2.2 regarding glioma progression remains to be 
discussed and further investigated. As already mentioned in the introduction (see 
paragraph 1.2.), Verhaak et al. classified glioblastomas into four distinct subtypes by 
their specific expression profiles (classical, mesenchymal, proneural, and neural) (18). 
Remarkably, Verhaak et al. further reported a high gene expression of Nkx2.2 (as well as 
Olig2) for the proneural subtype, which is mainly characterized by an amplification of 
Pdgfra (18). Moreover, it was shown that most secondary glioblastomas are of the 
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proneural subtype (18). Secondary glioblastoma arise from lower-grade gliomas such as 
astrocytomas or oligodendrogliomas. On the other side, it is known that most 
glioblastomas are primary glioblastomas, i.e. they emerge de novo. Interestingly, 
Muraguchi et al. examined also the expression of Nkx2.2 in high-grade gliomas 
(glioblastomas) versus lower-grade gliomas (anaplastic astrocytomas and anaplastic 
oligodendrogliomas) via immunostaining: Whereas Nkx2.2 was clearly expressed in 
lower-grade gliomas, it was not detectable in most of the glioblastoma samples (142). 
However, analysis of microarray data obtained from the REMBRANDT database 
revealed no significant difference in Nkx2.2 expression between astrocytomas, 
glioblastomas and normal brain tissue (Figure 2.24 B). Additionally, Nkx2.2 expression 
was previously reported to be higher in grade II and III oligodendrogliomas than in 
astrocytomas or glioblastomas (177).  
Taken together, one could speculate that there is a connection between the malignancy 
of gliomas on the one hand and Nkx2.2 expression on the other hand. Expression of 
Nkx2.2 could indicate a lower malignancy of the glioma since it is obviously expressed 
in lower-grade gliomas (or secondary glioblastomas that emerged from lower-grade 
gliomas). In contrast, Nkx2.2 is weakly expressed in high-grade, primary glioblastomas. 
Furthermore, it was shown previously that primary glioblastoma also contain 
significantly more CSCs, in particular CD133-positive cells, than secondary 
glioblastomas (26). Therefore, it is not unlikely that Nkx2.2 expression has an negative 
effect on the genesis of CSCs. The results of this thesis showing that Nkx2.2 can 
suppress the formation neurosphere-like colonies and of Muraguchi et al. support this 
hypothesis. A direct effect of Nkx2.2 on the CD-133 population would be interesting to 
investigate in further experiments. 
Remarkably, Nkx2.2 also suppresses the expression of Pdgfra via direct regulation of its 
promoter (133). This is essential during oligodendrocyte development. However, de-
regulated Pdgfra signaling is also frequently associated with glioblastoma progression 
(16, 17). As pointed out above, the proneural subtype is characterized by Pdgfra 
amplification and elevated Nkx2.2 expression. The higher Nkx2.2 expression observed 
for this subtype is probably due to the origin of these glioblastomas: Proneural 
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glioblastomas are often also classified as secondary glioblastomas. These arise 
presumably from a lower-grade glioma in which Nkx2.2 is expressed at higher levels, 
e.g. an oligodendroglioma. It is further possible that in lower-grade gliomas Nkx2.2 
counteracts Pdgfra expression by direct repression. This could be beneficial for the lower 
malignancy and an interruption of this repression promotes probably the progression of 
a secondary, proneural glioblastoma. Consistently, this would further support the 
correlation between Nkx2.2 expression and glioma malignancy. 
This thesis showed further evidence that the transcriptional activator Nkx2.2 has tumor 
suppressive abilities, at least for glioblastoma. In contrast, it was also reported that 
Nkx2.2 is necessary for oncogenic transformation in Ewing's sarcoma, a highly 
aggressive bone-associated tumor. In this type of tumor, Nkx2.2 is up-regulated by the 
EWS/FLI fusion protein which frequently occurs in Ewing's sarcoma (178). 
Furthermore, Nkx2.2 functions as a transcription repressor in this kind of tumor for 
which its TN domain (transcriptional repression domain) is essential (besides the HD 
and Nk-2 SD) (179). Thereby, this repression is probably caused by the recruitment of 
histone deacetylases (179), most likely in a similar manner as Nkx2.2 represses MBP or 
Sirt2 during oligodendrocyte development (135, 136) (see also paragraph 1.5.2.). 
Since Nkx2.2 carries both a transcriptional activation and repression domain, it is not 
surprising that it can act in two ways. The prevailing response depends most likely on 
the cellular context and, in this regard, on the Nkx2.2 interactome. 
Besides, it is common for an Nk-2 class protein that it can act both as a tumor 
suppressor and as an oncogene. Nkx2.1 was previously reported to be a tumor 
suppressor (180, 181) as well as an oncogene (182) during lung cancer progression 
(summarized in (183)). Lung cancer is very heterogeneous and it has been suggested 
that Nkx2.1 can act in these two ways depending on the cellular origin. 
Taken together, Nk-2 class proteins are indeed two-sided proteins. This is reflected by 
the presence of functional repression and activation domains and their oppositional roles 
during cancer progression. The role of Nk-2 class proteins in cancer development shows 
exemplary that cancer biology is extremely complex and diverse – not only for tumors 
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emerging from different tissues, but even for tumors occurring in the same organ. 
Hence, for the development of new therapy approaches, in particular of personalized 
therapies, it is important to know from which cellular linage one particular tumor 
originates and how this is reflected by the specific alterations in the genome, 
transcriptome, and interactome of certain key molecules, so called "biomarkers". 
Consequently, the identification and characterization of such biomarkers is highly 
relevant for personalized cancer medicine and patient-adapted therapies become more 
and more important due to the increasing understanding of the molecular-pathological 
diversity of many cancer types including glioblastomas. During the recent years, 
biomarkers for the various glioblastoma subtypes have been studied extensively, aiming 
to identify potential therapeutic targets for this highly malignant cancer type (17, 18, 
184). In this context, a further characterization of the Nkx2.2 cellular interaction 
network will be beneficial to develop targeted treatment strategies. A current draft of 
this network is described in the following paragraph.  
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3.3. Expanding the working model 
This thesis further supports the concept of an interaction between the two transcription 
factors CAMTA1 and Nkx2.2, which was hypothesized for tumor suppression of 
glioblastomas. Furthermore, this thesis and previous findings of Schraivogel et al. 
reveals NPPA as a potential target for CAMTA1/Nkx2.2. Analogous to the 
collaboration of CAMTA2 and Nkx2.5 in the heart, it is likely that CAMTA1 co-
activates the NPPA promoter together with Nkx2.2 as well. In turn, the induction of 
NPPA is probably responsible for the antiproliferative effect caused by these tumor 
suppressors. This is supported by the previously reported observation that ANP 
signaling via its main receptor NPR-A negatively affects proliferation of various types of 
cancer cells. Moreover, this expanded model, which is illustrated in Figure 3.2, might be 
an important pathway to suppress the formation of high-malignant glioblastoma CSCs. 
Certain de-regulated factors such as miR-9/9* counteract this pathway which in turn 
promotes cancer progression and the maintenance of glioblastoma CSCs. However, 
several aspects of this model still need to be proven experimentally, in particular those 
regarding the impact on glioblastoma CSCs.    
Nevertheless, this model reflects likely cellular mechanisms, which are important for a 
further understanding of cancer biology in general and glioblastoma CSCs biology in 
particular.  
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Figure 3.2: Expanded working model. The activation of NPPA by a cooperation of CAMTA1 
and Nkx2.2 leads to a secretion of ANP. This peptide hormone acts in autocrine/paracrine manner 
to stimulate signaling via its receptor NPR-A. Activation of NPR-A causes in turn the conversion 
of GTP to cGMP, a secondary messenger which inhibits various intracellular signaling pathways. 
This inhibition finally leads to an antiproliferative effect on cancer cells.  
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4. Material and Methods 
4.1. Materials 
4.1.1. Consumables and Chemicals 
If not indicated else wise, all used chemicals were purchased from Carl Roth (Karlsruhe, 
Germany), Merck (Darmstadt, Germany), AppliChem GmbH (Darmstadt, Germany), 
Sigma-Aldrich (Steinheim, Germany), Roche Diagnostics (Penzberg, Germany), GE 
Healthcare (Buckinghamshire, UK), Bio-Rad (Hercules, USA) Calbiochem-Behring 
(La Jolla, USA), Thermo Fischer Scientific (Waltham, USA), and USB Corporation 
(Cleveland, USA) at the highest degree of purity.  
Nucleotides, double stranded DNA-ladders, and molecular weight markers were 
procured from Thermo Fischer Scientific. 
Kits and the applications for which they were used are stated in Table 4.1. 
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Table 4.1: Used kits listed with the corresponding application. 
kit company application
Amaxa® Cell Line 
Nucleofector® Kit R 
Lonza (Cologne, Germany) transfection of human LNT229 
cells 
Amaxa® Mouse Neural Stem 
Cell Nucleofector® Kit 
Lonza transfection of human primary 
R11 cells 
First-Strand cDNA Synthesis 
Kit 
Thermo Fischer Scientific cDNA synthesis 
iScriptTM cDNA Synthesis Kit Bio-Rad cDNA synthesis 
NucleoBond®-Xtra-Midi MACHEREY-NAGEL
(Düren, Germany) 
plasmid purification, large scale 
NucleoSpin®-Extract MACHEREY-NAGEL DNA purification from agarose 
gel slices, PCRs reactions or 
other enzymatic reactions  
NucleoSpin®-Plasmid MACHEREY-NAGEL plasmid purification, small scale 
NucleoSpin®-RNA MACHEREY-NAGEL RNA purification 
pGEM®-T Easy vector system  Promega (Fitchburg, USA) molecular cloning 
 
 
4.1.2. Buffers 
For each method the composition of the respective buffer(s) is specified and listed there. 
 
 
4.1.3. Enzymes 
Restriction enzymes were obtained either from Thermo Fischer Scientific or New 
England Biolabs (Ipswich, USA). For each construct generated in this thesis, the 
corresponding restriction enzymes used for molecular cloning is listed in Table 4.4, 
paragraph 4.1.6.  
All other enzymes were purchased from Thermo Fischer Scientific, unless mentioned 
otherwise.  
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4.1.4. DNA-oligonucleotides 
All used DNA-oligonucleotides were synthesized by Metabion (Martinsried, 
Germany). DNA-oligonucleotides used for quantitative real-time PCR are listed in 
Table 4.2, for molecular cloning and sequencing in Table 4.3 (pages 94 to 96).   
 
Table 4.2: DNA-oligonucleotides used as primers for qRT-PCR. The particular NCBI accession 
numbers of the targets, the targeted exons, and the amplicon lengths (AL) are stated as indicated. 
[fwd.: forward primer (p), rev.: reverse primer] 
designation sequence (5‘ to 3‘) target (NCBI 
accession number) 
exon AL 
[bp] 
CAMTA1 p1 fwd. 
 
GAGAGGCACCGCTGGAACACTAATGAG 
 
CAMTA1
(NM_015215.2) 
3 125
CAMTA1 p1 rev. GAGTATCATTGAGCCATTCTGTGGTCTTG 
 
CAMTA1 5 
CAMTA1 p2  fwd. AGGTGGTTAGCCATTCTTCG     
 
CAMTA1 3 146
CAMTA1 p2  rev. TGTCTGCCGAAATGTTCAAG     
 
CAMTA1 4 
CAMTA1 p3  fwd. CTGCTGTGCTCATCCAAAAG CAMTA1 20 140
CAMTA1 p3 rev. TTTTCGAGCAGCTTGATCCT CAMTA1 21 
GAPDH fwd. TGGTATCGTGGAAGGACTCATGAC 
 
GAPDH
(NM_002046.5) 
7 189
GAPDH rev. ATGCCAGTGAGCTTCCCGTTCAGC 
 
GAPDH 8 
Nkx2.2  fwd. GCCCGAGCCAGCCAAGAGG Nkx2.2
(NM_002509.3) 
1 159
Nkx2.2 rev. GCCAGACCGTGCAGGGAGTA Nkx2.2 2 
NPPA  fwd. CAGGATGGACAGGATTGGA 
 
NPPA
(NM_006172.3) 
2 64
NPPA  rev. TCTTCAGTACCGGAAGCTGTT 
 
NPPA 3 
NPR-A  fwd. TCGAAACCACCAAACTCCTC     
 
NPR-A
(NM_000906) 
20 147
 
NPR-A  rev. AGTGGTGGGACTGAAGATGC     
 
NPR-A 21 
β-Actin  fwd. GGACTTCGAGCAAGAGATGG 
 
β-Actin
(NM_001101.3) 
2 138
β-Actin rev. AGGAAGGAAGGCTGGAAGAG 
 
β-Actin 2 
 
 
 94 
 
 
Table 4.3: DNA-oligonucleotides used for molecular cloning and sequencing. The particular primer melting temperatures (Tm), sites for restriction enzymes (RE), 
and corresponding applications are stated as indicated (fwd.: forward primer, rev.: reverse primer, S.: sense, AS.: antisense).  
designation sequence (5‘ to 3‘) Tm
[°C] 
application (RE) 
CAMTA1 AscI rev. ATACGGCGCGCCTCAAGTTCCTTGGCCTTTTTCAATTCTTTCACTCC 81.5 cloning (AscI)
CAMTA1 C-term. FseI fwd. ATATGGCCGGCCATGTGGGCGAAGTCCAAGCACTTG 80 cloning (FseI)
CAMTA1 C-term. fwd. TGGGCGAAGTCCAAGCACTTGATCC 69.1 cloning
CAMTA1 FseI fwd. ATATGGCCGGCCATGTGGCGCGCGGAGGGGAAATG 82.4 cloning(FseI)
CAMTA1 M AscI rev. ATACGGCGCGCCTCAGCAGGCTCGGCTCATCATC 81.3 cloning (AscI)
CAMTA1 M FseI fwd. ATATGGCCGGCCATGCAGACGGGCCACAGCCC 81.5 cloning (FseI)
CAMTA1 N-term. 600 rev. GCTGAAGCTGGACGTGTAGTCCTTG 69.1 cloning
CAMTA1 seq. 1215 fwd. GTGTTCATGTCAGAGGTCACC 61.3 sequencing
CAMTA1 seq. 1861 fwd. GAGCTTCTTCCTGCAGGACG 62.5 sequencing
CAMTA1 seq. 2508 fwd. CCTGCAGCTGAGCAGCTCG 63.8 sequencing
CAMTA1 seq. 3185 fwd. GCACTTGATCCACTCAAAGAC 59.4 sequencing
CAMTA1 seq. 3805 fwd. CCACTGCACTGAGTCTGGAAG 63.3 sequencing
CAMTA1 seq. 4316 fwd. CATTAGCAGTACAATGAGCTG 57.4 sequencing
CAMTA1 seq. 537 fwd. GACATCGTCCTGGTGCACTAC 63.3 sequencing
CAMTA1-F3 BamHI TEV 
fwd. 
CCAGGATCCGAAAACCTGTATTTTCAGGGAGTGTCTACAGTACAGGTGACTGG 70.6 cloning (BamHI); introducing 
TEV protease cleavage site  
CAMTA1-F3 SalI rev. ATATGTCGACTCAACTGACGGGAGAGCCAAC 73.6 cloning (SalI)
CAMTA1 ΔN FseI fwd. ATATGGCCGGCCATGGGCAAGCCTTGCGGCCCCATC 83.5 cloning (FseI)
CAMTA1 ΔN600 FseI fwd. ATATGGCCGGCCATGCAGACGGGCCACAGCCC 81.5 cloning (FseI)
 Table continued on next page 
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designation sequence (5‘ to 3‘) Tm
[°C] 
application (RE) 
CAMTA ΔC  AscI rev. ATACGGCGCGCCTCAGAAAGTCTTTGAGTGGATCAAGTGCTTG 80.8 cloning (AscI)
CMV promoter seq. fwd. CGCAAATGGGCGGTAGGCGTG 67 sequencing
M13 seq. fwd. TGTAAAACGACGGCCAGT 53.8 sequencing
M13 seq. rev. CAGGAAACAGCTATGACCATG 59.4 sequencing
miR106b target site AS CCTGGAGTGCGTAGGTCTAATTAAAGTGCTGACAGTGCAGATGGCTTAAACAAGGTGGCGATA - Cloning, full complementary 
miR-106b target site 
(5': SpeI; 3': SacI) 
miR-106b target site S CTAGTATCGCCACCTTGTTTAAGCCATCTGCACTGTCAGCACTTTAATTAGACCTACGCACTCCAGGAGCT - cloning, full complementary 
miR-106b target site 
(5': SpeI; 3': SacI) 
miR-17  target site S CTAGTATCGCCACCTTGTTTAAGCCCTACCTGCACTGTAAGCACTTTGATTAGACCTACGCACTCCAGGAGCT - cloning, full complementary 
miR-17 target site 
(5': SpeI; 3': SacI) 
miR-17 target site AS CCTGGAGTGCGTAGGTCTAATCAAAGTGCTTACAGTGCAGGTAGGGCTTAAACAAGGTGGCGATA - cloning, full complementary 
miR-106b target site 
(5': SpeI; 3': SacI) 
Nkx2.2 3'UTR fwd. AGTACAACGCCCAGTACAG 57.3 cloning (nested PCR) 
Nkx2.2 3'UTR NaeI rev. ACACGCCGGCTTTTAAACACAGGATTTTTATTAAAATTC 71.5 cloning (NaeI)
Nkx2.2 3'UTR rev. TTTTAAACACAGGATTTTTATTAAAATTC 57.7 cloning (nested PCR) 
Nkx2.2 3'UTR SpeI fwd ATATACTAGTGCGCCGCCCCAACGAGAC 73 cloning (SpeI)
 Table continued on next page 
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designation sequence (5‘ to 3‘) Tm
[°C] 
application (RE) 
Nkx2.2 3'UTR[mut] fwd. AAAGCAAGTGGAGAAGGATCCAAAAATACAGAGAATTTC 72.6 cloning; site-directed 
mutagenesis 
Nkx2.2 3'UTR[mut] rev. GAAATTCTCTGTATTTTTGGATCCTTCTCCACTTGCTTT 72.6 cloning; site-directed 
mutagenesis 
Nkx2.2 BamHI fwd. ATACGGATCCATGTCGCTGACCAACACAAAGAC 74 cloning (BamHI) 
Nkx2.2 BamHI rev. ATACGGATCCTCACCAAGTCCACTGCTG 72 cloning (BamHI) 
Nkx2.2 C-term. fwd. GCCGAGAAAGGTATGGAGGTG 63.3 cloning
Nkx2.2 EcoRV fwd. ATACGATATCATGTCGCTGACCAACACAAAGAC 71 cloning (EcoRV) 
Nkx2.2 NotI fwd. ATATGCGGCCGCATGTCGCTGACCAACACAAAG 76.4 cloning (NotI)
Nkx2.2 N-term. rev. CTTGCCGGCGTCCCC 57 cloning
Nkx2.2 Y181C [mut] fwd. TTCCAGAACCACCGCTGCAAGATGAAGCGCGCC 78.9 cloning; site-directed 
mutagenesis 
Nkx2.2 Y181C [mut] rev. GGCGCGCTTCATCTTGCAGCGGTGGTTCTGGAA 78.9 cloning; site-directed 
mutagenesis 
pGEX seq. fwd. GGGCTGGCAAGCCACGTTTGGTG 70 sequencing
pGEX seq. rev. GGAGCTGCATGTGTCAGAG 59.5 sequencing
pIRES/VP5 seq. rev. CCCAACAGCTGGCCCTCGCAGA  
 
69.6 sequencing
T7 promoter seq. fwd. TAATACGACTCACTATAGGG 54 sequencing
 
 
 
4.1. Materials 97 
 
 
4.1.5. RNA-oligonucleotides 
The used RNA-oligonucleotides were synthesized either at the Max-Planck Institute 
for Biochemistry (Martinsried, Germany) or by Metabion and are listed in Table 4.4.  
 
Table 4.4: RNA-oligonucleotides. The particular oligonucleotides are stated with their 
corresponding targets in the case of siRNAs and miRNA inhibitors (S: sense, AS: antisense, r: 
ribose, d: desoxyribose, 2'-OMe: 2'-O-methylated). 
designation S/AS sequence (5‘ to 3‘) target (exon) comment; 
application 
CAMTA1 si1  S r(CUACCGAAGUUAUAAGAAAU)dT CAMTA1 (20) siRNA; RNAi 
CAMTA1 si1  AS r(UUUCUUAUAACUUCGGUAGU)dT CAMTA1 (20) siRNA; RNAi 
CAMTA1 si2  S r(CCAAAUAUCAGGAAGCAAAU)dT CAMTA1 (16) siRNA; RNAi 
CAMTA1 si2  AS r(UUUGCUUCCUGAUAUUUGGC)dT CAMTA1 (16) siRNA; RNAi 
CAMTA1 si3 S r(CCAAAUAUCAGGAAGCAAAU)dT 
 
CAMTA1 (16) siRNA; RNAi 
CAMTA1 si3 AS r(AAAUUCUCCUGCUUGAUUCG)dT 
 
CAMTA1 (16) siRNA; RNAi 
CAMTA1 si4 S r(CCCGACUGUUUCCUUAAUAUU) 
 
CAMTA1 (16) siRNA; RNAi 
CAMTA1 si4 AS r(UAUUAAGGAAACAGUCGGGUU) 
 
CAMTA1 (16) siRNA; RNAi 
CAMTA1 si5 S r(GCCGAAAUGUUCAAGUUUA)dTdT 
 
CAMTA1 (16) siRNA; RNAi 
CAMTA1 si5 AS r(UAAACUUGAACAUUUCGGC)dTdT 
 
CAMTA1 (16) siRNA; RNAi 
siNkx2.2 S r(CGCCGUGUUUACAGAAUGU)dTdT Nkx2.2 siRNA; RNAi 
siNkx2.2 AS r(ACAUUCUGUAAACACGGCG)dTdT Nkx2.2 siRNA; RNAi 
UNBIAS S r(UUGUCUUGCAUUCGACUAAU)dT 
 
no target 
 
ctrl. siRNA; RNAi 
UNBIAS AS r(UUAGUCGAAUGCAAGACAAU)dT 
 
no target ctrl. siRNA; RNAi 
miR-17-5p S r(CAAAGUGCUUACAGUGCAGGUAG)dT 
	
- hsa-miR-17-5p 
mimic; miR binding 
site validation 
miR-17-5p AS r(UACCUGCACUGUAAGCACUUUGU)dT 
	
- hsa-miR-17-5p 
mimic; miR binding 
site validation 
 Table continued on next page 
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designation S/AS sequence (5‘ to 3‘) target (exon) comment; 
application 
miR-106b S r(AAAAGUGCUUACAGUGCAGGUAG)dT 
	
- hsa-miR-106b 
mimic; miR binding 
site validation 
miR-106b AS r(UACCUGCACUGUAAGCACUUUUU)dT 
	
- hsa-miR-106b 
mimic; miR binding 
site validation 
miR-122a S r(AACGCCAUUAUCACACUAAAUA)dT 
	
- hsa-miR-122 mimic; 
miR binding site 
validation 
miR-122a AS r(UGGAGUGUGACAAUGGUGUUUG)dT 
	
- hsa-miR-122 mimic; 
miR binding site 
validation 
miR-17-5p 
inihb. 
AS r[2'-OMe](ACUACCUGCACUGUAAGCACUUUG)dT 
 
hsa-miR-17-5p inhibition of human 
miR-17-5p; miR 
binding site 
validation 
miR-106b 
inhib. 
AS r[2'-OMe](AUCUGCACUGUCAGCACUUUA)dT 
 
hsa-mir106b inhibition of human 
miR-106b; miR 
binding site 
validation 
miR-122a 
inhib. 
  
AS r[2'-OMe](ACAAACACCAUUGUCACACUCCA)dT 
 
hsa-miR122a inhibition of human 
liver specific miR-
122; miR binding site 
validation 
 
 
4.1.6. Plasmids 
Table 4.5 contains all plasmids and constructs that were already available at the 
beginning of this thesis in the department Biochemistry I (University of Regensburg). 
All used plasmids contain the sequence encoding for the ampicillin resistance gene. 
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Table 4.5: Used plasmids. The here listed plasmids were available at Biochemistry I, University of 
Regensburg. For each plasmid the particular promoter(s) [upstream of insert(s)], inserts, sequences 
for protein tags (if encoded), and applications are stated as indicated. 
designation promoter  insert 
(NCBI accession 
number) 
sequence for protein 
tag 
application/comment 
pCS2 CMV empty N-terminal 6 × myc 
tag 
eukaryotic expression vector 
pCS2-Ago2 CMV Argonaute 2 6 × myc tag over expression of myc-Ago2  
pCS2-Dicer CMV Dicer 6 × myc tag over expression of myc-Dicer  
pCS2-TOE1 CMV Toe 1 6 × myc tag over expression of myc-Toe1  
pCS2-XP5 CMV Exportin 5 6 × myc tag over expression of myc-Exportin5 
pGEM®-T easy T7 - - sub-cloning vector 
pGEX-6p1 tac empty N-terminal GST tag bacterial expression vector 
pGL3 basic - firefly luciferase - luciferase assay (promoter regulation) 
pGL3-NPPA-P NPPA firefly luciferase - luciferase assay (promoter regulation) 
pIRES-CAMTA1 CMV CAMTA1 
(NM_015215.2) 
- over expression of  wild type 
CAMTA1 in human cell lines 
pIRES-CAMTA1ΔN CMV CAMTA1ΔN 
aa 1 to 188 deleted 
- over expression of CAMTA1ΔN  
(N-terminal deletion mutant) 
pIRESpuro-3 CMV empty - eukaryotic expression vector 
pMIR-CAMTA1-
3'UTR 
HSV-TK (firefly) 
SV40 (renilla) 
firefly+CAMTA1-
3'UTR; renilla 
- luciferase assay (miRNA binding site 
validation) 
pMIR-HMGA2-
3'UTR 
HSV-TK (firefly) 
SV40 (renilla) 
firefly+HMGA2-
3'UTR; renilla 
- luciferase assay (miRNA binding site 
validation) 
pMIR-HMGA2-
3'UTR[mut] 
HSV-TK (firefly) 
SV40 (renilla) 
firefly+HMGA2-
3'UTR mutated; 
renilla 
- luciferase assay (miRNA binding site 
validation) 
pMIR-RNL-TK HSV-TK (firefly) 
SV40 (renilla) 
firefly/renilla 
luciferase 
- luciferase assay (miRNA binding site 
validation) 
pRL-TK HSV-TK renilla luciferase - luciferase assay (promoter regulation) 
pSUPER-miR-106b H1-RNA gene  precursor hsa-miR-
106b 
- luciferase assay (miRNA binding site 
validation) 
pSUPER-miR-17-5p H1-RNA gene  precursor hsa-miR-
17-5p 
- luciferase assay (miRNA binding site 
validation) 
VP5 CMV empty N-terminal FLAG-
HA 
eukaryotic expression vector 
VP5-GFP CMV GFP N-terminal FLAG-
HA tag 
transfection and IP control 
VP5-T6B[mut] -GFP CMV mutated T6B peptide N-terminal FLAG-
HA-tag; C-terminal 
GFP-tag 
luciferase assay (miRNA binding site 
validation) 
VP5-T6B-GFP CMV T6B peptide N-terminal FLAG-
HA-tag; C-terminal 
GFP-tag 
luciferase assay (miRNA binding site 
validation) 
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 All constructs, generated in this thesis are listed in Table 4.6. Here, also the respective 
cloning strategy and restriction enzymes for every particular construct are specified. 
 
Table 4.6: Cloned constructs. For the particular constructs the corresponding inserts and cloning 
strategy is specified as indicated. 
designation insert (NCBI accession 
number) 
cloned via 
pIRES-Nkx2.2 Nkx2.2 
(NM_002509.3) 
EcoRV/BamHI 
pIRES-Nkx2.2Y181C Nkx2.2 mutant  (Y181 
mutated to C) 
EcoRV/BamHI 
pIRES-Nkx2.2ΔHD Nkx2.2 deletion mutant 
(ΔHD) 
EcoRV/BamHI; blunt end 
fusion of N-and C-terminus 
VP5-Nkx2.2 Nkx2.2 NotI/BamHI 
pCS2-CAMTA1 CAMTA1 (NM_015215.2) AscI/FseI 
pCS2-CAMTA1ΔN CAMTA1 deletion mutant 
(Δaa 1-188) 
AscI/FseI 
pCS2-CAMTA1ΔN600 CAMTA1 deletion mutant 
(Δaa 1-600) 
AscI/FseI 
pCS2-CAMTA1 N+C CAMTA1 deletion mutant 
(Δaa 600-1054) 
AscI/FseI; blunt end fusion of 
N-and C-terminus 
pCS2-CAMTA1 M CAMTA1 deletion mutant 
(Δaa 1-600 and 1054-1673) 
AscI/FseI 
pCS2-CAMTA1 ΔC CAMTA1 deletion mutant 
(Δaa 1064-1673) 
AscI/FseI 
pCS2-CAMTA1 C CAMTA1 deletion mutant 
(Δaa 1-1054) 
AscI/FseI 
pMIR-Nkx2.2 3'-UTR 3'-UTR of Nkx2.2 SpeI/NaeI 
pMIR-Nkx2.2 3'-UTR[mut] 3'-UTR of Nkx2.2; miR-
17/106b site mutated 
SpeI/NaeI 
pMIR-miR17site full complementary, artificial 
miR-17-5p target site 
SpeI/SacI 
pMIR-miR106bsite full complementary, artificial 
miR-106b target site 
SpeI/SacI 
pGEX-CAMTA1-F3 CAMTA1 fragment (aa 1330-
1480) 
BamHI/SalI 
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4.1.7. Antibodies 
Antibodies used for western blot (see paragraph 4.2.3.7.), immunofluorescences (see 
paragraph 4.2.3.11.) as primary antibodies and/or immunoprecipitations (see paragraph 
4.2.3.2.), are itemized in Table 4.8 (see next page).  
 
 
4.1.8. Bacterial strains and bacterial growth medium  
Table 4.7 contains a list of bacterial Escherichia coli (E. coli) strains used for this thesis 
together with their features. Bacteria were inoculated and cultivated at 37°C in LB-
medium composed of: 
NaCl  1 % (w/v)
yeast extract  0.5 % (w/v)
bacto-tryptone  1 % (w/v)
pH = 7.2 - 7.5  
 
Table 4.7: Bacterial strains. 
strain features
Rosetta F- dcm ompT lon hsdSB (rB- mB-) gal λ(DE3) pRARE (CamR) 
XL1-blue F–  recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac 
F’[proAB lacIqZ_M15 Tn10 (TetR)] 
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Table 4.8: Used antibodies. The particular antibodies are listed with their amounts used for the corresponding methods: western blot (WB), immunofluorescence (IF), 
and immunoprecipitation (IP); (purf.: purified). 
designation working solution/amount IgG origin (mono- or polyclonal) obtained from
 for WB for IF for IP
anti-HA 1:1,000 in TBS-T 
+ 2% (w/v) milk 
- - mouse 
(monoclonal) 
Covance (Princeton, USA)
anti-c-myc 1:500 in TBS-T + 
2% (w/v) milk 
1:60 in IF blocking 
solution 
2.5 - 5 μg rabbit (polyclonal) Sigma-Aldrich
anti-α-Tubulin 1:5,000 in TBS-T 
+ 2% (w/v) milk 
- - mouse 
(monoclonal) 
Sigma-Aldrich
anti-laminA/C 1:1,000 in TBS-T 
+ 2% (w/v) milk 
- - rabbit (polyclonal) Santa Cruz biotechnology Inc. (Dallas, 
USA) 
anti-CAMTA1 1886 serum
 
1:200 in TBS-T + 
2% (w/v) milk 
1:100 in IF 
blocking solution 
0.1 - 0.2 % (v/v) of 
an IP preparation 
rabbit (polyclonal) Biochemistry I, University of Regensburg 
anti-CAMTA1 1901 serum
 
1:200 in TBS-T + 
2% (w/v) milk 
1:100 in IF 
blocking solution 
0.1 - 0.2 % (v/v) of 
an IP preparation 
rabbit (polyclonal) Biochemistry I, University of Regensburg 
anti-CAMTA1 SY6160 
serum/purified 
1:100 in TBS-T +  
2% (w/v) milk 
1:100 in IF 
blocking solution 
10 μg
(purf. serum) 
rabbit (polyclonal) Eurogentec (Liège, Belgium), generated 
in this thesis 
anti-CAMTA1 SY6161
serum/purified 
1:100 in TBS-T + 
2% (w/v) milk 
1:100 in IF 
blocking solution 
10 μg
(purf. serum) 
rabbit (polyclonal) Eurogentec, generated in this thesis 
anti-Nkx2.2 74.5A5 1:3 in TBS-T 1:10 in IF blocking 
solution 
10 μg mouse (monoclonal, hybridoma clone) Developmental Studies Hybridoma Bank 
(University of Iowa, Iowa City, USA) 
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4.1.9. Human cell lines 
All used human cell lines are listed in Table 4.9. The primary glioblastoma cell line R11 
was previously described in (53). The ZH161 cell line was obtained from the University 
Hospital Zurich (Department of Neurology, Prof. Michael Weller). 
 
Table 4.9: Human cell lines. 
cell line specification
HEK293-T embryonic kidney cells
HeLa cervical cancer cells
HeLa-S3 suspension culture cervical cancer cells
LNT229 stable glioma cells
T98G stable glioma cells
R11 primary glioblastoma cells 
ZH161 primary glioblastoma cells 
 
 
4.1.10. Software and databases 
Often used software and databases are stated in Table 4.10 (see next page).  
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Table 4.10: Software and databases. 
software/database application company 
CFX-Manager qPCR Bio-Rad 
Leica LAS-AF confocal laser scanning 
microscopy 
Leica (Wetzlar, 
Germany) 
Protein-Scape mass spectrometry raw data 
analysis 
Bruker Daltonics 
(Billerica, USA) 
Odyssey application software 3.0 western blot scanning Licor 
iQ 2.1 qPCR Bio-Rad 
http://www.ebi.ac.uk/ bioinformatic tools
http://www.expasy.org/ bioinformatic tools
http://www.ncbi.nlm.nih.gov/ general database
http://genome.ucsc.edu/ database, mouse and human 
genome browser 
http://www.uniprot.org/ protein database
http://www.proteinatlas.org/ protein database (SWISS-
PROT) 
http://www.mirbase.org/ miRNA database
http://www.targetscan.org/ TargetScan 6.2.; miRNA 
binding sites prediction for 3'-
UTRs 
http://www.microrna.org/ miRNA binding sites 
prediction for 3'-UTRs 
http://mirtarbase.mbc.nctu.edu.tw/ database for experimentally 
validated miRNA-target 
interactions 
http://sirna.wi.mit.edu/ siRNA design
https://caintegrator.nci.nih.gov/rembrandt/ molecular pathologic database 
for gliomas (REMBRANDT 
database) 
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4.1.11. Devices 
Frequently used devices and their application are listed in Table 4.11. 
  
Table 4.11: Frequently used devices. 
device company application 
ÄKTA purifier GE Healthcare fast protein liquid 
chromatography 
Branson Sonifier 450 Branson (Danbury, USA) cell sonication  
C1000 thermal cycler/CFX96 Real 
time System 
Bio-Rad qRT-PCR 
GeneAmp PCR Sytems 9700 Applied Biosystems PCR
iCycler/MyiQ Bio-Rad qRT-PCR 
Leica TCS SP8 Leica confocal laser scanning microcopy 
(immunofluorescence) 
Mastercycler gradient Eppendorf 
(Hamburg, Germany) 
PCR
Mithras LB 940 Luminometer Berthold technologies 
(Bad Wildbad, Germany) 
luciferase assays 
Nanodrop® spectrophotometer ND-
100 
Thermo Fischer Scientific determination of DNA-, RNA or 
protein concentrations 
Nucleofector®-Device II Lonza transfection of human cells
Odyssey IR Imager Licor western blot 
peqSTAR Thermocycler Peqlab (Erlangen, 
Germany) 
PCR
Thermal cycler 2720 Applied Biosystems 
(Delaware, USA) 
PCR
Zeiss Axiovert 200M Zeiss (Oberkochen, 
Germany) 
phase contrast fluorescence 
microscopy 
(immunofluorescence) 
Zeiss Axiovert 35 Zeiss phase contrast fluorescence 
microscopy (human cell culture) 
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4.2. Methods 
4.2.1. Working with DNA 
4.2.1.1. Polymerase chain reaction 
Polymerase chain reaction (PCR) 
Gene amplification for molecular cloning via PCR was performed using the Phusion® 
high-fidelity DNA-polymerase. The used types of templates and their particular 
quantities for a single PCR (total reaction volume was always 50 μl) are specified in 
Table 4.12. DMSO was added to a final concentration of 3 % (v/v) for every PCR. The 
final concentration of the other components (buffer, nucleotides, forward and reverse 
primer) conformed to the manufacturer's instructions (Thermo Fischer Scientific). The 
general PCR program is indicated hereinafter: 
step temperature time
1 98°C 10 s
2 98°C 10 s
3 annealing temperature; 2-3°C 
below the Tm of the particular 
primer 
30 s
4 72°C 30 s per kb
5 72°C  10 min
6 4°C ∞
   
Whereupon, step two to four is the amplification cycle. Normally, the total number of 
cycles was 35. If a particular primer contained a longer non-complementary part, the 
initial amplification was performed for five cycles at an annealing temperature 
corresponding to the complementary part. This initial amplification was then followed 
by the main amplification (30 cycles) at the annealing temperature corresponding to the 
whole primer. In the case of an annealing temperature above the elongation temperature 
of the polymerase, the annealing was performed at 72°C. 
For subsequent applications every PCR was purified via agarose-gel electrophoresis 
using gels with a agarose concentration of 0.8 to 2 % (w/v). After the electrophoresis 
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run (at 120 V for 30 to 45 minutes) the DNA fragments were extracted from ethidium 
bromide-stained gels via the NucleoSpin®-Extract kit. 
 
Table 4.12: Templates used for PCR. 
type of template amount used for PCR 
Human Brain, whole Marathon-ReadyTM cDNA, conc. 
0,1 ng/μl (Clontech, Mountain View, USA) 
4 % (v/v) of a PCR reaction  
human cDNA (1:10 diluted), generated as stated in 
4.2.2.2.  
4  - 10 % (v/v) of a PCR 
reaction 
human genomic DNA 250 - 500 ng 
plasmid DNA 50 - 100 ng
PCR product 1 - 4 % (v/v) of a PCR 
reaction 
 
PCR-directed mutagenesis 
The primers for the PCR-directed mutagenesis were designed in a way that the non-
complementary,  mutated single nucleotide or sequence was flanked by 15 to 20 
complementary nucleotides. For the PCR reaction 1 μM (final concentration) of each 
primer and 50 ng template (plasmid DNA) were used. The PCR was performed using 
the Phusion®-Polymerase, with an annealing temperature of 58°C and a total cycle-
number of 15. 
The PCR was then purified (NucleoSpin®-Extract kit) and used for a DpnI-digestion 
(30 μl total reaction volume). The DpnI-digestion results in a degradation of 
methylated, not mutated plasmids (originating from bacterial amplification) and was 
performed for 2 to 6 hours at 37°C, followed by enzyme inactivation at 80°C for 5 
minutes. The whole digestion reaction was then used for transformation of 120 μl XL1-
blue bacteria suspension according to the below mentioned method (see paragraph 
4.2.1.2.). Effective mutagenesis was finally confirmed by sequencing as described in the 
next paragraph.  
 
108 4.2. Methods  
 
 
4.2.1.2. Molecular cloning and sequencing 
Molecular cloning via restriction enzymes generating cohesive ends 
Gel-purified PCR products (generated by primers bearing the required restriction sites) 
and destination vectors were digested with the required restriction enzymes for 2 to 4 
hours at 37°C. For the preparative digestion, up to 2 μg DNA and up to 7 % (v/v) 
enzyme in a total reaction volume of 30 μl were used. To prevent re-ligation, vectors 
were then also dephosphorylated using Alkaline-Phosphatase FastAP®.   
The ligation of the insert with the destination-vector was performed using 25 up to 70 
ng vector and a stoichiometric ratio vector/insert of 1:2. The total reaction volume of a 
ligation was always 10 μl containing 10 % T4-DNA ligase (5 U/μl). Ligation reactions 
were incubated 2 to 3 hours at room temperature or over night at 16°C. 
The entire ligation reaction was then used for transformation of 60 μl chemically 
competent XL1-blue bacteria suspension. The transformation was carried out using the 
calciumphosphate-heat shock method, described in (185). Afterwards the bacteria were 
plated out on LB-Agar plates composed of LB-medium containing 1.5 % (w/v) agar 
and the required amount of antibiotic for selection (e.g. 0.1 mg/ml ampicillin). 
Screening for efficient cloning was carried out for each putative positive clone by 
inoculating 5 ml LB-medium (containing antibiotic), small-scale plasmid isolation 
(NucleoSpin®-Plasmid), and finally small-scale (10 μl total reaction volume) test 
digestion with restriction enzymes. 
Plasmids of clones identified as potential successful cloned were sequenced as described 
below. In such a way verified constructs were then purified in large scale using the 
NucleoBond®-Xtra-Midi kit.  
  
Molecular cloning using pGEM®-T easy as sub-cloning vector 
For cloning of DNA-fragments generated by PCR into pGEM®-T easy vectors, the 
PCR-products had to be A-tailed first (due to the T-overhangs of the linear pGEM®-
T easy vector at the multiple cloning site). This was performed in a reaction (10 μl total 
reaction volume) with recombinant DNA-Polymerase from Thermus aquaticus (0.25 
U/μl final concentration) and dATP (0.2 mM final concentration) at 72°C for 30 
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minutes. After purification of the A-tailed product (NucleoSpin®-Extract kit) the 
ligation with the pGEM®-T easy vector was performed according to the manufacturer's 
instructions. Subsequently, 10 μl of the ligation was used for transformation of 60 μl  
XL1-blue bacteria suspension. After transformation, the bacteria were finally plated out 
on LB-plates containing ampicillin as well as 40 μl X-gal (20 mg/ml) and 4 μl IPTG (1 
M) for blue-white-screening of positive clones (pGEM®-T easy vectors carry the lacZ 
gene at the multiple cloning site). 
 
Molecular cloning via blunt ends 
PCRs using the Phusion® polymerase result in DNA fragments bearing per se blunt 
ends. These fragments had to be phosphorylated for the ligation with the destination 
vector. Phosphorylation via T4-Polynucleotide-Kinase of blunt end inserts and ligation 
were carried out in one reaction, because the used kinase is also active in the used 
ligation buffer. The ratio vector/insert of 1:4 was for the ligation of blunt ends. First the 
inserts were phosphorylated in reaction volume of 10 μl (with 10 % (v/v) kinase and 1 μl 
ligation buffer) at 37°C for 30 minutes, then the reaction was stopped at 75°C for 10 
minutes. Finally, the reaction was filled up with 1 μl ligation buffer, 25 to 70 ng 
linearized vector, 2 μl PEG 4000 solution [50 % (w/v)], 1 μl ligase, and water to a total 
end volume of 20 μl. The subsequent steps were then carried out in the same manner as 
already described for cohesive end cloning strategy. 
For some constructs, two inserts bearing sticky ends as well as blunt ends were fused via 
the blunt ends and ligated with the linearized vector by the sticky ends in one single 
ligation reaction. This kind of ligation was carried out like the "normal" blunt end 
ligation. This was for example the case for cloning the constructs "pCS2-CAMTA1-
N+C" and "pIRES-Nkx2.2ΔHD". 
 
Molecular cloning using single stranded oligonucleotides 
Artificial, single stranded oligonucleotides needed to be annealed and  phosphorylated 
first before the ligation step was performed. This was the case for the generation of 
artificial, full-complementary binding sites for miRNA-17-5p and miR-106b fused to 
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the coding sequence of firefly luciferase. The annealing was performed in the same way 
as described for the annealing of two complementary siRNA-oligonucleotides (see 
paragraph 4.2.2.3.). The ligation including phosphorylation was carried out as before 
mentioned for blunt end cloning. Here, the molar ratio insert/vector was 1:2. The 
subsequent steps were then the same as for the other cloning strategies. 
 
Sequencing 
All constructs generated in this thesis were confirmed by Sanger-sequencing carried out 
by GATC (Cologne, Germany) or Macrogen Europe (Amsterdam, Netherlands). 
 
4.2.1.3. Quantitative real-time polymerase chain reaction (qRT-PCR) 
The real-time quantification of DNA-amplicons during PCR was performed in using 
fluorescent dyes which bind specifically double-stranded DNA molecules. The basic 
principle of this qRT-PCR method is described in (186-188).  
For qRT-PCR, the iCylcer equipped with the MyiQ real-time detection system (Bio-
Rad) or the C1000 thermal cycler CFX98TM Real Time System (Bio-Rad) were used. 
The qRT-PCR reaction was performed using the MESA GREEN qPCR mastermix 
(Eurogentec) for the MyiQ cycler and the SSoFastTM EvaGreenTM Supermix (Bio-Rad) 
for the CFX98TM Real Time System. The templates for qRT-PCR were generated by 
cDNA synthesis (see paragraph 4.2.2.2.) and were used for the reaction as a 1:10 
dilution (in nuclease-free water). One single qRT-PCR reaction contained 5 μl diluted 
cDNA as template, forward and reverse qRT-PCR primers (each with a final 
concentration of 50 to 200 nM), and 10 μl two-times concentrated qRT-PCR 
mastermix, filled up to a total reaction volume of 20 μl with nuclease-free water.   
Every reaction was performed in technical triplicates. The qRT-PCR programs for the 
two different mastermixes is specified hereinafter.  
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MESA GREEN EvaGreenTM
Step temperature time temperature time
1 95°C 3 min 98°C 1 min 
2 95°C 10 s 98°C 5 s
3 60°C 30 s 60°C 10-15 s 
 
The amplification was completed within 40 cycles (step two and three). For every qRT-
PCR reaction a melt peak analysis was performed after the amplification phase in order 
to check the quality of the respective amplicons. 
Data for qRT-PCRs were evaluated using the "ddCt-method" with GAPDH or β-actin 
as reference mRNAs. The ddCt-method is described in (188). For every qRT-PCR the 
mean of the triplicate Ct values was used to calculate the corresponding ddCt value. The 
calculation of the error bars was carried out as described in (188). 
 
4.2.2. Working with RNA 
4.2.2.1. Isolation of RNA from cultured cells 
The isolation and purification of total RNA from cultured cells was performed using the 
NucleoSpin®-RNA kit according to the manufacturer's instructions. The standard 
procedure for this kit includes also an DNase I digestion to remove residual DNA 
contaminations. 
 
4.2.2.2. Reverse Transcription 
For the synthesis of cDNA, 200 ng up to 2 μg total RNA was used as templates. The 
synthesis was performed using either the iScriptTM or the First-Strand cDNA synthesis 
kit, in both cases according to the instructions of the manufactures. For the First-Strand 
cDNA synthesis always random DNA-hexamers were used as primers. 
After cDNA synthesis, the reaction was diluted 1:10 in nuclease-free water and used for 
downstream applications such as molecular cloning and/or qRT-PCR. 
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4.2.2.3. Annealing of siRNA-oligonucleotides for RNA interference 
SiRNAs for a siRNA-mediated gene knockdown were designed using the siRNA 
selection program of http://sirna.wi.mit.edu/. The single-stranded full-complementary 
siRNA-oligonucleotides had to be annealed first. The duplex was then transfected into 
cultured cells (see paragraph 4.2.4.2.). The annealing of complementary siRNA-strands 
was performed in siRNA-annealing buffer (specified hereinafter) at 95°C for one 
minute, followed by incubation at 37°C for one hour (at constant shaking). 
annealing buffer
magnesium acetate 2 mM 
potassium acetate 100 mM 
HEPES 30 mM
pH = 7.4
 
The concentrations of the single-stranded oligonucleotides was determined before and 
the amounts taken for the annealing resulted in a solution containing 20 or 40 μM 
double-stranded RNA-oligonucleotide. 
The efficiency of the annealing reaction was verified by agarose-gel electrophoresis 
using gels with agarose concentrations of 4 % (w/v), followed by ethidium bromide 
staining. 
 
4.2.3. Working with proteins 
4.2.3.1. Preparation of whole cell protein lysates 
For the preparation of whole cell lysates, cultured human cells were first harvested at a 
confluence of 80 to 95 %. Transfected cells overexpressing the protein(s) of interest were 
harvested 48 hours after transfection (see paragraph 4.2.4.2.). After removal of the 
cultivation medium, cells were pelletized (500 g, five minutes, 4°C) and washed twice 
with PBS, composed of as stated hereinafter. 
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PBS
NaCl 140 mM 
KCl 2.7 mM 
Na2HPO4 (× 2 H2O) 10 mM 
KH2PO4 1.8 mM
pH = 7.5
 
The washed cell pellet was then resuspended in a lysis buffer which was suitable for the 
respective downstream application. 
 
Lysis using nuclear lysis buffer 
For an effective lysis of the whole cell including the nucleus a lysis buffer was used 
containing the detergents SDS and sodium deoxycholate. The exact composition of this 
nuclear lysis buffer was: 
TRIS 50 mM 
EDTA 10 mM 
SDS 1 %  (w/v)
sodium deoxycholate 0.1 % (w/v)
AEBSF 2 mM
pH = 8
 
Before lysis, the nuclear lysis buffer was supplemented with DNase I (final 
concentration of 5 U/ml). Cells were then resuspended in the appropriate volume of 
nuclear lysis buffer (e.g. 500 μl lysis buffer for an amount of 90 % confluent cells from a 
10 cm-cell culture dish) and incubated for 20 minutes at room temperature. Afterwards 
cells were sonicated for 10 to 20 seconds on a Branson Sonifier 450. Finally, lysates 
were cleared by centrifugation at 20,000 g for 20 minutes and 4°C. The cleared lysate 
(supernatant) was then used for western blot analysis. 
 
Lysis for immunoprecipitation 
Two different procedures were performed to lyse cells for IPs (see paragraph 4.2.3.2.) of 
nuclear proteins such as CAMTA1 and Nkx2.2. 
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One method includes the usage of a lysis buffer containing sodium deoxycholate for 
nuclear lysis. This lysis buffer (referred to as "IP-lysis buffer 1") was composed of: 
NaCl 140 mM 
KCl 2.7 mM 
Na2HPO4 (× 2 H2O) 10 mM 
KH2PO4 1.8 mM
sodium deoxycholate 0.25 % (w/v)
NP-40 1 % (v/v)
DTT 1 mM
AEBSF 1 mM
pH = 7.5 
 
Harvested cells were lysed by resuspending the cell pellet in the appropriate volume of 
IP-lysis buffer 1 (e.g. 1 ml lysis buffer for an amount of 90 % confluent cells from a 15 
cm-cell culture dish). The suspension was then incubated for 15 to 20 minutes at 4°C 
and cleared afterwards by centrifugation (20,000 g for 20 min and 4°C). The 
supernatant was finally used as input for IP. 
For the second IP-lysis method, a hypotonic lysis buffer (stated as "IP-lysis buffer 2") 
containing no monovalent salt (except of NaF at a very low concentration) was used: 
TRIS 50 mM 
EDTA  5 mM 
NaF 5 mM  
NP-40 0.2 % (v/v)
DTT 1 mM
AEBSF 1 mM
pH = 7.5 
  
For lysis, harvested cells were incubated for 20 minutes at 4°C and constant rotation 
with the appropriate volume of IP-lysis buffer 2 (e.g. 1 ml for one 15 cm-cell culture 
dish). This hypotonic treatment leads to an osmotic swelling and breaking of the cells. 
After this first incubation, NaCl was added to final concentration of 150 mM to extract 
nuclear proteins. The lysate was then incubated again for 20 minutes at 4°C and 
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constant rotation. Finally, the lysate was shortly sonified (10 to 20 seconds) and  
centrifuged (20,000 g for 20 min and 4°C). The supernatant was used as input for IP. 
 
4.2.3.2. Immunoprecipitation 
The inputs for IPs were prepared as described in the previous paragraph. After taken a 
certain amount as an input-sample (normally 0.5 to 2 % of the input), the protein of 
interest was immunoprecipitated by adding the input to 40 - 50 μl beads (amount for a 
single IP), which were pre-coupled to a protein-specific antibody.  The list of antibodies 
as well as their amount used for coupling is stated in Table 4.7. (see paragraph 4.1.7.). 
The choice of the beads (protein A- or protein G-SepharoseTM beads; both purchased 
from GE Healthcare) complied with the species origin of the particular antibody IgG. 
Rabbit-IgGs were coupled to protein A- or  G-SepharoseTM and murine IgGs to 
protein G-SepharoseTM beads. Accordingly, either normal rabbit IgG (Santa Cruz) or 
beads only (in the case of using antibodies from mouse) were used as IP-controls. The 
antibody coupling was performed in PBS over night at 4°C and constant rotation, after 
washing the beads once with PBS-T (PBS containing 0.1 % (v/v) Tween-20) and once 
with PBS (each time: 3,000 g and 4°C for 2 minutes). For the IP of FLAG-tagged 
proteins, 40 - 50 μl slurry of ANTI-FLAG® M2 affinity agarose (Sigma-Aldrich) was 
used (washed twice with PBS-T before). 
The IP reaction was performed for 3 to 5 hours at 4°C while rotating. Afterwards, beads 
were spun down (at 3,000 g and 4°C for 2 minutes) and washed four times with IP-
wash buffer, composed of: 
NaCl  300 mM 
TRIS 50 mM
MgCl2  (× 6 H2O) 5 mM 
NaF 1 mM
NP-40 0.01 % (v/v) 
pH = 7.5
 
Finally, the proteins were eluted from beads after a last washing step with PBS. The 
elution was performed by adding an equivalent volume of two-times concentrated 
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Laemmli sample buffer [composition described in (189)] to the beads, followed by 
boiling at 95°C for five minutes. The IP-eluate was cleared from beads by short 
centrifugation and then used for downstream applications such as western blot analysis 
(see paragraph 4.2.3.7.) or mass spectrometry (see paragraph 4.2.3.8.). 
 
4.2.3.3. Generation of nuclear extracts 
Nuclear extracts from HeLa-S3 suspension culture cells 
For nuclear extracts from HeLa-S3 suspension culture, cells were cultivated (see 
paragraph 4.2.4.1.) until they had reached a confluence of one billion cells per liter 
culture volume. The extraction was performed as described previously by Dignam et al. 
(190) with some adjustments. 
First, cells were harvested by centrifugation (500 g, room temperature) and subsequently 
washed once with PBS. The further extraction steps were performed at 4°C. Next, 
pelletized cells were washed once (1,000 g for 5 minutes) with 5 × pellet volume 
hypotonic Roeder A buffer, composed of: 
HEPES  10 mM 
KCl  10 mM 
MgCl2  (× 6 H2O) 1.5 mM  
DTT 0.5 mM
AEBSF 0.5 mM
pH = 7.9 
 
The cells were then incubated with 3 × pellet volume Roeder A buffer for 15 minutes 
for osmotic swelling. Afterwards, this suspension was transferred to an glass 
homogenizer. Breaking of the cells was archived by moving the pestle at least ten times 
up and down and was confirmed by Trypan-blue exclusion staining. Subsequently, 
fractionating of the cell cytoplasm was performed by centrifugation at 3000 g for ten 
minutes. The supernatant (raw cytoplasmic fraction) was further purified by adding 0.1 
pellet volume Roeder B buffer (composition specified below) and another centrifugation 
step at 100,000 g for 60 minutes. This yielded the cleared cytoplasmic fraction 
(supernatant after removal of the lipid layer). After taken the raw cytoplasmic fraction, 
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the remaining cell debris was washed two times with 5 × pellet volume Roeder A buffer 
(each time: 1,000 g for 5 minutes) and the pellet was subsequently resuspended in 3 ml 
per 109 cells hypertonic Roeder C buffer composed of as indicated below. The nuclei 
were broke by transferring the suspension into a homogenizer and douncing ten times. 
This crude nuclear extract was then further incubated for 30 minutes while stirring, 
followed by centrifugation at 25,000 g for 20 minutes. The supernatant which is the 
soluble nuclear fraction was kept until further analysis and the pellet was resuspended in 
3 ml per 109 cells Roeder C. Finally, this suspension was sonified on a Branson Sonifier 
450 (four times 20 seconds) and cleared by centrifugation at 25,000 g for 20 minutes. 
The resulting supernatant was kept as nuclear insoluble fraction for further analysis. The 
purity of the cytoplasmic/nuclear fractionation was controlled by western blot analyses 
(see paragraph 4.2.3.7.) using antibodies against lamin A/C and α-Tubulin.  
Roeder B Roeder C  
HEPES 300 mM HEPES 20 mM 
KCl 1.4 mM KCl 100 mM 
MgCl2  (× 6 H2O) 30 mM MgCl2  (× 6 H2O) 1.5 mM 
DTT 0.5 mM EDTA 0.2 mM 
AEBSF 0.5 mM glycerol 20 % (v/v) 
 DTT 0.5 mM 
 AEBSF 0.5 mM 
pH = 7.9 pH = 7.9  
 
Nuclear extracts from HEK293-T cells 
The preparation of nuclear extracts from adherent growing HEK293-T cells was 
performed at a cell confluence of 80 %. First, cells were harvested by centrifugation at 
500 g and room temperature for five minutes, followed by washing once with PBS. The 
pelletized cells were then resuspended in 5 ml/g cell pellet TB buffer, composed of as 
stated hereinafter. 
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TB buffer 
HEPES  20 mM 
potassium acetate 110 mM 
magnesium acetate (× 4 H2O) 2 mM  
EGTA 1 mM
DTT 1 mM
AEBSF 1 mM
pH = 7.3 
 
Cells were then subsequently lysed by adding 10 ml/g cell pellet digitonin (100 μg/ml 
stock solution). Digitonin treatment was performed at 4°C until approximately 90 % of 
the cells were lysed (checked by Trypan-blue exclusion staining). Next, the cell debris 
was spun down at 1,000 g for 5 minutes at 4°C. The supernatant yielded then the 
cleared cytoplasmic extract. The pellet was further purified by washing three times with 
10 ml/g cell pellet TB buffer containing 0.3 % (v/v) NP-40 (at each washing step the 
suspension was vortexed thoroughly for 10 seconds). After the last washing step, the 
pellet was resuspended in 5 ml TB buffer per g cell pellet. This crude nuclear extract 
was finally sonified on a Branson Sonifier 450 (four times 20 seconds) and cleared by 
centrifugation at 20,000 g for 20 minutes at 4°C. The resulting supernatant (cleared 
nuclear extract) was kept for further analysis. The purity of the cytoplasmic/nuclear 
fractionation was confirmed by western blot detection (see paragraph 4.2.3.7.) of lamin 
A/C and α-Tubulin. 
 
4.2.3.4. Determination of protein concentrations 
Total protein concentrations in lysates were determined on the Nanodrop® 
spectrophotometer at a wavelength of 280 nm, if the nuclear lysis buffer was used. In all 
other cases, measurement of total protein concentrations was performed using  the 
Bradford protein assay, described in (191). For the assay, Roti®-Quant (Carl Roth) was 
used according to the manufacturer's instructions with dissolved BSA (in serial 
dilutions) as calibrating protein.  
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4.2.3.5. SDS-polyacrylamide gel electrophoresis 
Separation of proteins by their molecular weight using denaturating SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed as described by 
Laemmli (189).  
The composition of the stacking and separating gel is specified hereinafter. 
stacking gel separating gel
TRIS 125 mM TRIS 380 mM
SDS 0.1 % (w/v) SDS 0.1 % (w/v)
TEMED 0.15 % (v/v) TEMED 0.1 % (v/v)
APS 0.05 % (w/v) APS 0.05 % (w/v)
acrylamide/bis solution (37.5:1) 5 % (v/v) acrylamide/bis solution (37.5:1) 10 % (v/v)
pH = 6.8 pH = 8.8
 
Unless stated otherwise, separating gels with an acrylamide concentration of 10 % were 
used. 
Before loading, samples for SDS-PAGE were mixed with Laemmli buffer and boiled at 
95°C for 5 minutes (except of IP-eluates since they were already boiled during the 
elution step, see paragraph 4.2.3.2.). Protein separation was performed at a constant 
current of 50 mA using a running buffer composed of: 
TRIS base 25 mM 
glycine 192 mM 
SDS 0.1 % (w/v)
  
4.2.3.6. Coomassie and silver staining of SDS-polyacrylamide gels 
Coomassie staining 
Coomassie staining of SDS-PAGE gels was performed over night at room temperature 
with Coomassie staining solution, composed of: 
acetic acid 10 % (v/v) 
ethanol 30 % (v/v) 
Coomassie R250 0.25 % (w/v)
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For destaining (at room temperature until protein bands were clearly visible) the 
following solution was used: 
acetic acid 10 % (v/v) 
ethanol 30 % (v/v) 
 
Silver staining 
Sliver staining of protein gels was performed according to Blum et al. (192) with some 
adaptations. 
Gels were first fixed with 50 % (v/v) methanol and 12 % (v/v) acetic acid for 1.5 hours 
at room temperature. This was followed by washing once with 50 % (v/v) and once with 
30 % ethanol (each time: for 10 to 30 minutes at room temperature). Gels were then 
treated for one minute with 0.02 % (w/v) sodium thiosulfate and afterwards rinsed three 
times with water. Subsequently, gels were incubated for 20 minutes at room 
temperature with a 0.1 % (w/v) silver nitrate solution, rinsed two times with water, and 
finally developed with freshly prepared 6 % (w/v) sodium carbonate solution containing 
0.074 % (v/v) formaldehyde and 400 μg/l sodium thiosulfate. The developing reaction 
was stopped with 5 % (v/v) acetic acid (for 5 minutes at room temperature) when the 
protein bands of interest were clearly visible. However, developing was not longer 
performed than 10 minutes. 
 
4.2.3.7. Western blot 
Semi-dry transfer 
For the semi-dry transfer of proteins from a SDS-PAGE gel to a nitrocellulose blotting 
membrane (AmershamTM ProteanTM, GE Healthcare), the following transfer buffer was 
used: 
TRIS  25 mM 
glycine  192 mM 
methanol 20 % (v/v)
pH = 8.6
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The transfer was performed using semi-dry transfer chambers purchased from Bio-Rad. 
On the bottom electrode (anode) of the chamber four Whatman®-papers (Biometra, 
Göttingen, Germany), soaked with transfer buffer, were first positioned. The 
membrane was placed on the Whatman®-papers, followed by the gel (both incubated 
shortly with transfer buffer). To complete the "transfer-sandwich", the gel was covered 
by again four soaked Whatman®-papers. 
The semi-dry blot was carried out at constant current of 2 mA per square centimeter 
Whatman®-paper and for approximately 1 minute per kDa molecular weight 
corresponding to the protein of interest. 
 
Wet blot transfer 
A wet blot was performed to transfer proteins with a high molecular weight such as 
CAMTA1. The wet blot transfer was carried out using the Trans-blot® Cell wet blot 
chamber (Bio-Rad) and a transfer buffer, composed of: 
TRIS 25 mM 
glycine 192 mM 
pH = 8.3
 
The set-up of the "transfer-sandwich" was in principle the same as described for the 
semi-dry blot. Wet blot transfer was performed over night at 4°C and constant voltage 
of 30 V. 
 
Further procedure after transfer 
After the transfer, membranes were incubated for one hour at room temperature or over 
night at 4°C with 5 % (w/v) milk in TBS-T as blocking solution. TBS-T was composed 
of: 
NaCl 150 mM 
TRIS 10 mM 
Tween-20 0.1 % (v/v)
pH = 8.0
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Subsequent to the blocking step, membranes were incubated with a primary antibody 
solution listed in Table 4.7 (see paragraph 4.1.7.) for at least one hour at room 
temperature or over night at 4°C. Primary antibodies were diluted in TBS-T containing 
2 % (w/v) milk and 0.02 % (v/v) sodium azid, except of the anti-Nkx2.2 hybridoma 
supernatant, which was diluted in TBS-T with sodium azid only. In the case of using 
the Nkx2.2 antibody, the membrane was washed twice with TBS-T after blocking.  
After incubation with primary antibody, the membrane was washed three times with 
TBS-T (each time 5 minutes while shaking). Subsequently, the secondary antibody 
solution was deployed on the membrane. The used secondary antibodies are coupled to 
fluorescent dyes and were all purchased by Licor. Depending on the species origin of 
the primary antibody either anti-Mouse-IgG-IRDye®-800CW/-680 or anti-Rabbit-
IgG-IRDye®-800CW/-680 were used as 1:10,000 dilutions in TBS-T (containing 2 % 
(w/v) milk and 0.02 % (v/v) sodium azid). The incubation with the secondary antibody 
was performed for one hour at room temperature (light-protected), followed by washing 
three times with TBS-T. Finally, protein and marker bands were visualized at the 
Odyssey IR Imager (Licor). 
 
4.2.3.8. Mass spectrometry 
Protein bands for mass spectrometry analysis were cut out from silver stained gels and 
transferred to 2 ml-Eppendorf cups. From these gel slices proteins were extracted, 
purified, and digested with trypsin. This procedure and identification of proteins via 
analytical mass spectrometry were carried out in collaboration with the group of Prof. 
Rainer Deutzmann (Department Biochemistry I, University of Regensburg). The raw 
data gained from mass spectrometry were interpreted by the Protein-Scape software 
(Bruker Daltonics) using the Mascot search engine (v2.3.02) to identify proteins. 
Thereby, SWISS-PROT database search was carried out for identification. Detected 
proteins were tabularly ordered according to their particular Mascot protein score (from 
high to low values). For further analysis the list of identified proteins was cleared from 
contaminations such as keratin, which were caused obviously by sample preparation. 
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4.2.3.9. Purification of recombinant expressed GST-tagged proteins via fast protein 
liquid chromatography 
Large scale purification of recombinant expressed human GST-tagged proteins was 
performed via fast protein liquid chromatography (FPLC) on an ÄKTA purifier (GE 
Healthcare). Thereby, "large scale" means more than one liter of expression culture. 
 First, for the bacterial expression of human proteins, chemically competent bacteria of 
the Rosetta E. coli strain were transformed (by heat shock) with a pGEX-6p1 plasmid 
encoding for the protein of interest and an N-terminal GST-tag. The Rosetta stain is 
characterized by bearing an additional plasmid coding for chloramphenicol resistance 
and human tRNAs which are rarely used in E. coli.  
On the day of expression, a large volume (e.g. 4 l) of LB medium containing final 
concentrations of 100 μg/ml ampicillin (pGEX-6p1) and 50 μg/ml chloramphenicol 
was inoculated 1:50 by a pre-culture (cultivated over night at 37°C). Bacterial growing 
was then continued at 37°C until the culture had reached an OD600 around 0.6. 
Afterwards, the culture was incubated for 30 to 60 minutes at the optimal temperature 
for protein expression (e.g. 25 °C) until OD600 was between 0.6 and 0.9. Next, protein 
expression was induced by adding IPTG to a final concentration of 1 mM. After 
induction, the incubation at the expression temperature was continued for the optimal 
expression time (e.g. 5 hours). The optimal expression temperature and time was 
determined before by small scale (up to 100 ml culture volume) expression tests.  
After expression, bacteria were harvested (5,000 g for 15 minutes at 4°C) and 
resuspended in bacterial lysis buffer (20 ml per liter culture volume), composed of: 
NaCl 500 mM 
TRIS 50 mM 
MgCl2 5 mM
AEBSF 1 mM
pH = 7.5
 
Before use, Benzonase® Endonuclease (Merck; 10 U/ml final concentration) and 
lysozym (1 mg/ml final concentration) were added to the lysis buffer. To lyse the cells, 
bacteria were sonified with a Branson Sonifier 450 (pulses at an intensity 7 to 8 for 3 × 3 
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minutes). The raw bacterial lysate was subsequently centrifuged at 30,000 g for 30 
minutes at 4°C and cleared by filtration. The lysate was then loaded on a glutathione 
SepharoseTM column (GSTrap FF, GE Healthcare) using the ÄKTA FPLC system to 
purify the overexpressed GST-tagged protein. After washing the column with 10 
column volume of bacterial lysis buffer, GST-tagged proteins were eluted from the 
column using bacterial lysis buffer at pH of 8.0 supplemented with 3 mg/ml reduced 
glutathione. Finally, fractions containing the GST fusion protein with the highest 
amounts (peak fractions) were pooled together. 
As mentioned above, for the purification of GST-CAMTA1-F3 an anion exchange 
chromatography was necessary as a further purification step. Thereby, pooled fractions 
containing GST-CAMTA1-F3 were first concentrated to a total volume of 10 ml. 
Afterwards, this concentrated protein solution was desalted by chromatography (HiPrep 
26/10 Desalting, GE Healthcare) using a low salt buffer (50 mM NaCl, 20 mM TRIS), 
which had a pH value 2.5 units above the theoretical pI of GST-CAMTA1-F3 (4.94), 
i.e. pH of 7.5. This buffer was also used to equilibrate the ion exchange column 
(RESOURCETM Q, GE Healthcare). The fractions of the desalted protein were pooled 
and loaded on the ion exchange column. After washing with 1 to 2 column volume of 
the above mentioned low salt puffer, GST-CAMTA1-F3 was eluted with a high salt 
elution buffer (500 mM NaCl, 20 mM TRIS, pH 7.5). Fractions containing the fusion 
protein at highest degree of purity (confirmed by SDS-PAGE) were pooled and further 
concentrated. The protein concentration was then determined with a photometer at 280 
nm. Finally, the protein solution was stored at -80°C after adding glycerol (5 % (v/v) 
final concentration) and fast-freezing with liquid nitrogen. 
 
4.2.3.10. Generation and purification of polyclonal antibodies 
The polyclonal antibody sera anti-CAMTA1 SY6160 and  anti-CAMTA1 SY6161 
were generated by immunization of rabbits at Eurogentec using GST-CAMTA1-F3 as 
antigen. 
For purification of polyclonal antibody sera via affinity chromatography, the 
corresponding antigen was covalently coupled to a cyanogen bromide-Sepharose4TM 
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matrix (CNBr-activated-Sepharose4TM Fast Flow, GE Healthcare). For one coupling 
reaction 300 mg of activated Sepharose4TM was incubated with hydrogen chloride (1 
mM) for 30 minutes at 4°C (for swelling). The swollen matrix was then transferred into 
a 15 ml-Poly Prep chromatography column (Bio-Rad). This was followed by adjusting 
the pH of the matrix to 8.3 with coupling buffer, composed of: 
NaCl 0.5 M 
NaHCO3 192 mM 
pH = 8.3
 
Before the antigen peptide solution was loaded on the matrix, the antigen was dialyzed 
against 1 l coupling buffer over night at 4°C (Dialysis Tubing Visking, cellulose, 10 -14 
kDa molecular weight cutoff, Roth). The matrix was then incubated with the antigen 
over night at 4°C while rotating for coupling.  
Afterwards, the matrix was washed with 5 × matrix volume coupling buffer and 
subsequently resuspended in 5 × matrix volume ethanolamine (1 M, pH 8), followed by 
two hours incubation at room temperature for blocking. Then, the matrix was washed 
alternately with wash buffer 1 (pH 3 to 4) and wash buffer 2 (pH 8 to 9), eight times in 
total beginning with wash buffer 1 (each time: one column volume buffer). The exact 
composition of wash buffer 1 and 2 was: 
wash buffer 1 wash buffer 2  
sodium acetate 100 mM TRIS 100 mM 
NaCl 500 mM NaCl 500 mM 
pH = 3 to 4 pH = 8 to 9  
 
After a final washing step with PBS, the antibody serum was deployed on the antigen-
coupled matrix for purification and incubated over night at 4°C while rotating. Finally, 
after washing twice with PBS (each time: one column volume), the purified antibody 
solution was eluted  by 10 ml glycine at a pH of 2.3. The eluate was fractionated as 1 
ml-fractions. At the end, the pH value of each fraction was adjusted to a not acidic level 
with 100 μl/fraction TRIS (1 M, pH 8.8). To store the purified antibody solution, 
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glycerol (5 % (v/v) final concentration) was added to each fraction, followed by fast-
freezing with liquid nitrogen. 
 
4.2.3.11. Immunofluorescence 
For IFs, cells were cultivated in 24-well cell culture plates on microscopy cover slips 
(circular, 12 mm diameter) until they had reached a confluence between 50 and 80 %. 
After removing the cultivation medium, cells were washed once with [pre-warmed 
(37°C)] PBS, followed by fixation with (pre-warmed) PBS containing 4 % (w/v) 
paraformaldehyde at 37°C for ten minutes. Fixation was then stopped by replacing 
PBS-paraformaldehyde with (pre-warmed) PBS containing 100 mM glycine. After 
incubation at 37°C for 5 minutes, cover slips were washed twice with (pre-warmed, 
37°C) PBS. Afterwards, the cells were permeabilized for 15 minutes at room 
temperature using PBS with 0.2 % (v/v) Triton X-100. This was followed by washing 
twice with blocking solution composed of PBS containing 0.05 % (v/v) Triton X-100 
and 1 % (w/v) BSA. Subsequently, cells were incubated for one hour at room 
temperature with blocking solution. Then, primary antibody solutions were deployed on 
the cover slips. Primary antibodies used for IF are sated in Table 4.7 (see paragraph 
4.1.7.). All antibodies used in IF were diluted in blocking solution (see also Table 4.7 
for the particular amounts used for IF of the respective antibodies). Cells were 
incubated for one to two hours at room temperature with primary antibodies, followed 
by washing four-times with blocking solution. Afterwards, secondary antibodies 
conjugated to fluorescent dyes were deployed on the cells for one hour (at room 
temperature and protected from light). According to the species origin of the primary 
antibody IgG, either Alexa Fluor® 555 Goat Anti-Rabbit IgG (H+L) or Alexa Fluor® 
555 Goat Anti-Mouse IgG (H+L) secondary antibodies were used, diluted 1:400 in 
blocking solution. Both secondary antibodies were purchased from Life Technologies 
(Carlsbad, USA). After incubation with secondary antibodies, the cover slips were 
washed once with blocking solution, three times with PBS, and at last with water. 
Finally, one drop of ProLong® Gold Antifade Mountant with DAPI (Life 
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Technologies) for each cover slip was deployed on a microscopy slide, before the cover 
slips were transferred to these slides (with the cell covered surface down to the 
mounting solution). The usage of this solution for mounting resulted also in DAPI-
staining of nuclei. After transferring the slips, the prepared slides were dried for at least 
24 hours (light-protected, at 4°C) before IFs were visualized. Thereby, either the 
Axiovert 200M fluorescence microscope (Zeiss) or the TCS SP8 confocal laser scanning 
microscope (Leica) was used. 
 
4.2.4. Human cell culture 
4.2.4.1. Cultivation of human cell lines 
All cell lines listed in Table 4.9 were cultivated at 37°C in an atmosphere with 95 % 
humidity and a CO2-content of 5 %. 
For the cultivation of HEK293-T, HeLa, and stable glioma cell lines (LNT229 and 
T98G) Dulbecco's Modified Eagle's Medium (DMEM) was used containing 10 % 
(v/v) FBS and 1 % (v/v) Penicillin/Streptomycin stock solution. DMEM, FBS, and 
Penicillin/Streptomycin were all purchased from Sigma-Aldrich. These adherent 
growing cell lines were passaged normally three times a week using Trypsin-EDTA 
(Sigma-Aldrich). 
For the cultivation of HeLa-S3 suspension culture cells Joklik's Medium was used, 
which was composed of: 
Minimum essential medium Joklik's modified 
(Sigma-Aldrich) 
11.02 g/l  
NaHCO3 2 g/l 
L-glutamine (Sigma-Aldrich) 0.29 g/l 
MEM non-essential amino acids
(Life Technologies) 
1 % (v/v) 
Penicillin/Streptomycin stock solution 1 % (v/v) 
FBS 5 % (v/v) 
pH = 7  
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The cells were cultivated (up to one liter culture volume) in glass flasks while constant 
stirring. These suspension cells were normally passaged every third day by inoculating 
fresh cultivation medium with a certain amount of cells resulting in confluence of 
400,000 to 600,000 cells/ml. 
The R11 primary glioblastoma cell line was cultivated in neural stem cell medium as 
previously described in (53). This medium was also used for the cultivation of the 
primary glioblastoma cell line ZH161. R11 cells were passaged every four to five days, 
ZH161 every seven to ten days, by detaching with a pipette. 
 
4.2.4.2. Transfection 
Transfection using calcium phosphate precipitation 
This method was used for transfection of HEK293-T cells cultivated in 15 cm-cell 
culture dishes. Transfection was performed at a confluence of 15 to 25  % and at least 
six hours after the last passage via trypsinization. For the transfection of one single 15-
cm cell culture dish, a DNA/CaCl2 solution with a total volume of 1.13 ml was 
prepared first. This solution contained 10 up to 20 μg total plasmid DNA diluted in 
(sterile) water and a final concentration of 243 mM CaCl2. Afterwards 1.13 ml of two-
times concentrated HBS was added drop by drop while constant shaking. HBS was 
composed of: 
NaCl 137 mM 
Na2HPO4 (× 2 H2O) 0.75 mM 
HEPES  27.3 mM 
pH = 7.1 
 
Before the transfection solution was deployed on the cultivated cells, the solution was 
incubated for 5 to 10 minutes at room temperature to ensure the efficient formation of 
calcium-DNA complexes.  
Transfected HEK293-T cells were harvested for further downstream applications 48 
hours after transfection.  
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Transfection via lipofection 
Either LipofectamineTM 2000 or  LipofectamineTM RNAiMAX was used for lipofection 
of cells with plasmid-DNA and/or RNA-oligonucleotides. Both reagents were 
purchased from Life Technologies. Transfection with plasmid-DNA together with 
RNA or with plasmid-DNA only was performed via LipofectamineTM 2000, whereas 
transfection for RNAi with pre-annealed siRNA-strands (see paragraph 4.2.2.3.) was 
achieved by LipofectamineTM RNAiMAX. In both cases the transfection procedure was 
carried out according to the manufacturer's instructions. For the transfection, cells were 
cultivated in medium without antibiotics. DNA and RNA as well as the lipofection 
reagents were diluted with Opti-MEM® (Life Technologies).  
The transfection for a gen-specific knockdown with LipofectamineTM RNAiMAX was 
always carried out in 6-well cultivation plates. The total concentration of siRNAs was 
40 nM per well. Transfections using LipofectamineTM 2000 were performed in 6-well 
and 48-well plates. The amount of transfected DNA/RNA is stated in the 
corresponding downstream application. 
Cultivation medium was changed 24 hours after lipofection and the transfected cells 
were used for downstream applications after a further cultivation period of 24 hours.    
 
Transfection via Nucleofection®  
Nucleofection® uses electroporation and transfection reagents with nuclear localization 
signals for an efficient transfection. In this thesis, LNT229 and R11 cells were 
transfected by this method. Thereby, the Amaxa® Cell Line Nucleofector® Kit R was 
used for the transfection of LNT229 cells, whereas R11 cells were transfected with the 
Amaxa® Mouse Neural Stem Cell Nucleofector® Kit. Both kits were purchased from 
Lonza. The electroporation was carried out for both kits at the Nucleofector®-Device II 
(Lonza).  
Both kits use in principle the same transfection protocol. For one single transfection 3 × 
106 cells (cultivated in antibiotics-free medium) and 5 μg total plasmid-DNA were 
used. The transfection was carried out according to the manufacturer's instructions. 
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After the electroporation step cells were seeded in 10 cm-cell culture dishes and 
cultivated for at least 24 hours until they were used for further downstream applications.  
 
4.2.4.3. Proliferation assays 
In this thesis, the effects of Nkx2.2 and Nkx2.2 mutants on cell proliferation of stable 
glioma LNT229 cells were examined. For this assay, LNT229 cells were first 
transfected with eukaryotic expression vectors encoding for the particular proteins by 
the above mentioned Nucleofection® method. One day after transfection, 40,000 cells 
(per one single transfection) were seeded into μDish Grid-500 (35 mm) counting plates 
(ibidi, Planegg, Germany) and further cultivated. These plates contain a microscopic 
grid for counting on the bottom surface (4 × 10 × 10 squares with 500 × 500 μm2). One 
day after seeding, cells in an area of 6 × 6 squares were counted (per transfection). On 
the three subsequent days, the number of cells in this area was further quantified to 
determine the cell proliferation rate. For analysis, the mean number of cells per square 
(in the counting area) was calculated for every day of counting. 
 
4.2.4.4. Neurosphere assays using primary glioblastoma cell lines 
To investigate the effects of Nkx2.2 and Nkx2.2 mutants on the neurosphere-forming 
capability of primary glioblastoma cells, R11 and ZH161 were transfected with 
plasmids coding for the particular proteins. The transfection of R11 cells was performed 
by Nucleofection® as described in 4.2.4.3., whereas ZH161 cells were transfected in 6-
well plates with LipofectamineTM 2000. Thereby, an amount between 300,000 and 
500,000 cells was transfected with 4 μg plasmid-DNA for one single transfection. One 
to two days after transfection R11 or ZH161 cells were singularized and counted (using 
a Neubauer hemocytometer). Afterwards, 1,000 cells were transferred into every second 
well of a 96-well cell culture plate. These plated cells were further diluted 1:10 in 
cultivation medium and seeded into the remaining wells of the plates. Plated cells were 
then further cultivated until the formation of neurosphere-like clones was observed in 
those wells containing the diluted cells. This was normally the case seven days after 
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transfection of R11 cells or approximately 14 days after transfection of ZH161. 
Neurosphere-like clones were quantified for every well, followed by calculating the 
mean number of clones per well. For analysis, results from several biological replicates 
were used. Significance was assessed by two-sided Student's t-test for unequal sample 
variance. P-values less than 0.05 were considered as significant. 
 
4.2.5. Dual luciferase reporter assays 
4.2.5.1. Validation of promoter regulation by transcription factors 
For investigation of potential promoter regulation by transcription factors such as 
Nkx2.2, the pGL3/pRL luciferase reporter vectors (Promega) were used. Thereby, the 
pGL3-basic vector encodes for firefly luciferase with a multiple cloning site located 
upstream of the luciferase open reading frame to clone the promoter of interest in front 
of the luciferase. For normalization of the firefly activity, the pRL-TK vector coding for 
renilla luciferase (under control of the constitutively active HSV-TK promoter) was co-
transfected. The third co-transfected plasmid was a pIRES-expression vector encoding 
e.g. for wildtype Nkx2.2. The co-transfections were preformed as biological 
quadruplicates using LipofectamineTM 2000. They were carried out in 48-well plates 
with 50,000 HEK293-T cells and 240 ng total plasmid-DNA per well (80 ng of each 
type of vector). One day after transfection cultivation medium was changed. Finally, cell 
lysis and measurement of  the luciferase activities was performed 48 hours after 
transfection. For the lysis, cultivation medium was replaced by 100 μl/well passive lysis 
buffer (Promega). Cells were then incubated with lysis buffer for 20 minutes on room 
temperature while shaking. Firefly and renilla activities were determined separately on a 
Mithras LB 940 Luminometer (Berthold technologies) by transferring for each 
measurement 20 μl lysate from each well to special 96-well plates characterized by a 
high reflectivity for an efficient luminescence measurement (BRANDplates® 
pureGradeTM, Brand, Wertheim, Germany). The respective buffers in which firefly or 
renilla luciferase were active were composed of as stated hereinafter. 
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firefly luciferase buffer renilla luciferase buffer
Na2EDTA 0,1 mM Na2EDTA 2.2 mM  
MgSO4 (× 7 H2O) 5.34 mM K3PO4 220 mM  
tricine 20 mM BSA 0.44 mg/ml 
ATP 530 μM NaCl 1.1 M 
coenzyme A 270 μM NaN3 1.3 mM 
D-luciferin 470 μM coleenterazin 1.43 nM 
DTT 33.3 mM
pH = 8.0  pH = 5.1
 
The ratios of firefly to renilla activity were calculated after the separate measurements. 
For analysis, the average ratio was assessed for each quadruplicate. The mean values 
were then double-normalized: first to the corresponding average ratio of the pIRES 
empty vector control and second to the corresponding average ratios of pGL3-basic 
empty vector samples. Significance was assessed from biological replicates using two-
sided Student's t-test for unequal sample variance. P-values less than 0.05 were 
considered as significant. 
 
4.2.5.2. Validation of miRNA binding sites in 3'-UTRs 
To validate in silico identified potential miRNA binding sites in the 3'-UTR of Nkx2.2, 
pMIR-RNL-TK dual luciferase reporter vectors were used. These vectors [previously 
described in (146)] are characterized by a multiple cloning site at the 3'-end of the 
firefly luciferase coding sequence. Cloning of a 3'-UTR in these vectors leads to a fusion 
of the firefly luciferase with this 3'-UTR. Moreover, these vectors contain the sequence 
encoding for renilla luciferase to normalize the firefly activity.  
For investigation of miRNA regulation either endogenous miRNAs were inhibited by 
transfection of miRNA-specific 2'-O-methylated antisense oligonucleotides or 
concentrations of certain miRNAs were increased by transfection of duplex mimics or 
pSUPER plasmids. Furthermore, general miRNA-regulation was examined by the 
overexpression of the T6B peptide. In all cases transfections were performed with 
LipofectamineTM 2000 using 48-well plates. In each well an amount of 50,000 cells were 
plated. Per well, either 80 nM final concentration 2'-O-methylated inhibitors, 10 to 20 
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nM duplex mimic, or 200 ng pSUPER plasmid were co-transfected with 120 to 150 ng 
reporter vector. The assays using the T6B peptide were performed by co-transfection of 
125 ng per well of the peptide expression vector (VP5-T6B-GFP) with 125 ng per well 
reporter vector. All transfections were carried out in biological quadruplicates. 
The further procedure and the readout were in principle the same as described in the 
paragraph before (4.2.5.1). Analysis was here also performed by double normalization of 
the average ratio values with the corresponding values of the controls. Thereby, the 
following controls were used: pMIR-RNL-TK empty vector and the miR-122 inhibitor 
for the assays with miRNA-specific inhibitors, pMIR-RNL-TK empty and the 
pSUPER empty vectors in the case of assays with pSUPER vectors. Negative controls 
for the T6B peptide assay were the empty reporter vector and the VP5-GFP expression 
vector. 
 
4.2.6. Analysis of molecular-pathological data from glioma patients  
Data for the analyses of patient survival and gene expression in gliomas was obtained 
from the REMBRANDT database (193, 194), as mentioned above. Further 
information can be found at https://caintegrator.nci.nih.gov/rembrandt/. 
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Appendix 
Table A.1 contains the complete list of the mass-spectrometric analysis of FH-Nkx2.2 
(co-)immunoprecipitates (see paragraph 2.2.2.). 
 
Table A.1: Complete mass-spectrometric analysis of FH-Nkx2.2 (co-)immunoprecipitates. 
Identified proteins are stated as indicated with molecular weight (MW), Mascot protein scores, 
number of peptides (#peptides), and sequence coverage (SC). 
band identified protein MW 
[kDa] 
scores #peptides SC [%] 
a Myosin-9  226.4 842.1  20 11.0 
  Nuclear pore complex protein Nup205 227.8 739.0 17 8.3 
  U5 small nuclear ribonucleoprotein 200 kDa helicase  244.4 396.2  10 5.2 
  Dedicator of cytokinesis protein 4  225.1 259.2 6 3.8 
  HEAT repeat-containing protein 1  242.2 111.0 3 1.4 
  Phosphatidylinositol 4-kinase alpha  231.2 91.6  2 0.9 
  DNA-dependent protein kinase catalytic subunit  468.8 83.9  3 1.0 
  Ubiquitin-40S ribosomal protein S27a  18.0 65.2  2 16.0 
  Nuclear mitotic apparatus protein  238.1 63.2 1 0.8 
 G-protein coupled receptor 98 692.6 48.3  1 0.1 
 Dedicator of cytokinesis protein 7 242.4 44.8  1 0.7 
 CAD protein  242.8 42.3  1 0.4 
 Plectin  531.5 40.6  1 0.1 
 Sperm-specific antigen 2  138.3 38.2  1 0.8 
      
b Structural maintenance of chromosomes protein 1A 143.1 257.4  6 5.3 
  Bifunctional glutamate/proline-tRNA ligase  170.5 233.3  6 4.6 
  OTU domain-containing protein 4 123.8 178.0  5 7.3 
  Dynactin subunit 1 141.6 168.0  4 3.6 
  Eukaryotic translation initiation factor 3 subunit A  166.5 117.8 4 2.3 
  Heat shock 70 kDa protein 1-like  70.3 95.1  2 3.9 
  Myb-binding protein 1A 148.8 94.7  3 4.4 
  Clathrin heavy chain 1 191.5 78.3  2 1.5 
  Homeobox protein Nkx-2.2 30.1 72.1  2 6.2 
  Ig alpha-1 chain C region 37.6 67.8  1 2.8 
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band identified protein MW 
[kDa] 
scores #peptides SC [%] 
  Integrin alpha-X 127.7 60.0  2 2.9 
  Insulin receptor substrate 4 133.7 58.5 2 2.1 
  Plectin  531.5 54.3  1 0.1 
  Nesprin-2  795.9 53.2  1 0.1 
  Ubiquitin-40S ribosomal protein S27a 18.0 47.9  1 10.3 
  Tyrosine-protein phosphatase non-receptor type 1  49.9 45.6  1 1.8 
  Lactadherin 43.1 45.2  1 2.3 
  Midasin 632.4 44.1 1 0.2 
  Sperm-specific antigen 2 138.3 43.5 1 0.8 
  Nesprin-1 1010.4 43.0 1 0.1 
  Copine-2 61.2 39.5  1 1.6 
  Long-chain fatty acid transport protein 4 72.0 39.3 1 1.2 
      
 c Heterogeneous nuclear ribonucleoprotein U  90.5 678.2  14 21.3 
  Tyrosine-protein kinase JAK1 133.2 490.7 13 13.1 
  Importin-8 119.9 451.6  8 8.6 
  Matrin-3 94.6 384.5  10 15.7 
  Kinesin-like protein KIF11 119.1 329.9 9 9.2 
  Helicase-like transcription factor 113.9 319.6 7 8.2 
  Poly [ADP-ribose] polymerase 1 113.0 319.6 8 10.4 
  116 kDa U5 small nuclear ribonucleoprotein component 109.4 262.7 9 10.6 
  RNA-binding protein 10 103.5 201.1 4 5.3 
  Cullin-associated NEDD8-dissociated protein 1 136.3 126.9 3 2.7 
  Ankyrin repeat and FYVE domain-containing protein 1 128.3 96.2  2 2.7 
  Ig kappa chain V-II region Cum 12.7 93.1 1 11.3 
  Importin-7 119.4 83.0  2 1.9 
  Ubiquitin carboxyl-terminal hydrolase 15 112.3 81.7 2 2.1 
  Importin-4 118.6 74.4  2 2.4 
  Putative trypsin-6 26.5 70.1 6 4.0 
  Ryanodine receptor 2 564.2 53.0 1 0.2 
  Heat shock cognate 71 kDa protein 70.9 51.0 1 2.0 
  Transcriptional regulator ATRX 282.4 43.3 1 0.6 
  Homeobox protein Nkx-2.2 30.1 42.3  2 7.3 
  Nucleolar and coiled-body phosphoprotein 1 73.6 39.5 1 2.7 
      
 d Kinesin-like protein KIF11 119.1 981.8  24 25.1 
  Heat shock protein 105 kDa 96.8 859.7 25 22.5 
  Heat shock 70 kDa protein 4 94.3 760.3 16 20.0 
  Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 114.7 348.0 8 10.1 
  Monofunctional C1-tetrahydrofolate synthase, mitochondrial  105.7 347.5 10 11.2 
  Unconventional myosin-Ic 121.6 279.5  7 6.6 
  Exportin-1 123.3 238.0  8 8.9 
  UDP-N-acetylglucosamine--peptide N-acetylglucosaminyltransferase 110 kDa subunit  116.8 230.3 5 5.7 
  Chromodomain-helicase-DNA-binding protein 1-like  100.9 227.8 7 7.7 
  ER degradation-enhancing alpha-mannosidase-like 3  104.6 198.5 6 7.8 
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band identified protein MW 
[kDa] 
scores #peptides SC [%] 
  C-1-tetrahydrofolate synthase, cytoplasmic 101.5 182.2 4 4.8 
  Exportin-2 110.3 161.0  3 2.9 
  Pre-mRNA-processing factor 6 106.9 157.9 5 6.5 
  Putative ribosomal RNA methyltransferase NOP2 89.2 136.7 4 6.7 
  Ribosome biogenesis protein BOP1 83.6 135.9 3 3.4 
  Heat shock 70 kDa protein 1A/1B 70.0 126.6 3 5.3 
  Eukaryotic translation initiation factor 3 subunit B  92.4 124.6 3 3.9 
  Interleukin enhancer-binding factor 3 95.3 104.3 3 4.4 
  Homeobox protein Nkx-2.2  30.1 92.9  3 12.8 
  Ig kappa chain V-II region Cum 12.7 88.2  1 11.3 
  26S proteasome non-ATPase regulatory subunit 1 105.8 85.1 2 2.0 
  Uncharacterized protein C2orf16 224.2 74.9 1 0.5 
  Serum albumin 69.3 74.2  2 3.6 
  Heat shock cognate 71 kDa protein 70.9 70.2 1 2.0 
  General vesicular transport factor p115 107.8 70.2 1 1.9 
  DNA replication licensing factor MCM6 92.8 65.1 1 1.2 
  Eukaryotic translation initiation factor 3 subunit C 105.3 64.0 2 1.9 
  Replication factor C subunit 1 128.2 63.3 1 1.0 
  Putative trypsin-6 26.5 57.3 6 4.0 
  RING finger protein 219 81.1 51.9 1 1.4 
      
 e Importin subunit beta-1 97.1 475.9 11 11.5 
  Nucleolar RNA helicase 2 87.3 434.9 12 17.2 
  MMS19 nucleotide excision repair protein homolog 113.2 396.5 12 14.9 
  Sodium/potassium-transporting ATPase subunit alpha-1 112.8 159.7 3 3.4 
  26S proteasome non-ATPase regulatory subunit 2  100.1 138.6 3 6.1 
  A-kinase anchor protein 8 76.1 110.3  1 2.9 
  Transitional endoplasmic reticulum ATPase 89.3 104.9 2 3.0 
  Heat shock 70 kDa protein 1-like 70.3 98.4 2 3.9 
  Methionine--tRNA ligase, cytoplasmic 101.1 97.2 4 4.1 
  Ig kappa chain V-II region Cum 12.7 92.1 1 11.3 
  RNA-binding protein 10 103.5 75.0 2 2.5 
  Serum albumin 69.3 66.1 1 2.5 
  Leucine-rich repeat-containing protein 16B 150.1 58.1 1 0.7 
  Homeobox protein Nkx-2.2 30.1 56.4 2 6.2 
  tRNA (cytosine(34)-C(5))-methyltransferase 86.4 49.9 1 1.4 
  Plectin 531.5 47.9 0 0.0 
  Histone-lysine N-methyltransferase, H3 lysine-36 and H4 lysine-20 specific 296.5 47.5  1 0.4 
  Dynein heavy chain domain-containing protein 1 533.3 46.3 2 0.5 
  Transducin-like enhancer protein 3 83.4 42.6 2 3.4 
  Protein sel-1 homolog 1 88.7 42.3 1 2.1 
  STEAP family member 1B 28.8 39.7 1 2.9 
  Coiled-coil domain-containing protein 62 77.7 38.5 1 0.7 
      
 f X-ray repair cross-complementing protein 5  82.7 1495.8 40 41.9 
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scores #peptides SC [%] 
  DNA replication licensing factor MCM7 81.3 1295.4 27 42.7 
  Mitochondrial inner membrane protein 83.6 215.3 6 9.5 
  Delta-1-pyrroline-5-carboxylate synthase 87.2 206.0 6 9.8 
  Ig kappa chain V-II region MIL 12.0 172.7 2 11.6 
  Heat shock 70 kDa protein 1-like 70.3 97.1 2 4.5 
  Serine/threonine-protein kinase RIO1 65.5 79.3 2 4.8 
  Serum albumin 69.3 73.2 2 3.6 
  Serotransferrin 77.0 65.3 2 7.4 
  Putative trypsin-6 26.5 56.0 6 4.0 
  Eukaryotic translation initiation factor 4B 69.1 43.7 1 1.5 
  Filamin-B  278.0 41.8 1 1.0 
  Alpha-actinin-1 103.0 41.1 0 0.0 
  Uncharacterized protein C2orf16 224.2 40.3 2 0.5 
  DnaJ homolog subfamily C member 10 91.0 40.0 1 1.3 
  Spectrin beta chain, non-erythrocytic 1 274.4 39.2 1 0.5 
  Small G protein signaling modulator 1 129.6 38.3 1 0.8 
      
 g 78 kDa glucose-regulated protein 72.3 2489.4 46 48.6 
  Eukaryotic translation initiation factor 4B 69.1 651.3 12 25.2 
  Heat shock cognate 71 kDa protein 70.9 650.9 10 19.7 
  Heat shock 70 kDa protein 1-like 70.3 510.9 7 13.1 
  Heat shock 70 kDa protein 1A/1B 70.0 507.6 10 17.8 
  ATP-dependent RNA helicase DDX3X 73.2 288.3 8 13.3 
  DBIRD complex subunit ZNF326 65.6 188.9 4 8.8 
  Serum albumin 69.3 123.2 3 4.8 
  Ubiquitin-40S ribosomal protein S27a 18.0 116.2 2 16.0 
  X-ray repair cross-complementing protein 5 82.7 106.4 2 2.9 
  Serotransferrin 77.0 81.4  2 6.7 
  ATP-binding cassette sub-family F member 2 71.2 80.8 2 3.7 
  Ig kappa chain V-II region Cum 12.7 68.2 1 11.3 
  Putative trypsin-6 26.5 61.7 5 4.0 
  Nesprin-1 1010.4 59.5  0 0.0 
  Homeobox protein Nkx-2.2  30.1 57.6 2 8.8 
  Protein arginine N-methyltransferase 5 72.6 57.0 1 1.6 
  DNA replication licensing factor MCM7 81.3 56.0 2 3.8 
  Plectin 531.5 53.4 1 0.3 
  Melanoma-associated antigen D2 64.9 46.1 1 2.1 
  Ryanodine receptor 2 564.2 42.1 2 0.7 
  Synaptopodin-2  117.4 38.1 2 1.1 
  Pericentrin 377.8 38.0 2 0.6 
      
 h Heat shock 70 kDa protein 1A/1B 70.0 2695.2 71 51.5 
  Heat shock cognate 71 kDa protein 70.9 2299.3 71 50.9 
  Stress-70 protein, mitochondrial 73.6 1660.8 30 40.1 
  X-ray repair cross-complementing protein 6 69.8 1312.0 29 39.9 
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  Heat shock 70 kDa protein 1-like 70.3 1145.3 32 31.5 
  Heat shock 70 kDa protein 6 71.0 1096.3 25 21.8 
  Heat shock-related 70 kDa protein 2 70.0 978.9 22 18.3 
  Protein arginine N-methyltransferase 5 72.6 961.7 24 34.2 
  Lamin-B1 66.4 335.8 6 11.3 
  78 kDa glucose-regulated protein 72.3 259.3 6 4.3 
  Replication protein A 70 kDa DNA-binding subunit  68.1 225.3 4 7.1 
  Calcium-binding mitochondrial carrier protein Aralar2 74.1 197.9 4 7.6 
  Ig kappa chain V-II region MIL 12.0 156.3 2 11.6 
  Heterogeneous nuclear ribonucleoprotein M 77.5 92.5 2 3.6 
  Zinc finger protein Helios 59.5 57.8 1 1.5 
  G-protein coupled receptor 98 692.6 53.1 1 0.1 
  Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 77.0 43.6 1 5.4 
      
 i Tubulin beta chain 49.6 1245.6 27 50.0 
  Heat shock cognate 71 kDa protein 70.9 1098.7 19 26.5 
  Tubulin beta-4B chain 49.8 1048.9 22 43.4 
  Heat shock 70 kDa protein 1A/1B 70.0 1046.6 18 30.0 
  Eukaryotic initiation factor 4A-I 46.1 758.0 17 36.9 
  Vimentin 53.6 652.2 14 33.7 
  Eukaryotic initiation factor 4A-III 46.8 440.8 10 24.3 
  Heterogeneous nuclear ribonucleoprotein F 45.6 440.2 12 23.4 
  Elongation factor 1-alpha 1 50.1 307.3 6 14.5 
  Nuclease-sensitive element-binding protein 1 35.9 232.1 4 22.2 
  Serpin H1 46.4 207.6 3 9.1 
  Elongation factor Tu, mitochondrial 49.5 194.0 3 10.0 
  Eukaryotic translation initiation factor 4B 69.1 152.3  2 4.1 
  Protein arginine N-methyltransferase 5 72.6 130.0  2 4.7 
  Homeobox protein Nkx-2.2 30.1 118.7 3 8.8 
  Tubulin alpha-1B chain 50.1 100.7 2 5.1 
  Ig kappa chain V-II region Cum 12.7 89.2  1 11.3 
  26S protease regulatory subunit 7 48.6 83.6 2 6.5 
  Eukaryotic translation initiation factor 3 subunit E  52.2 77.7 2 4.5 
  Abnormal spindle-like microcephaly-associated protein 409.5 74.4 2 0.7 
  26S protease regulatory subunit 8 45.6 67.7 3 9.9 
  Splicing factor 3B subunit 4 44.4 65.3 1 3.3 
  Trifunctional enzyme subunit beta, mitochondrial  51.3 62.2 1 1.9 
  Elongation factor 1-gamma 50.1 59.3  1 3.0 
  Putative trypsin-6 26.5 57.4 6 4.0 
  Plectin 531.5 56.5 0 0.0 
  Alpha-enolase 47.1 55.9 2 6.7 
  ATP-dependent Clp protease ATP-binding subunit clpX-like, mitochondrial 69.2 54.1 1 2.1 
  Serum albumin 69.3 52.6 2 2.5 
  Transmembrane channel-like protein 3 125.6 49.8 1 0.9 
  Hydroxysteroid dehydrogenase-like protein 2 45.4 48.9  1 4.3 
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 Titin 3813.7 48.0 1 0.0 
  Cyclin-dependent kinase 3 35.0 47.8 1 2.3 
  Zinc finger protein 148 88.9 43.2 1 1.1 
  Heat-stable enterotoxin receptor 123.3 41.8 1 0.9 
  Rab GDP dissociation inhibitor beta 50.6 40.4 1 1.8 
  Utrophin 394.2 39.0 0 0.0 
  Transmembrane protein 132C 121.7 38.9 1 0.8 
      
 j Elongation factor Tu, mitochondrial 49.5 1293.7 26 54.2 
  Heat shock 70 kDa protein 1A/1B 70.0 724.7 14 22.5 
  Heat shock cognate 71 kDa protein 70.9 509.6 9 16.3 
  Cytochrome b-c1 complex subunit 2, mitochondrial 48.4 462.7 9 25.4 
  Ornithine aminotransferase, mitochondrial 48.5 257.2 7 15.7 
  Tubulin beta chain 49.6 231.9 5 14.4 
  Homeobox protein Nkx-2.2 30.1 215.0 7 37.0 
  Heterogeneous nuclear ribonucleoprotein F 45.6 204.6 5 14.5 
  Eukaryotic initiation factor 4A-I 46.1 166.5 3 10.6 
  DnaJ homolog subfamily A member 1 44.8 142.0 3 9.3 
  60S ribosomal protein L3  46.1 106.7 3 7.9 
  Ig kappa chain V-II region Cum 12.7 106.3 1 11.3 
  Serpin H1 46.4 92.7 2 5.5 
  Glutaryl-CoA dehydrogenase, mitochondrial 48.1 86.0 3 8.7 
  Vimentin 53.6 79.3 2 4.3 
  26S proteasome non-ATPase regulatory subunit 11 47.4 76.5 2 6.2 
  Serum albumin 69.3 75.3 2 3.6 
  Tubulin alpha-1B chain 50.1 70.7 2 5.1 
  Elongation factor 1-alpha 1 50.1 69.4 1 2.4 
  Heterogeneous nuclear ribonucleoprotein D0 38.4 63.5  1 3.9 
  Ribonuclease inhibitor 49.9 60.6 2 6.5 
  Eukaryotic translation initiation factor 3 subunit E 52.2 58.2 2 4.5 
  Eukaryotic translation initiation factor 4B 69.1 58.1 1 2.6 
  Alpha-centractin 42.6 57.8 1 4.3 
  G-protein coupled receptor 98 692.6 53.3 1 0.1 
  Obscurin 867.9 52.8 1 0.2 
  Eukaryotic initiation factor 4A-III 46.8 50.0 2 6.3 
  Protein arginine N-methyltransferase 5 72.6 48.1 1 1.6 
  Eukaryotic translation initiation factor 3 subunit F 37.5 47.8 1 3.4 
  Cell division cycle protein 20 homolog B 57.3 44.7 1 2.3 
  Calcium-binding mitochondrial carrier protein SCaMC-1 53.3 41.7 1 2.7 
      
 k Homeobox protein Nkx-2.2 30.1 1046.9 20 66.7 
  Methylosome protein 50 36.7 586.2 10 30.4 
  Heat shock 70 kDa protein 1A/1B 70.0 513.2 8 16.4 
  Heat shock cognate 71 kDa protein 70.9 344.8 8 16.7 
  Heterogeneous nuclear ribonucleoproteins C1/C2 33.6 340.6 7 22.5 
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 Replication factor C subunit 3 40.5 235.1 6 13.8 
  Actin, cytoplasmic 1 41.7 209.3 4 14.7 
  Elongation factor Tu, mitochondrial 49.5 153.5 3 11.3 
  Probable cytosolic iron-sulfur protein assembly protein CIAO1 37.8 96.8 2 8.8 
  Ig kappa chain V-II region Cum 12.7 95.2 1 11.3 
  Probable rRNA-processing protein EBP2 34.8 76.6 1 3.3 
  Heterogeneous nuclear ribonucleoprotein A/B 36.2 72.2 1 3.9 
  Plectin 531.5 70.9 1 0.1 
  Serum albumin 69.3 68.5 1 2.5 
  E3 ubiquitin-protein ligase HERC2 526.9 60.2 1 0.2 
  Putative trypsin-6 26.5 54.8  6 4.0 
  MMS19 nucleotide excision repair protein homolog 113.2 45.3 1 1.0 
  FYVE, RhoGEF and PH domain-containing protein 3 79.4 43.6 2 2.5 
  Rab-interacting lysosomal protein 44.2 42.4  1 4.7 
  Plexin-D1 OS=Homo sapiens GN=PLXND1 PE=1 SV=3 211.9 40.6 1 0.4 
  Zinc finger protein 148 88.9 39.4 1 1.1 
  DNA excision repair protein ERCC-6 168.3 39.2  1 0.9 
  Probable ATP-dependent RNA helicase DDX11 108.2 38.9 2 1.4 
  Monocarboxylate transporter 1 53.9 38.5 1 3.0 
      
 l Homeobox protein Nkx-2.2 30.1 2075.1 46 66.7 
  Methylosome protein 50 36.7 538.4 11 37.4 
  Heat shock 70 kDa protein 1A/1B 70.0 235.4 4 8.1 
  DnaJ homolog subfamily A member 3, mitochondrial 52.5 171.2 4 8.5 
  40S ribosomal protein SA 32.8 146.8 3 12.9 
  7-dehydrocholesterol reductase 54.5 133.7 2 5.1 
  Heterogeneous nuclear ribonucleoproteins C1/C2  33.6 115.3 2 9.2 
  Heat shock cognate 71 kDa protein 70.9 93.4 2 3.9 
  Ig kappa chain V-II region Cum 12.7 91.5 1 11.3 
  Serum albumin 69.3 87.5 2 3.6 
  Protein SET 33.5 84.4 3 8.3 
  TraB domain-containing protein 42.3 80.6 1 3.2 
  Putative trypsin-6 26.5 70.6 7 4.0 
  Activator of 90 kDa heat shock protein ATPase homolog 1 38.3 70.4 3 13.3 
  Ancient ubiquitous protein 1 53.0 60.9 3 8.0 
  Keratin, type I cytoskeletal 16 51.2 59.2 3 5.1 
  Developmentally-regulated GTP-binding protein 1 40.5 57.7 2 7.9 
  Histone H1.2 21.4 50.6 2 9.9 
  MMS19 nucleotide excision repair protein homolog 113.2 50.2 1 1.0 
  Plectin 531.5 48.0 1 0.1 
  Ribosome biogenesis protein BRX1 homolog 41.4 47.5 1 3.1 
  Monocarboxylate transporter 1 53.9 46.2 1 3.0 
  Rab-interacting lysosomal protein 44.2 45.2 1 4.7 
  Casein kinase II subunit alpha 45.1 43.9 1 4.6 
  Zinc finger protein 148 88.9 43.7 1 1.1 
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 m Homeobox protein Nkx-2.2 30.1 3899.2 84 84.2 
  Glutaminyl-peptide cyclotransferase-like protein  42.9 474.1  12 23.3 
  Nucleophosmin  32.6 286.8 8 18.7 
  Methylosome protein 50 36.7 246.4 6 23.4 
  Homeobox protein Nkx-2.3 38.4 205.2 5 6.9 
  Methylosome subunit pICln 26.2 171.1 3 18.6 
  Core histone macro-H2A.1 39.6 155.9 2 11.3 
  Heat shock 70 kDa protein 1A/1B 70.0 147.1 3 6.7 
  Protein transport protein Sec61 subunit alpha isoform 1 52.2 138.0 3 6.3 
  Poly(rC)-binding protein 1 37.5 112.9 3 9.3 
  Heterogeneous nuclear ribonucleoproteins A2/B1 37.4 112.8 3 13.9 
  Ig kappa chain V-II region Cum 12.7 91.8 1 11.3 
  Plectin 531.5 72.8 0 0.0 
  Rab-interacting lysosomal protein 44.2 67.2 1 4.7 
  A-kinase anchor protein 9 453.4 55.8 2 0.4 
  Stomatin-like protein 2 38.5 53.8 3 9.0 
  Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5 837.8 46.1 1 0.1 
  Caytaxin 42.1 45.7 2 2.4 
  Trypsin-3 32.5 43.5 0 0.0 
  DNA polymerase zeta catalytic subunit 352.6 42.0 2 0.3 
  Collagen alpha-5(VI) chain 289.7 41.6 1 0.5 
  Erlin-1 38.9 40.2 1 4.3 
  Centrosomal protein KIAA1731 295.0 39.4 1 0.3 
  Platelet glycoprotein V 60.9 39.2 1 1.4 
  Coiled-coil domain-containing protein 88B 164.7 38.9 1 0.5 
  Pseudopodium-enriched atypical kinase 1 193.0 38.6 1 0.9 
  5' exonuclease Apollo 60.0 38.4 1 1.3 
  Solute carrier family 52, riboflavin transporter, member 1 46.3 38.3 1 1.6 
      
 n Homeobox protein Nkx-2.2 30.1 2982.4 62 70.3 
  Heterogeneous nuclear ribonucleoproteins C1/C2 33.6 434.3 9 21.6 
  Glutaminyl-peptide cyclotransferase-like protein 42.9 431.4 10 25.9 
  Heterogeneous nuclear ribonucleoproteins A2/B1  37.4 317.9 7 19.5 
  Replication factor C subunit 2 39.1 274.7 6 23.4 
  Homeobox protein Nkx-2.3 38.4 195.6 4 6.0 
  Ig kappa chain V-II region Cum 12.7 92.4 1 11.3 
  3-hydroxyacyl-CoA dehydratase 3 43.1 91.5 2 6.9 
  DnaJ homolog subfamily A member 3, mitochondrial  52.5 87.0 3 5.8 
  Heat shock 70 kDa protein 1A/1B 70.0 69.6 1 2.5 
  Rab-interacting lysosomal protein 44.2 67.2 0 0.0 
  Nesprin-1 1010.4 63.1 2 0.3 
  Heterogeneous nuclear ribonucleoprotein H3 36.9 55.7 1 3.5 
  A-kinase anchor protein 9 453.4 55.6 2 0.4 
  1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 138.7 51.6 1 1.2 
  Golgin subfamily B member 1 375.8 50.1 1 0.2 
 Table continued on next page 
Appendix 159 
 
 
band identified protein MW 
[kDa] 
scores #peptides SC [%] 
  Mucin-16 2353.1 50.1 1 0.0 
  Unconventional myosin-IXb 243.2 45.9 1 0.5 
  Poly(rC)-binding protein 1 37.5 45.8 1 3.1 
  DDB1- and CUL4-associated factor 7 38.9 45.2 1 4.4 
  G-protein coupled receptor 98 692.6 44.8 1 0.1 
  Spectrin alpha chain, erythrocytic 1 279.8 44.7 0 0.0 
  Heat shock cognate 71 kDa protein 70.9 43.9 1 2.6 
 Platelet glycoprotein V 60.9 43.1 1.4 3.92 
 Putative uncharacterized protein C8orf73 77.1 41.6 1.1 16.13 
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